[{"orgOrder":0,"company":"Biosidus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ARGENTINA","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biosidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biosidus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biosidus \/ Inapplicable"},{"orgOrder":0,"company":"Medibiofarma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MBF-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Medibiofarma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medibiofarma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Medibiofarma \/ Inapplicable"},{"orgOrder":0,"company":"Nihon Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NPB-01","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nihon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Nihon Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nihon Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxalta Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Baxalta Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SHP648","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxalta Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Baxalta Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Baxalta Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant), Plasma","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Baxalta Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baxalta Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Baxalta Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Biopharma","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UKRAINE","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Biopharma \/ Global Blood Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Biopharma \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Cellatoz Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLZ-2002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cellatoz Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Cellatoz Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cellatoz Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Connecta Therapeutics","sponsor":"Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CTH120","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Connecta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Connecta Therapeutics \/ Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain","highestDevelopmentStatusID":"6","companyTruncated":"Connecta Therapeutics \/ Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQG203","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TQ-B3234","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Alfa","moa":"Coagulation factor VII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Activated Coagulation Factor VIII","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Chia Tai Tianqing Pharmaceutical Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TQ05105","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chia Tai Tianqing Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Chia Tai Tianqing Pharmaceutical Group \/ Inapplicable"},{"orgOrder":0,"company":"Elpida Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Melpida Gene Therapy","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Elpida Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elpida Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elpida Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Data Management 365 | Atlant Clinical | R-Pharm | UNIMED Laboratories | Exacte Labs | Key Stat | Inpharmus | Ascot E\u011fitim ve Dan\u0131\u015fmanl\u0131k"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Solution","sponsorNew":"R-Pharm \/ Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat","highestDevelopmentStatusID":"8","companyTruncated":"R-Pharm \/ Atlant Clinical | UNIMED Laboratories | Data Management 365 | R-Pharm | Inpharmus | Exacte Labs | Key Stat"},{"orgOrder":0,"company":"Respirion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RSP-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Respirion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Respirion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Respirion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FRSW107","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FRSW117","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"FRSW117","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SS109","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant), Plasma","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant), Plasma","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Gensciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SS109","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Gensciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Gensciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Gensciences \/ Inapplicable"},{"orgOrder":0,"company":"Nobias Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NB-001","moa":"HSV DNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nobias Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nobias Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nobias Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biotest","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biotest","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotest \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biotest \/ Inapplicable"},{"orgOrder":0,"company":"Aurion Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Neltependocel","moa":"Rho-associated protein kinase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurion Biotech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracameral Injection","sponsorNew":"Aurion Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurion Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Termination","leadProduct":"Olenasufligene Relduparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Sarepta Therapeutics \/ Lysogene","highestDevelopmentStatusID":"9","companyTruncated":"Sarepta Therapeutics \/ Lysogene"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AB-1001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FXS01","moa":"DGKk","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"SATT Conectus","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"FXS01","moa":"DGKk","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SATT Conectus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"SATT Conectus \/ Lysogene","highestDevelopmentStatusID":"4","companyTruncated":"SATT Conectus \/ Lysogene"},{"orgOrder":0,"company":"Allievex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AX250","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Allievex","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"Allievex \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Allievex \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Partnership","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0.81000000000000005,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.81000000000000005,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Nippon Shinyaku","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Nippon Shinyaku"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Spruce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Acquisition","leadProduct":"Tralesinidase Alfa","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Spruce Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Spruce Biosciences"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-111","moa":"Alpha-L-iduronidase (IDUA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"RGX-121","moa":"Iduronate 2-sulfatase (IDS)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Grace Science","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Andelyn Biosciences \/ Grace Science","highestDevelopmentStatusID":"7","companyTruncated":"Andelyn Biosciences \/ Grace Science"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"BlackfinBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Inapplicable"},{"orgOrder":0,"company":"BlackfinBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BFB-101","moa":"AP4B1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BlackfinBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"BlackfinBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BlackfinBio \/ Inapplicable"},{"orgOrder":0,"company":"Neurogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"NGN-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Neurogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Neurogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Neurogene \/ Inapplicable"},{"orgOrder":0,"company":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VGN-R08b","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Shanghai Vitalgen BioPharma Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Shanghai Vitalgen BioPharma Co., Ltd."},{"orgOrder":0,"company":"Triplet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"TTX-3360","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Triplet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Triplet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Triplet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GS-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grace Science","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"Grace Science \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grace Science \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Peking University First Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HG204","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular Injection","sponsorNew":"HuidaGene Therapeutics \/ Peking University First Hospital","highestDevelopmentStatusID":"1","companyTruncated":"HuidaGene Therapeutics \/ Peking University First Hospital"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"GEMMA Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ GEMMA Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ GEMMA Biotherapeutics"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"University of Pennsylvania","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PBKR03","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ University of Pennsylvania","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ University of Pennsylvania"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"LY3884961","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-Cisterna Magna","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ Inapplicable"},{"orgOrder":0,"company":"Passage Bio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"PBGM01","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Passage Bio","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Intra-cisterna magna Injection","sponsorNew":"Passage Bio \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Passage Bio \/ J.P. Morgan"},{"orgOrder":0,"company":"Medera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SRD-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Medera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracoronary Infusion","sponsorNew":"Medera \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Medera \/ Inapplicable"},{"orgOrder":0,"company":"Acceleron Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"ACE-083","moa":"Fc fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Acceleron Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Acceleron Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Acceleron Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Helixmith","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Donaperminogene Seltoplasmid","moa":"Hepatocyte growth factor (HGF)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Helixmith \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Helixmith \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FT-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran | Peking Union Medical College Hospital | Henan Provincial People's Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran | Peking Union Medical College Hospital | Henan Provincial People's Hospital","highestDevelopmentStatusID":"7","companyTruncated":"Frontera Therapeutics \/ Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical Sciences, Iran | Peking Union Medical College Hospital | Henan Provincial People's Hospital"},{"orgOrder":0,"company":"Frontera Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FT-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Frontera Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraocular Injection","sponsorNew":"Frontera Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Frontera Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-HTT01","moa":"HTT expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VY-HTT01","moa":"HTT expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VY-HTT01","moa":"HTT expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Voyager Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"Voyager Therapeutics, Inc \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Voyager Therapeutics, Inc \/ Sanofi"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"LETI-101","moa":"Mutant huntingtin protein level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraparenchymal Infusion","sponsorNew":"ElevateBio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ElevateBio \/ Inapplicable"},{"orgOrder":0,"company":"Versantis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VS-01","moa":"Ammonia clearance","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Versantis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intraperitoneal Injection","sponsorNew":"Versantis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Versantis \/ Inapplicable"},{"orgOrder":0,"company":"CalciMedica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GB-501","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CalciMedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrastromal Injection","sponsorNew":"CalciMedica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CalciMedica \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Onasemnogene Abeparvovec","moa":"||Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regenxbio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intrathecal Infusion","sponsorNew":"Regenxbio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Regenxbio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Agreement","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":1.1299999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1299999999999999,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alcyone Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Alcyone Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OAV-101","moa":"SMN1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"F. Hoffmann-La Roche \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"OAV101","moa":"SMN1","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OAV101","moa":"SMN1","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Tominersen","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"WVE-120101","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"WVE-120102","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Termination","leadProduct":"WVE-003","moa":"SNP3","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.26000000000000001,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-120102","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TSHA-101","moa":"Beta-hexosaminidase subunit alpha (HEXA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TSHA-101","moa":"Beta-hexosaminidase subunit alpha (HEXA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Alcyone Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACTX-401","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Alcyone Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Alcyone Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Alcyone Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT-GTX-501","moa":"Ceroid-lipofuscinosis neuronal protein 6 (CLN6)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT-GTX-501","moa":"Ceroid-lipofuscinosis neuronal protein 6 (CLN6)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ALN-HTT02","moa":"HTT mRNA","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ARO-ATXN2","moa":"Ataxin-2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"TSHA-101","moa":"Beta-hexosaminidase subunit alpha (HEXA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"TSHA-101","moa":"Beta-hexosaminidase subunit alpha (HEXA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Taysha Gene Therapies","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intrathecal Injection","sponsorNew":"Taysha Gene Therapies \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"Taysha Gene Therapies \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathecal Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Petrovax","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Licensing Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Petrovax","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Petrovax"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NICE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NICE","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NICE \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NICE \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Bluebird Bio","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Bluebird Bio"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"RoslinCT","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"RoslinCT","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"RoslinCT \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RoslinCT \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Hercules Capital","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Hercules Capital"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Medicaid","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Medicaid","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Medicaid"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"DDC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"DDC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Arup Laboratories","sponsor":"Medicover","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Arup Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arup Laboratories \/ Medicover","highestDevelopmentStatusID":"15","companyTruncated":"Arup Laboratories \/ Medicover"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Uniqure","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ HealthCare Royalty"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Labcorp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Labcorp","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Labcorp \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Labcorp \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"3W Fund Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2020","type":"Series E Financing","leadProduct":"Idursulfase Beta","moa":"Heparan sulfate | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ 3W Fund Management","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ 3W Fund Management"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Idursulfase Beta","moa":"Heparan sulfate | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Healthcare Royalty Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Healthcare Royalty Management","highestDevelopmentStatusID":"15","companyTruncated":"Regenxbio \/ Healthcare Royalty Management"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Charles River Laboratories, Inc \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Editas Medicine \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ NHS England"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Dalnacogene Ponparvovec","moa":"FIX gene","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Belief BioMed \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Belief BioMed \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lonza Group \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Sumitomo Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Sumitomo Pharma","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Sumitomo Pharma"},{"orgOrder":0,"company":"Petrovax","sponsor":"ISU ABXIS","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Petrovax \/ ISU ABXIS","highestDevelopmentStatusID":"15","companyTruncated":"Petrovax \/ ISU ABXIS"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Amicus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Agreement","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Amicus Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Amicus Therapeutics"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Velmanase Alpha","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Human Alpha1-Proteinase Inhibitor","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Taiba Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Taiba Healthcare","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Taiba Healthcare"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Option Care Health","sponsor":"NS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Option Care Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Option Care Health \/ NS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Option Care Health \/ NS Pharma"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"American Porphyria Foundation","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Oligonucleotide","year":"2020","type":"Funding","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"American Porphyria Foundation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Porphyria Foundation \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"American Porphyria Foundation \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Casimersen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"KabaFusion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ KabaFusion","highestDevelopmentStatusID":"15","companyTruncated":"GC Biopharma \/ KabaFusion"},{"orgOrder":0,"company":"Soleo Health","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Partnership","leadProduct":"Immune Globulin Intravenous, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Soleo Health \/ GC Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ GC Biopharma"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Partnership","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orsini Specialty Pharmacy \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Prime Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic factor recombinant","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Prime Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Prime Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Prime Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Morgan Stanley","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Morgan Stanley"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"LFB Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Thioredoxin reductase (PRDX5)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LFB Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ Inapplicable"},{"orgOrder":0,"company":"LFB Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eptacog Beta","moa":"Thioredoxin reductase (PRDX5)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LFB Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ Inapplicable"},{"orgOrder":0,"company":"H\u00e4mophilie-Zentrum Rhein Main","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"H\u00e4mophilie-Zentrum Rhein Main","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma","highestDevelopmentStatusID":"15","companyTruncated":"H\u00e4mophilie-Zentrum Rhein Main \/ Octapharma"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Sanofi","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Sanofi"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Simoctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Antihemophilic Factor Recombinant PEGylated","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"Medexus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ Medexus Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ Medexus Pharmaceuticals"},{"orgOrder":0,"company":"Aptevo Therapeutics","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Agreement","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aptevo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Aptevo Therapeutics \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Aptevo Therapeutics \/ XOMA"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eftrenonacog Alpha","moa":"Coagulation factor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Albutrepenonacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Human Coagulation Factor VIII Complex","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Antihemophilic Factor (recombinant), PeGylated","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hartford Hospital \/ Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho","highestDevelopmentStatusID":"11","companyTruncated":"Hartford Hospital \/ Merck & Co | Q2 Solutions | Connecticut Children's Medical Center | St. Christopher's Hospital for Children | UT Southwestern Medical Center | University of Pittsburgh Medical Center | Indiana University Health Methodist Hospital | James Whitcomb Riley Ho"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Imiglucerase","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Alglucosidase Alfa","moa":"Starch","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Idursulfase","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Agalsidase Alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHIRE PLC \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"alpha L Idosiduronase","moa":"Heparan sulfate | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alfa","moa":"Glycogen","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Idursulfase","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Rare Disease Research, LLC","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Golodirsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Rare Disease Research, LLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Rare Disease Research, LLC \/ Sarepta Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Rare Disease Research, LLC \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"ADMA Biologics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ADMA Biologics \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"ADMA Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Hartford Hospital","sponsor":"Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cefiderocol","moa":"Bacterial penicillin-binding protein","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hartford Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System","highestDevelopmentStatusID":"11","companyTruncated":"Hartford Hospital \/ Shionogi | Keystone Bioanalytical | Indiana University Health Methodist Hospital | University of Pittsburgh Medical Center | University of Texas System"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant)","moa":"F10","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Antihemophilic Factor (Recombinant)","moa":"F10","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ PSI CRO","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ PSI CRO"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Medexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Coagulation Factor Ix","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Medexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Medexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"OAV101","moa":"SMN1","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"LFB Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"LFB Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"LFB Group \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ J.P. Morgan"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PF-06939926","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"DTX401","moa":"Glucose-6-phosphatase (G6PC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"DTX401","moa":"||Glucose-6-phosphatase (G6PC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fidanacogene elaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alfa","moa":"Glycogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.22,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2021","type":"Financing","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Oberland Capital Management"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Coagulation Factor VIII","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"ApcinteX","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"SerpinPC","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ApcinteX","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ApcinteX \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ApcinteX \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Atlantic Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Green Cross Lab Cell \/ Atlantic Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Green Cross Lab Cell \/ Atlantic Research Group"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Birtamimab","moa":"Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Daniel Gaudet","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Daniel Gaudet","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Daniel Gaudet \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Daniel Gaudet \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Halozyme Therapeutics","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Halozyme Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Halozyme Therapeutics \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Halozyme Therapeutics \/ GSK"},{"orgOrder":0,"company":"Genmab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genmab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Birtamimab","moa":"||Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Birtamimab","moa":"||Light chain aggregates","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Prothena \/ Jefferies"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.5,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Caelum Biosciences","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Caelum Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Caelum Biosciences \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Caelum Biosciences \/ AstraZeneca"},{"orgOrder":0,"company":"Fortress Biotech","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Bortezomib","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fortress Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fortress Biotech \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Fortress Biotech \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"FibroGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"FibroGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"GC5107","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Kedrion IVIG","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Kedrion IVIG","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Kaufmann Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Kaufmann Funds","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Kaufmann Funds"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Kaufmann Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Kaufmann Funds","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Kaufmann Funds"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Antibody-protein Conjugate","year":"2020","type":"Inapplicable","leadProduct":"IVIG-PEG","moa":"Immunoglobulins","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Kedrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-protein Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Intravenous Immune Globulin","moa":"Immunoglobulins","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kedrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kedrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kedrion \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CTX001","moa":"B-cell lymphoma\/leukemia 11A (BCL11A)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Onasemnogene Abeparvovec","moa":"Survival motor neuron protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"DTX301","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2001","moa":"Transthyretin (TTR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SRP-9003","moa":"Beta-sarcoglycan (SGCB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SRP-9005","moa":"SGCG","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"||Hemoglobin subunit beta (HBB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Hemoglobin subunit beta (HBB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Hemoglobin subunit beta (HBB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Lovotibeglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bluebird Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Bluebird Bio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immunogen","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Immunogen","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Immunogen \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Immunogen \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"ClearPoint Neuro","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"DDC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PTC Therapeutics \/ ClearPoint Neuro","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ ClearPoint Neuro"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sangamo Therapeutics","amount2":2.7200000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":2.7200000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Biogen","highestDevelopmentStatusID":"10","companyTruncated":"Sangamo Therapeutics \/ Biogen"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Termination","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sangamo Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Sangamo Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Sangamo Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene fitelparvovec","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Sangamo Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Sangamo Therapeutics"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BBM-H901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Belief BioMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belief BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Uniqure","sponsor":"CSL Behring","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":2.0499999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":2.0499999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ CSL Behring","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ CSL Behring"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"San Raffaele-Telethon Institute for Gene Therapy","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ San Raffaele-Telethon Institute for Gene Therapy"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2020","type":"Series D Financing","leadProduct":"Idursulfase Beta","moa":"Heparan sulfate | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Rebisufligene Etisparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Nippon Shinyaku","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Capricor Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shinyaku \/ Capricor Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Catalent Pharma Solutions \/ Sarepta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Catalent Pharma Solutions \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Fordadistrogene Movaparvovec","moa":"Dystrophin (DMD)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"CRISPR Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ CRISPR Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ CRISPR Therapeutics"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mabxience","sponsor":"Biosidus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Enzyme","year":"2024","type":"Agreement","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mabxience \/ Biosidus","highestDevelopmentStatusID":"10","companyTruncated":"Mabxience \/ Biosidus"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Agalsidase Alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"SHIRE PLC \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"SHIRE PLC \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Avalglucosidase Alfa","moa":"Glycogen","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Agalsidase Alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Velaglucerase Alfa","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Chiesi Group"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Protalix BioTherapeutics","sponsor":"Psagot Investment House","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Protalix BioTherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Protalix BioTherapeutics \/ Psagot Investment House","highestDevelopmentStatusID":"15","companyTruncated":"Protalix BioTherapeutics \/ Psagot Investment House"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Kamada","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Alpha-1 Antitrypsin","moa":"ELA2\/HIV-1 protease\/Serine protease","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamada \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kamada \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Protalix BioTherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegunigalsidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Chiesi Group \/ Protalix BioTherapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Protalix BioTherapeutics"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cipaglucosidase Alpha","moa":"||Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Financing","leadProduct":"Cipaglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Amicus Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DEKA Research & Development","sponsor":"Zealand Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2021","type":"Collaboration","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"DEKA Research & Development","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DEKA Research & Development \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"DEKA Research & Development \/ Zealand Pharma"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nippon Shinyaku \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nippon Shinyaku \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Casimersen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Casimersen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Avalglucosidase Alpha","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Leerink Partners","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Leerink Partners"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.46000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"TD Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Public Offering","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ TD Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ TD Cowen"},{"orgOrder":0,"company":"Evolve Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Evolve Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Evolve Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Evolve Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Biotrial","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quince Therapeutics \/ Biotrial","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Biotrial"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Biotrial","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Quince Therapeutics \/ Biotrial","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Biotrial"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Marinus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Marinus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin | Leukocyte adhesion molecule-1 | Selectin E","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin | Leukocyte adhesion molecule-1 | Selectin E","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin | Leukocyte adhesion molecule-1 | Selectin E","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rivipansel","moa":"P-selectin | Leukocyte adhesion molecule-1 | Selectin E","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Fosdenopterin","moa":"phosphoro-derivatives","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"N8-GP","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nonacog Beta Pegol","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Vonicog Alfa","moa":"von Willebrand factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Recombinant, Pegylated Antihemophilic Factor","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Swedish Orphan Biovitrum AB \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Syneos Health"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Fusion Protein Linking Coagulation Factor Ix","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder for Solution","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Protein","year":"2021","type":"Divestment","leadProduct":"Plasminogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liminal BioSciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Liminal BioSciences \/ Kedrion","highestDevelopmentStatusID":"10","companyTruncated":"Liminal BioSciences \/ Kedrion"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"||VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Sanofi","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alpha","moa":"VWF","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"AB2 Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tadekinig Alpha","moa":"IL-18 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AB2 Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AB2 Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AB2 Bio \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Pabinafusp Alpha","moa":"Transferrin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"JCR Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Von Willebrand Factor","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"bb1111","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"OAV101","moa":"SMN1","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CSL222","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"OCTA-C1-INH","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lonoctocog Alfa","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Lyophilized Powder for Solution","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Sharmila Dorbala","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Radiolabeled Compounds","year":"2025","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sharmila Dorbala","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Sharmila Dorbala \/ Attralus","highestDevelopmentStatusID":"10","companyTruncated":"Sharmila Dorbala \/ Attralus"},{"orgOrder":0,"company":"Gritgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GS1191-0445","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Gritgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Gritgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gritgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Cellavita","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Mesenchymal Stem Cell","moa":"Stem cell proliferation","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Azidus Brazil \/ Cellavita","highestDevelopmentStatusID":"9","companyTruncated":"Azidus Brazil \/ Cellavita"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Glycomine","sponsor":"CTI Life Sciences Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ CTI Life Sciences Fund","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ CTI Life Sciences Fund"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BBM-H901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Belief BioMed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belief BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Idursulfase","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The Lundquist Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"The Lundquist Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"The Lundquist Institute \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"The Lundquist Institute \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.32000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.32000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Idursulfase","moa":"||IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Private Placement","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0.5,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tividenofusp Alfa","moa":"IDS*","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Tividenofusp Alfa","moa":"IDS*","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CSL889","moa":"Hemojuvelin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Mereo BioPharma Group"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"PF-06939926","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Acquisition","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Sanofi"},{"orgOrder":0,"company":"ApcinteX","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SerpinPC","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ApcinteX","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ApcinteX \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"ApcinteX \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Stichting European Myeloma Network","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stichting European Myeloma Network","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Stichting European Myeloma Network \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"Stichting European Myeloma Network \/ GSK"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AOC-1020","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Rezolute","sponsor":"Cam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Private Placement","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Cam Capital","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Cam Capital"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Public Offering","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Jefferies"},{"orgOrder":0,"company":"Rezolute","sponsor":"SLR Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Financing","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ SLR Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ SLR Capital Partners"},{"orgOrder":0,"company":"XOMA","sponsor":"Rezolute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"XOMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"XOMA \/ Rezolute","highestDevelopmentStatusID":"8","companyTruncated":"XOMA \/ Rezolute"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Annexon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ANX005","moa":"Complement C1s component (C1S)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Annexon Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Annexon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Annexon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Keystone Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Financing","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Keystone Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Keystone Capital Partners"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Private Placement","leadProduct":"Pepinemab","moa":"Semaphorin-4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Jefferies"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibody","year":"2020","type":"Collaboration","leadProduct":"Setrusumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Public Offering","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Scholar Rock","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ J.P. Morgan"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Private Placement","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Adage Capital Partners"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Ensoma","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ensoma \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Ensoma \/ Bluebird Bio"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Sarepta Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Cardiosphere-Derived Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Capricor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Capricor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Capricor Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Capricor Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Lonza Group \/ Capricor Therapeutics"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Olipudase Alfa","moa":"Sphingomyelin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Brogidirsen","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Delpacibart Etedesiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"GC Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ GC Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ GC Biopharma"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Ascension Healthcare Development","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Pegylated Liposome","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ascension Healthcare Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ascension Healthcare Development \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ascension Healthcare Development \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"I124-AT01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AOC-1001","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Novikang Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Novikang Medical Technology","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Novikang Medical Technology"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AT02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AOC-1044","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Steminent US, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Adipose-Derived Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Steminent US, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Steminent US, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Steminent US, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-CLS-628","moa":"CD3\/CLDN18.2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VX-670","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DNL126","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"DNL126","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Valoctocogene Roxaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ensoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ensoma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT190","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-02","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ACTUS-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SPK-8011","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Syncona Portfolio Limited"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Portfolio Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Portfolio Limited","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ Syncona Portfolio Limited"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"University College London","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ University College London","highestDevelopmentStatusID":"9","companyTruncated":"Spur Therapeutics \/ University College London"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"The Dion Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Partnership","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ The Dion Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ The Dion Foundation"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Citigroup","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Private Placement","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Citigroup","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Citigroup"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Public Offering","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Jefferies","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Jefferies"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"SGT-001","moa":"Micro-dystrophin gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Cirm"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"UX053","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"UX053","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-DM1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-N531","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Regenxbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RGX-202","moa":"Solute carrier family 6 member 8 (SLC6A8)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regenxbio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regenxbio \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regenxbio \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"HMI-102","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Homology Medicines","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Injection","sponsorNew":"Homology Medicines \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Homology Medicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"AOC-1020","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Columbia University","sponsor":"ITBMed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Siplizumab","moa":"T-cell surface antigen CD2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Columbia University \/ ITBMed","highestDevelopmentStatusID":"7","companyTruncated":"Columbia University \/ ITBMed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Etentamig","moa":"CD3E","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Clarametyx Biosciences","sponsor":"KAMRA Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Funding","leadProduct":"CMTX-101","moa":"Bacterial biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Clarametyx Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Clarametyx Biosciences \/ KAMRA Fund","highestDevelopmentStatusID":"7","companyTruncated":"Clarametyx Biosciences \/ KAMRA Fund"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jasper Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Delpacibart Zotadirsen","moa":"Dystrophin exon-44","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Public Offering","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Cowen","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Cowen"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2023","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2024","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Public Offering","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.37,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VTX-801","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kamau Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nula-Cel","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Kamau Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Kamau Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Kamau Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"EDIT-301","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AB-1003","moa":"FKRP","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SAR444836","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Shanghai MYGT Biopharmaceutical LLC","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BBM-H803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Belief BioMed \/ Shanghai MYGT Biopharmaceutical LLC","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Shanghai MYGT Biopharmaceutical LLC"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Lantu Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Vesemnogene Lantuparvovec","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lantu Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Lantu Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lantu Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBP-631","moa":"Steroid 21-hydroxylase (CYP21A2)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BBP-631","moa":"Steroid 21-hydroxylase (CYP21A2)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AccurEdit Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ART001","moa":"Amyloidogenic TTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AccurEdit Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AccurEdit Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AccurEdit Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Kamau Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Kamau Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Kamau Therapeutics"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Aruvant Sciences","sponsor":"Sickle Cell Disease Association Of America","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aruvant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aruvant Sciences \/ Sickle Cell Disease Association Of America","highestDevelopmentStatusID":"7","companyTruncated":"Aruvant Sciences \/ Sickle Cell Disease Association Of America"},{"orgOrder":0,"company":"Lonza Group","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2021","type":"Agreement","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lonza Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lonza Group \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Lonza Group \/ Aruvant Sciences"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HGB-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentiglobin","moa":"Hemoglobin subunit beta (HBB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CRISPR Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"CRISPR Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CRISPR Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"DRI Healthcare Trust","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ DRI Healthcare Trust","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ DRI Healthcare Trust"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Busulfan","moa":"||CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Memorial Sloan Kettering Cancer Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Memorial Sloan Kettering Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Memorial Sloan Kettering Cancer Center \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Memorial Sloan Kettering Cancer Center \/ Inapplicable"},{"orgOrder":0,"company":"Aldevron","sponsor":"Aruvant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"ARU-1801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aldevron \/ Aruvant Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Aldevron \/ Aruvant Sciences"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Partnership","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-04","moa":"Cystinosin (CTNS)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avrobio \/ University of California","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ University of California"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Cornell University","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Cornell University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Cornell University \/ Lexeo Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Cornell University \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Viralgen","sponsor":"Sio Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"AXO-AAV-GM1","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Viralgen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Viralgen \/ Sio Gene Therapies","highestDevelopmentStatusID":"7","companyTruncated":"Viralgen \/ Sio Gene Therapies"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"National Human Genome Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM1","moa":"||Beta-galactosidase (GLB1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sio Gene Therapies \/ National Human Genome Research Institute","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ National Human Genome Research Institute"},{"orgOrder":0,"company":"Audentes Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Audentes Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Audentes Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Audentes Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AT845","moa":"Lysosomal alpha-glucosidase (GAA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"AAV2\/8LSPhGAA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":4,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":4,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"AskBio","sponsor":"Scottish Enterprise","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AAV2\/8LSPhGAA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Scottish Enterprise","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Scottish Enterprise"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ASC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Expanded Collaboration","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Charles River Laboratories, Inc \/ ASC Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Charles River Laboratories, Inc \/ ASC Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BAY2599023","moa":"Coagulation factor VIII (F8)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bayer AG \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Bayer AG \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BBM-H803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Belief BioMed \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AAV5-hFIX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Financing","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Arch Ventures","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Arch Ventures"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Nextech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Nextech","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Nextech"},{"orgOrder":0,"company":"Thermo Fisher Scientific","sponsor":"Spur Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Verbrinacogene Setparvovec","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Thermo Fisher Scientific","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Thermo Fisher Scientific \/ Spur Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Thermo Fisher Scientific \/ Spur Therapeutics"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VTX-801","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VTX-801","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Vivet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"VTX-801","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Pfizer Inc \/ Vivet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Pfizer Inc \/ Vivet Therapeutics"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Marnetegragene Autotemcel","moa":"ITGB2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"UX111","moa":"AAV9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Bidridistrogene Xeboparvovec","moa":"SGCB","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1003","moa":"FKRP","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AB-1003","moa":"FKRP","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"AskBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LION-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AskBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AskBio \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Avalotcagene Ontaparvovec","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"iECURE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ iECURE","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ iECURE"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ECUR-506","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Medicinova","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SAR444836","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Medicinova \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Medicinova \/ Sanofi"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Cirm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Cirm","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Cirm"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Mustang Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sirion Biotech \/ Mustang Bio","highestDevelopmentStatusID":"7","companyTruncated":"Sirion Biotech \/ Mustang Bio"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Busulfan","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MB-207","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Minaris Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"MB-107","moa":"||IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Minaris Regenerative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Minaris Regenerative Medicine"},{"orgOrder":0,"company":"Sangamo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Isaralgagene Civaparvovec","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sangamo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sangamo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sangamo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"JR-171","moa":"Dermatan sulfate hydrolytic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"CAN103","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alpha","moa":"A2AR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Lepunafusp Alpha","moa":"Dermatan sulfate hydrolytic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"WRAIR_EPa11","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adaptive Phage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2022","type":"Inapplicable","leadProduct":"WRAIR_EPa11","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"BMN 351","moa":"DMD exon 51","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASC61","moa":"PD-L1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ASC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oncopeptides","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Melphalan Flufenamide","moa":"||DNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Oncopeptides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oncopeptides \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Oncopeptides \/ Inapplicable"},{"orgOrder":0,"company":"Sapience Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Irinotecan","moa":"||Wnt\/beta-catenin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sapience Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sapience Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sapience Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vesleteplirsen","moa":"Dystrophin expression","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AM-Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Ilofotase Alfa","moa":"ALPI","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AM-Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"AM-Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AM-Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Centessa Pharmaceuticals","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Oberland Capital Management","highestDevelopmentStatusID":"7","companyTruncated":"Centessa Pharmaceuticals \/ Oberland Capital Management"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"ApcinteX","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ ApcinteX","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ ApcinteX"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Serpinpc","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Tividenofusp Alpha","moa":"IDS","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Leiden University Medical Centre","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Leiden University Medical Centre","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Leiden University Medical Centre"},{"orgOrder":0,"company":"Denali Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Tividenofusp Alfa","moa":"IDS*","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Denali Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Denali Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Denali Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"STI-6129","moa":"CD38","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adrenas Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AAV BBP-631","moa":"AAV","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adrenas Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Adrenas Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Adrenas Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AOC-1001","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Vitalgen BioPharma Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VGB-R04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Shanghai Vitalgen BioPharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Vitalgen BioPharma Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Shanghai Vitalgen BioPharma Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LY3884961","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AOC-1044","moa":"DMD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sqy Therapeutics","sponsor":"Biotrial","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SQY51","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sqy Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sqy Therapeutics \/ Biotrial","highestDevelopmentStatusID":"7","companyTruncated":"Sqy Therapeutics \/ Biotrial"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VX-670","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Solution","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Intellia Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"REGV131","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Intellia Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Intellia Therapeutics"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BEAM-301","moa":"GAA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lingyi Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LY-M001","moa":"SARS-CoV-2 spike protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lingyi Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lingyi Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lingyi Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SAR446268","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-203","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HMI-203","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Novotech"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Hansa Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Hansa Biopharma","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Hansa Biopharma"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spur Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"FLT201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spur Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Spur Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"7","companyTruncated":"Spur Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"ATA-200","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atamyo Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Atamyo Therapeutics \/ Bpifrance"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Homology Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"HMI-103","moa":"PAH gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Homology Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Homology Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Homology Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexcella \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"DMD*","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Inhibrx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"INBRX-101","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inhibrx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Inhibrx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inhibrx \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vega Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vega Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Argenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ARGX-119","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Argenx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Argenx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Argenx \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":1.2,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.2,"dosageForm":"Intravenous Infusion","sponsorNew":"Prothena \/ Novo Nordisk","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Novo Nordisk"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Star Therapeutics","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series C Financing","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Star Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravenous Injection","sponsorNew":"Star Therapeutics \/ Sofinnova Investments","highestDevelopmentStatusID":"6","companyTruncated":"Star Therapeutics \/ Sofinnova Investments"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Antibody-protein Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Verenafusp Alfa","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTQ923","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"Cure Rare","sponsor":"University of Massachusetts, Worcester","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CRD-TMH-001","moa":"Dystrophin protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cure Rare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cure Rare \/ University of Massachusetts, Worcester","highestDevelopmentStatusID":"6","companyTruncated":"Cure Rare \/ University of Massachusetts, Worcester"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SRP-9003","moa":"Beta-sarcoglycan (SGCB)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SRP-6004","moa":"Dysferlin (DYSF)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SRP-9004","moa":"Sarcoglycan alpha (SGCA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sarepta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sarepta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Minovia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MNV-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Minovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Minovia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Minovia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Bluebird Bio"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Magenta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"MGTA-145","moa":"||CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Magenta Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Magenta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Magenta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ENCell","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ENCell","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ENCell \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ENCell \/ Inapplicable"},{"orgOrder":0,"company":"Gritgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GS1191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gritgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Gritgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gritgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Verve Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"VERVE-101","moa":"PCSK9","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Verve Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Verve Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Verve Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Titan Partners Group LLC","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Dystrophin Expressing Chimeric Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Dystrogen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genethon","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"GNT0004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genethon \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/ Inapplicable"},{"orgOrder":0,"company":"Rubius Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RTX-134","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rubius Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rubius Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rubius Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L301","moa":"PKLR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"RP-L301","moa":"PKLR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rocket Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Immix Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NXC-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Immix Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Immix Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Immix Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ISU ABXIS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Abcertin","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ISU ABXIS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"ISU ABXIS \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ISU ABXIS \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Public Offering","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ BofA Securities"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Janus Henderson Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Janus Henderson Investors","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Janus Henderson Investors"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"YOLT-201","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DT-216","moa":"FXN transcription","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CSL889","moa":"Hemojuvelin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CD68-ET3-LV Gene Therapy","moa":"CD68","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Expression Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Expression Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GNR-055","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"STI-6129","moa":"CD38","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Sorrento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sorrento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ExoRNA Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ER2001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ExoRNA Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"ExoRNA Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ExoRNA Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"923rd Hospital of Joint Logistics Support Force of PLA","sponsor":"Reforgene Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"RM-004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"923rd Hospital of Joint Logistics Support Force of PLA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"923rd Hospital of Joint Logistics Support Force of PLA \/ Reforgene Medicine","highestDevelopmentStatusID":"6","companyTruncated":"923rd Hospital of Joint Logistics Support Force of PLA \/ Reforgene Medicine"},{"orgOrder":0,"company":"Shanghai BDgene Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BD211","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shanghai BDgene Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Shanghai BDgene Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai BDgene Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ASP2016","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai Mianyi Biopharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BBM-D101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Shanghai Mianyi Biopharmaceutical Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Shanghai Mianyi Biopharmaceutical Co., Ltd."},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"PYC-003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series C Financing","leadProduct":"4D-310","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"4D Molecular Therapeutics \/ Viking Global Investors","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Viking Global Investors"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prime Medicine","amount2":0.13,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Public Offering","leadProduct":"PM359","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prime Medicine","amount2":0.16,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Intravenous Infusion","sponsorNew":"Prime Medicine \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Prime Medicine \/ J.P. Morgan"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"UX701","moa":"Copper-transporting ATPase 2 (ATP7B)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Forge Biologics","sponsor":"Perceptive Xontogeny Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"FBX-101","moa":"Galactocerebrosidase (GALC)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Forge Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Forge Biologics \/ Perceptive Xontogeny Venture Fund","highestDevelopmentStatusID":"7","companyTruncated":"Forge Biologics \/ Perceptive Xontogeny Venture Fund"},{"orgOrder":0,"company":"Ensoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ensoma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aro Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ABX1100","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Aro Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Aro Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aro Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Nulabeglogene Autogedtemcel","moa":"CRISPR\/HiFi Cas9","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Graphite Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Graphite Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Graphite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Azzur Group","sponsor":"Editas Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Renizgamglogene Autogedtemcel","moa":"CD34+","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Azzur Group","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Azzur Group \/ Editas Medicine","highestDevelopmentStatusID":"7","companyTruncated":"Azzur Group \/ Editas Medicine"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-191","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Lexeo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Adverum Biotechnologies \/ Lexeo Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ Lexeo Therapeutics"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-212","moa":"FXN","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SGT-212","moa":"FXN","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ASC618","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ASC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ASC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"ENTLEP001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entos Pharmaceuticals \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Entos Pharmaceuticals \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"GEN6050X","moa":"E50","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Suzhou GenAssist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mustang Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"MB-107","moa":"IL-2-gamma receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Mustang Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Mustang Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Mustang Bio \/ Inapplicable"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"MB-111","moa":"APOC-3","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Mammoth Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Mammoth Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Mammoth Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"WuXi Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"glucocerebrosidase","moa":"Glucocerebrosidase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CANbridge Pharmaceuticals \/ WuXi Biologics","highestDevelopmentStatusID":"8","companyTruncated":"CANbridge Pharmaceuticals \/ WuXi Biologics"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"DTx Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Acquisition","leadProduct":"DTx-1252","moa":"PMP22","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":1,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":1,"dosageForm":"Intravenous Injection","sponsorNew":"DTx Pharma \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Medipal Holdings Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"JCR Pharmaceuticals \/ Medipal Holdings Corporation","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Medipal Holdings Corporation"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"D1 Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ D1 Capital Partners","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ D1 Capital Partners"},{"orgOrder":0,"company":"Lexeo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LX2006","moa":"FXN","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lexeo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Lexeo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lexeo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ensoma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Ensoma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Partnership","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Forge Biologics","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Forge Biologics"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Solid Biosciences","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Private Placement","leadProduct":"SGT-003","moa":"Microdystrophin DNA sequence","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Solid Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Solid Biosciences \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Solid Biosciences \/ Perceptive Advisors"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"KRRO-110","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Korro Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Korro Bio \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Inclacumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jasper Therapeutics","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"Briquilimab","moa":"KIT","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jasper Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jasper Therapeutics \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"Jasper Therapeutics \/ Avrobio"},{"orgOrder":0,"company":"Attralus","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Series A Financing","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Attralus \/ Venbio Partners","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Venbio Partners"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Ersodetug","moa":"INSR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-251","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Myotonic Dystrophy Clinical Research Network","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2020","type":"Collaboration","leadProduct":"Del-Desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Myotonic Dystrophy Clinical Research Network"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2021","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"DYNE-101","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-3001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"VY-FXN01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.8700000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.8700000000000001,"dosageForm":"Intravenous Injection","sponsorNew":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"iqDNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Orchard Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Oxford Biomedica \/ Orchard Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ Orchard Therapeutics"},{"orgOrder":0,"company":"Capsida","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CAP-001","moa":"IDS","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Capsida \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Delandistrogene Moxeparvovec","moa":"||DMD*","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Genethon","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"GNT0004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Genethon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Genethon \/ Sarepta Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Genethon \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-0231.F","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"NT-0231.F","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"PGN-EDO53","moa":"Exon-53","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Financing","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Public Offering","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17999999999999999,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Entrada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDODM1","moa":"Exon51 skipping","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Vera Therapeutics","sponsor":"NeuBase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Acquisition","leadProduct":"NT0200","moa":"DMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vera Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Vera Therapeutics \/ NeuBase Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Vera Therapeutics \/ NeuBase Therapeutics"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"NT0200","moa":"DMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"NT0200","moa":"DMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"NeuBase Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NeuBase Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tessera Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tessera Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Intravenous Injection","sponsorNew":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Tessera Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-203","moa":"Alpha-L-iduronidase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shaare Zedek Medical Center","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Taliglucerase Alfa","moa":"Glucocerebroside","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Shaare Zedek Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Shaare Zedek Medical Center \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Shaare Zedek Medical Center \/ Pfizer Inc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Idursulfase","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai BDgene Co., Ltd.","sponsor":"Shanghai Children's Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"BD211","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shanghai BDgene Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Shanghai BDgene Co., Ltd. \/ Shanghai Children's Medical Center","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai BDgene Co., Ltd. \/ Shanghai Children's Medical Center"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAK-577","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"MED Institute Inc.","sponsor":"Signature Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Human Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MED Institute Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"MED Institute Inc. \/ Signature Biologics","highestDevelopmentStatusID":"1","companyTruncated":"MED Institute Inc. \/ Signature Biologics"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"HG302","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","sponsor":"Mabwell","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"MWAV201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Mabwell","highestDevelopmentStatusID":"1","companyTruncated":"Xinhua Hospital, Shanghai Jiaotong University School of Medicine \/ Mabwell"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Sepul Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Ultevursen","moa":"usherin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Laboratoires Thea \/ Sepul Bio","highestDevelopmentStatusID":"9","companyTruncated":"Laboratoires Thea \/ Sepul Bio"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Sepul Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"QR-421a","moa":"Usherin messenger RNA (USH2A mRNA)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Laboratoires Thea \/ Sepul Bio","highestDevelopmentStatusID":"9","companyTruncated":"Laboratoires Thea \/ Sepul Bio"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KIO-301","moa":"DHODH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"jCyte","sponsor":"Center for Breakthrough Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Center for Breakthrough Medicines","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Center for Breakthrough Medicines"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"Santen Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"Allogeneic Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Santen Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Santen Pharmaceutical"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Nanoscope Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Charles River Laboratories, Inc \/ Nanoscope Therapeutics"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Verana Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Verana Health","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Verana Health"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Sepul Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Laboratoires Thea \/ Sepul Bio","highestDevelopmentStatusID":"8","companyTruncated":"Laboratoires Thea \/ Sepul Bio"},{"orgOrder":0,"company":"Laboratoires Thea","sponsor":"Sepul Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Ultevursen","moa":"usherin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Laboratoires Thea","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Laboratoires Thea \/ Sepul Bio","highestDevelopmentStatusID":"9","companyTruncated":"Laboratoires Thea \/ Sepul Bio"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"jCyte","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"jCyte","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Human Retinal Progenitor Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"jCyte","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"jCyte \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"jCyte \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PYC-001","moa":"OPA1\/Tubulin\/VEGF","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kiora Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KIO-301","moa":"DHODH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kiora Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Kiora Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kiora Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"4D-125","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-125","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"4D-125","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Coave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Laboratoires Thea","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Intravitreal Injection","sponsorNew":"Coave Therapeutics \/ Laboratoires Thea","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Laboratoires Thea"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GS030","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"GenSight Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"GS030","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GenSight Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"GenSight Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GenSight Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Sonpiretigene Isteparvovec","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy-1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"QR-421a","moa":"Usherin messenger RNA (USH2A mRNA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ProQR Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ProQR Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"PYC-001","moa":"OPA1\/Tubulin\/VEGF","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ray Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ray Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Ray Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Aldeyra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Accelagen","sponsor":"Kiora Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KIO-301","moa":"DHODH","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Accelagen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Accelagen \/ Kiora Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Accelagen \/ Kiora Pharmaceuticals"},{"orgOrder":0,"company":"Zhongmou Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ZM-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Zhongmou Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Zhongmou Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhongmou Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InnoVec Biotherapeutics","sponsor":"Peking Union Medical College Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"IVB102","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"InnoVec Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"InnoVec Biotherapeutics \/ Peking Union Medical College Hospital","highestDevelopmentStatusID":"6","companyTruncated":"InnoVec Biotherapeutics \/ Peking Union Medical College Hospital"},{"orgOrder":0,"company":"Zhongmou Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ZM-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Zhongmou Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Zhongmou Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhongmou Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Adverum Biotechnologies","sponsor":"Ray Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"AAV.7m8","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Adverum Biotechnologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Adverum Biotechnologies \/ Ray Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Adverum Biotechnologies \/ Ray Therapeutics"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Ray Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Novo Holding","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Series A Financing","leadProduct":"RTx-015","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ray Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Novo Holding","highestDevelopmentStatusID":"6","companyTruncated":"Ray Therapeutics \/ Novo Holding"},{"orgOrder":0,"company":"WuXi Biologics","sponsor":"ViGeneron","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2020","type":"Partnership","leadProduct":"VG901","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"WuXi Biologics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"WuXi Biologics \/ ViGeneron","highestDevelopmentStatusID":"5","companyTruncated":"WuXi Biologics \/ ViGeneron"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ViGeneron \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"ViGeneron \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Biogen"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Financing","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ 4BIO Capital","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ 4BIO Capital"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Funding","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"Ray-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ray Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Ray Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Ray Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"vMCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"VMCO-I","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy-1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"STK-002","moa":"Optic atrophy-1 protein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai General Hospital","sponsor":"Innostellar Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LX103","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Shanghai General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"Shanghai General Hospital \/ Innostellar Biotherapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai General Hospital \/ Innostellar Biotherapeutics"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Recordati Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Recordati Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Recordati Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Recordati Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Leadiant Biosciences","sponsor":"AllianceRx Walgreens","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Cysteamine Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Leadiant Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Leadiant Biosciences \/ AllianceRx Walgreens","highestDevelopmentStatusID":"15","companyTruncated":"Leadiant Biosciences \/ AllianceRx Walgreens"},{"orgOrder":0,"company":"Endogena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"EA-2353","moa":"Progenitor cell","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Endogena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Suspension","sponsorNew":"Endogena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Endogena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"HG004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Ophthalmic Injection","sponsorNew":"HuidaGene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"ARYA Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.59999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.59999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ ARYA Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ ARYA Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"MSN Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ MSN Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ MSN Laboratories"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Blackstone Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theravia","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cytotoxic Drug","year":"2025","type":"Acquisition","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Theravia \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Theravia \/ Norgine"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lobe Sciences","sponsor":"Pentec Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Dietary Supplement","year":"2023","type":"Agreement","leadProduct":"DHA","moa":"DHA level","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lobe Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lobe Sciences \/ Pentec Health","highestDevelopmentStatusID":"15","companyTruncated":"Lobe Sciences \/ Pentec Health"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Optum Frontier Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Partnership","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Optum Frontier Therapies","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Optum Frontier Therapies"},{"orgOrder":0,"company":"Zevra Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Zevra Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Zevra Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Zevra Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Suspension","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Christopher Schelling","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Christopher Schelling","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Christopher Schelling"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Zevra Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Zevra Therapeutics"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pint Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Erkim","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"TURKEY","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Erkim","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Erkim \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Erkim \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Pint Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Pint Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Pint Pharma"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Swixx BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Swixx BioPharma"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Pharmaceuticals","sponsor":"KYE Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Catalyst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Catalyst Pharmaceuticals \/ KYE Pharmaceuticals"},{"orgOrder":0,"company":"Sperogenix Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sperogenix Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Sperogenix Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ASTE","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ASTE","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ASTE"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"GENESIS Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ GENESIS Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ GENESIS Pharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"R-Bridge Healthcare Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ R-Bridge Healthcare Fund"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Clinigen Group","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Clinigen Group"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Asembia","sponsor":"Emmaus Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Asembia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Asembia \/ Emmaus Life Sciences","highestDevelopmentStatusID":"15","companyTruncated":"Asembia \/ Emmaus Life Sciences"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":1.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":1.5,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Spinal Muscular Atrophy Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Spinal Muscular Atrophy Foundation"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.48999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.48999999999999999,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":5.4000000000000004,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":5.4000000000000004,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":5.4000000000000004,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Global Blood Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Global Blood Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Horizon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cysteamine Bitartrate","moa":"Cystine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Horizon Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"Horizon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Horizon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jadeite Medicines","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jadeite Medicines","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jadeite Medicines"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Divestment","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Jefferies"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"PANTHERx Rare Pharmacy","sponsor":"ITF Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PANTHERx Rare Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PANTHERx Rare Pharmacy \/ ITF Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"PANTHERx Rare Pharmacy \/ ITF Therapeutics"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Medis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Medis","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Medis"},{"orgOrder":0,"company":"Duchesnay","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Duchesnay","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Duchesnay \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Duchesnay \/ Inapplicable"},{"orgOrder":0,"company":"SYSNAV Healthcare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"SYSNAV Healthcare","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"SYSNAV Healthcare \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SYSNAV Healthcare \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Satiogen","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Satiogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Satiogen \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Satiogen \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"CANbridge Pharmaceuticals \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Trientine Tetrahydrochloride","moa":"#N\/A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trientine Tetrahydrochloride","moa":"#N\/A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine Tetrahydrochloride","moa":"#N\/A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine Tetrahydrochloride","moa":"#N\/A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Trientine Tetrahydrochloride","moa":"#N\/A","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Deutetrabenazine","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"15","companyTruncated":"Jiangsu Nhwa Pharmaceutical \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Teva Pharmaceutical Industries \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Diurnal Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Steroid","year":"2022","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"EffRx Pharmaceuticals \/ Diurnal Group","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Diurnal Group"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deutivacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Aptar Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Pharmaxis \/ Aptar Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Pharmaxis \/ Aptar Pharma"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Australian Pharmaceutical Benefits Scheme","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Australian Pharmaceutical Benefits Scheme","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Australian Pharmaceutical Benefits Scheme"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Aifa","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Aifa","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Aifa"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"French Health Authorities For The Cystic Fibrosis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ French Health Authorities For The Cystic Fibrosis","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ French Health Authorities For The Cystic Fibrosis"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Spanish Government","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Spanish Government","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Spanish Government"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":7.2999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":7.2999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":7.2999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":7.2999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Zinc Acetate Dihydrate","moa":"Intestinal cell metallothionein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Teva Pharmaceutical Industries \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Medis","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SLOVENIA","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medis","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Medis \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Medis \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"AVAS Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ AVAS Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ AVAS Pharmaceuticals"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Celnova Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Celnova Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Celnova Pharma"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Torrent Pharmaceuticals Limited","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dichlorphenamide","moa":"Carbonic anhydrase I | Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Torrent Pharmaceuticals Limited"},{"orgOrder":0,"company":"Strongbridge Biopharma","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Dichlorphenamide","moa":"Carbonic anhydrase I | Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Strongbridge Biopharma","amount2":0.27000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.27000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Strongbridge Biopharma \/ Xeris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Strongbridge Biopharma \/ Xeris Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Fsio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lumacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Fsio","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Fsio"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ AnGes"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"AnGes","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ AnGes","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ AnGes"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Sentynl Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Sentynl Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Sentynl Therapeutics"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"The Progeria Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ The Progeria Research Foundation"},{"orgOrder":0,"company":"KYE Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KYE Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"KYE Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KYE Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Breckenridge Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Aggrega Pharma","sponsor":"Breckenridge Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aggrega Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Aggrega Pharma \/ Breckenridge Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Aggrega Pharma \/ Breckenridge Pharmaceutical"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Granules India Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Penicillamine","moa":"Copper","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dichlorphenamide","moa":"Carbonic anhydrase I | Carbonic anhydrase II | Carbonic anhydrase XII | Carbonic anhydrase IV","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Torrent Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"Oakrum Pharma, LLC","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Oakrum Pharma, LLC","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Oakrum Pharma, LLC \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Analog Pharma","sponsor":"Dipharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Analog Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Analog Pharma \/ Dipharma","highestDevelopmentStatusID":"15","companyTruncated":"Analog Pharma \/ Dipharma"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Immediate-Release Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"One-Two Therapeutics Assets Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Termination","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ One-Two Therapeutics Assets Limited"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Solution","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Pancrelipase","moa":"Fatty acids | Starch | Polypeptides","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Delayed Release","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Emmaus Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Emmaus Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Emmaus Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Emmaus Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"QOL Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Sacrosidase","moa":"Sucrose","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"QOL Medical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"QOL Medical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"QOL Medical \/ Inapplicable"},{"orgOrder":0,"company":"Paul Beringer","sponsor":"Paratek Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Omadacycline","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Paul Beringer","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Paul Beringer \/ Paratek Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Paul Beringer \/ Paratek Pharmaceuticals"},{"orgOrder":0,"company":"Taipei Veterans General Hospital","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BH4","moa":"Phenylalanine hydroxylase (PAH)","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Taipei Veterans General Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taipei Veterans General Hospital \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"Taipei Veterans General Hospital \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Elizabeth Yang","sponsor":"Pediatrix | University of California, San Francisco | Global Blood Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Elizabeth Yang","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Elizabeth Yang \/ Pediatrix | University of California, San Francisco | Global Blood Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Elizabeth Yang \/ Pediatrix | University of California, San Francisco | Global Blood Therapeutics"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Indiana Hemophilia &Thrombosis Center, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Indiana Hemophilia &Thrombosis Center, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hannover Medical School","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Hannover Medical School","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Hannover Medical School \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"11","companyTruncated":"Hannover Medical School \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"NHS England","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"NHS England","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"NHS England \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"NHS England \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"DISC-1459","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Prilenia \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ipsen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ipsen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ipsen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ipsen \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Discovery Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Discovery Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Discovery Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Discovery Partners \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Palladio Biosciences","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Biosciences \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Biosciences \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tasimelteon","moa":"Melatonin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lucerastat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Lucerastat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Idorsia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Morningside Ventures","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Morningside Ventures"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Sands Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Sands Capital","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Sands Capital"},{"orgOrder":0,"company":"Prilenia therapeutics","sponsor":"Ferrer Internacional","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Prilenia therapeutics","amount2":0.56999999999999995,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56999999999999995,"dosageForm":"Oral Hard Capsule","sponsorNew":"Prilenia therapeutics \/ Grupo Ferrer Internacional","highestDevelopmentStatusID":"10","companyTruncated":"Prilenia therapeutics \/ Grupo Ferrer Internacional"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"NICE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ NICE","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ NICE"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"ABCC8(SUR1)\/KCNJ11(KIR6.2)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Kyowa Kirin","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Kyowa Kirin","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Kyowa Kirin"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"FCN-159","moa":"MEK1 \/ MEK2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fosun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Partnership","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ CPRIT","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ CPRIT"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"RAD011","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Global Health Uganda","sponsor":"Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cytotoxic Drug","year":"2021","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Global Health Uganda","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Global Health Uganda \/ Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Global Health Uganda \/ Columbia University | The University of Pittsburgh School of Medicine | Gabrail Cancer Center Research | Mulago Hospital, Uganda | Makerere University | Gansu Provincial Maternal and Child Health Care Hospital"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Dornase Alfa","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SYNB1934","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Science 37 Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Partnership","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Science 37 Holdings","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Science 37 Holdings"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Dispersible","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lumacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Huntington Study Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Huntington Study Group","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Huntington Study Group"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Coagulation factor IIa (F2)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Maggie's Pearl","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Epalrestat","moa":"Aldose reductase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Maggie's Pearl","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maggie's Pearl \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Maggie's Pearl \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PXT3003","moa":"PMP22 overexpression","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Tianjin Tasly Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tianjin Tasly Group \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"ML Bio Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ML Bio Solutions","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ML Bio Solutions \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ML Bio Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Lupin Ltd"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Lupin Ltd \/ Lupin Ltd","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Lupin Ltd"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"IntraBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"N-Acetyl-L-Leucine","moa":"Calcium channel","graph1":"Genetic Disease","graph2":"Phase III","graph3":"IntraBio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granules for Suspension","sponsorNew":"IntraBio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"IntraBio \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Ardelyx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tenapanor","moa":"Sodium\/hydrogen exchanger 3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Massachusetts General Hospital \/ Ardelyx","highestDevelopmentStatusID":"10","companyTruncated":"Massachusetts General Hospital \/ Ardelyx"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Relief Therapeutics \/ Acer Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Relief Therapeutics \/ Acer Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Marathon Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Marathon Asset Management","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Marathon Asset Management"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2022","type":"Expanded Collaboration","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"Centogene","sponsor":"Agios Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centogene","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Centogene \/ Agios Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Centogene \/ Agios Pharmaceuticals"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Torii Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Torii Pharmaceutical"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Albireo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Albireo Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco S.p.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Italfarmaco S.p.A","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco S.p.A \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Italfarmaco S.p.A \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Nitisinone","moa":"4-hydroxyphenylpyruvate dioxygenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.19,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.19,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Alpha Blue Ocean","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Inapplicable"},{"orgOrder":0,"company":"Pharnext","sponsor":"Neovacs","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharnext","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Solution","sponsorNew":"Pharnext \/ Neovacs","highestDevelopmentStatusID":"10","companyTruncated":"Pharnext \/ Neovacs"},{"orgOrder":0,"company":"Charcot Marie Tooth Association","sponsor":"Pharnext","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Baclofen","moa":"||GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Charcot Marie Tooth Association","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Charcot Marie Tooth Association \/ Pharnext","highestDevelopmentStatusID":"10","companyTruncated":"Charcot Marie Tooth Association \/ Pharnext"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Canaccord Genuity","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Canaccord Genuity"},{"orgOrder":0,"company":"Aytu BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aytu BioPharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Aytu BioPharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aytu BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allos Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allos Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Allos Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Allos Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Allos Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Seaside Therapeutics \/ Allos Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Allos Pharma"},{"orgOrder":0,"company":"Galactosemia Foundation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Galactosemia Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Galactosemia Foundation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Galactosemia Foundation \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Advanz Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Advanz Pharma"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Perceptive Advisors","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Perceptive Advisors"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ SVB Securities"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Venrock Healthcare Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Venrock Healthcare Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Venrock Healthcare Capital Partners"},{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Monopar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Huntington Study Group","sponsor":"Prilenia therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Pridopidine","moa":"Dopamine D2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Huntington Study Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Huntington Study Group \/ Prilenia therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Huntington Study Group \/ Prilenia therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Inapplicable"},{"orgOrder":0,"company":"The Italfarmaco Group","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"The Italfarmaco Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"The Italfarmaco Group \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"The Italfarmaco Group \/ Syneos Health"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Idebenone","moa":"CYP450-2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"CYP450-2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"CYP450-2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"CYP450-2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Idebenone","moa":"CYP450-2C9","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Blackstone Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palladio Zannini Industrie","sponsor":"Samsara BioCapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palladio Zannini Industrie","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Palladio Zannini Industrie \/ Samsara BioCapital","highestDevelopmentStatusID":"10","companyTruncated":"Palladio Zannini Industrie \/ Samsara BioCapital"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series A Financing","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ General Atlantic"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Lixivaptan","moa":"Vasopressin V2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Centessa Pharmaceuticals","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Oral Capsule","sponsorNew":"Centessa Pharmaceuticals \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Centessa Pharmaceuticals \/ Morgan Stanley"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Adage Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Adage Capital Partners","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Adage Capital Partners"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Folia Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Folia Health","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Folia Health"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Nantahala Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Nantahala Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Nantahala Capital Management"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oppenheimer & Co. Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oppenheimer & Co. Inc.","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oppenheimer & Co. Inc."},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Oxford Finance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Oxford Finance","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Oxford Finance"},{"orgOrder":0,"company":"Soleno Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Diazoxide","moa":"Potassium channel, inwardly rectifying, subfamily J, member 8 | Potassium channel, inwardly rectifying, subfamily J, member 11","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Soleno Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Soleno Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"10","companyTruncated":"Soleno Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Coagulation factor IIa (F2)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Medicure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pyridoxal Phosphate","moa":"Coagulation factor IIa (F2)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Medicure","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Medicure \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Medicure \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Ataxia Foundation","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"National Ataxia Foundation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"National Ataxia Foundation \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"National Ataxia Foundation \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Benchmark Company"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"The Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ The Benchmark Company","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ The Benchmark Company"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Blue Owl Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0.5,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.5,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Blue Owl Capital","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Blue Owl Capital"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BridgeBio Pharma","amount2":0.25,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ J.P. Morgan","highestDevelopmentStatusID":"15","companyTruncated":"BridgeBio Pharma \/ J.P. Morgan"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"Acoramidis HCl","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Bayer AG"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Netherlands Enterprise Agency","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Funding","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Solution","sponsorNew":"Khondrion \/ Netherlands Enterprise Agency","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ Netherlands Enterprise Agency"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Taiho Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAS-205","moa":"15-LOX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Taiho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Taiho Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Taiho Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAK-625","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Cancer Prevention Pharmaceuticals","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Cancer Prevention Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Cancer Prevention Pharmaceuticals \/ Panbela Therapeutics"},{"orgOrder":0,"company":"Panbela Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Eflornithine Hydrochloride","moa":"||Ornithine decarboxylase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Panbela Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Panbela Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Panbela Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Kubota Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Emixustat Hydrochloride","moa":"Retinoid isomerohydrolase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kubota Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Kubota Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kubota Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis","moa":"TTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"DISC-1459","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osivelotor","moa":"Hemoglobin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Osivelotor","moa":"Hemoglobin","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"RAD011","moa":"CB1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Vanderbilt University Medical Center","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deutetrabenazine","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Vanderbilt University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Vanderbilt University Medical Center \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"9","companyTruncated":"Vanderbilt University Medical Center \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Royalty Pharma"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"General Atlantic","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ General Atlantic","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ General Atlantic"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Retrotope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Linoleic Acid","moa":"Lipid peroxidation","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Retrotope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Retrotope \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Retrotope \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Novo Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Novo Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Novo Ventures"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bardoxolone Methyl","moa":"Peroxisome proliferator-activated receptor gamma | Keap1\/Nrf2 | Inhibitor of nuclear factor kappa B kinase beta subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.16,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Morgan Stanley"},{"orgOrder":0,"company":"Disc medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Hercules Capital","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Hercules Capital"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Jefferies"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Jefferies","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Jefferies"},{"orgOrder":0,"company":"Belite Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DISC-1459","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lenabasum","moa":"cannabinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Galicaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"QED Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"QED Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"QED Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"QED Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Sionna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Galicaftor","moa":"||Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AbbVie Inc \/ Sionna Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Sionna Therapeutics"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor; agonist GABA site","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Ovid Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ovid Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SOM3355","moa":"Synaptic vesicle amine transporter (SLC18A2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Duchenne Uk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Edasalonexent","moa":"Nuclear factor NF-kappa-B complex","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Catabasis Pharmaceuticals \/ Duchenne Uk","highestDevelopmentStatusID":"10","companyTruncated":"Catabasis Pharmaceuticals \/ Duchenne Uk"},{"orgOrder":0,"company":"Saniona","sponsor":"Foundation for Prader-Willi Research","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Foundation for Prader-Willi Research","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Foundation for Prader-Willi Research"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vatiquinone","moa":"Quinone reductase 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"PRG Science & Technology Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PRG Science & Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PRG Science & Technology Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PRG Science & Technology Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ National Institutes of Health"},{"orgOrder":0,"company":"ReveraGen BioPharma","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReveraGen BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"ReveraGen BioPharma \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ReveraGen BioPharma \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Ataluren","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc | ImagingNMD | SYSNAV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc | ImagingNMD | SYSNAV Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc | ImagingNMD | SYSNAV Healthcare"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Gabrail Cancer Center Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Gabrail Cancer Center Research","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Gabrail Cancer Center Research"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Theravia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Theravia \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Theravia \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Braidwell LP","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Braidwell LP","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Braidwell LP"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Infigratinib","moa":"Fibroblast growth factor receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"Vesalius Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ Vesalius Biocapital","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ Vesalius Biocapital"},{"orgOrder":0,"company":"Hangzhou Zede Pharma-Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CN128","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hangzhou Zede Pharma-Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hangzhou Zede Pharma-Tech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zede Pharma-Tech \/ Inapplicable"},{"orgOrder":0,"company":"Hangzhou Zede Pharma-Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CN128","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hangzhou Zede Pharma-Tech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Hangzhou Zede Pharma-Tech \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hangzhou Zede Pharma-Tech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Insight | Biodexa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Insight | Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ CPRIT","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ CPRIT"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Ladenburg Thalmann & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2024","type":"Public Offering","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Ladenburg Thalmann & Co"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Aradigm","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Acquisition","leadProduct":"Ciprofloxacin","moa":"Bacterial DNA gyrase | Topoisomerase IV","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aradigm","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Aradigm \/ Grifols International","highestDevelopmentStatusID":"8","companyTruncated":"Aradigm \/ Grifols International"},{"orgOrder":0,"company":"Spexis","sponsor":"SPRIM Global Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibiotic","year":"2023","type":"Financing","leadProduct":"Colistimethate Sodium","moa":"Cell membrane","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spexis \/ SPRIM Global Investments","highestDevelopmentStatusID":"10","companyTruncated":"Spexis \/ SPRIM Global Investments"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Arrevus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Arrevus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrevus \/ Inapplicable"},{"orgOrder":0,"company":"Biodexa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Biodexa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biodexa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biodexa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"SYNB1618","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"SYNB1618","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Morgan Stanley"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Universit\u00e9 de Sherbrooke","sponsor":"Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Universit\u00e9 de Sherbrooke","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke","highestDevelopmentStatusID":"8","companyTruncated":"Universit\u00e9 de Sherbrooke \/ Canadian Institutes of Health Research | Jazz Pharmaceuticals | Centre de recherche du Centre hospitalier universitaire de Sherbrooke"},{"orgOrder":0,"company":"Benuvia Therapeutics","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Benuvia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Solution","sponsorNew":"Benuvia Therapeutics \/ Radius Health","highestDevelopmentStatusID":"8","companyTruncated":"Benuvia Therapeutics \/ Radius Health"},{"orgOrder":0,"company":"Radius Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Radius Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Radius Health \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Radius Health \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Decitabine","moa":"DNA (cytosine-5)-methyltransferase 1 | DNA | DNA (cytosine-5)-methyltransferase 3A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Public Offering","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Porcine PERT","moa":"||Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"First Wave BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Yeast Recombinant Lipase","moa":"Dietary triglyceride ester bond hydrolysis","graph1":"Genetic Disease","graph2":"Phase II","graph3":"First Wave BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"First Wave BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"First Wave BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cad-1883","moa":"Calcium-activated potassium channel KCa2 (KCNN)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Imara","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cardurion Pharmaceutical \/ Imara","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Imara"},{"orgOrder":0,"company":"Jeffrey Zwicker","sponsor":"Quercegen Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jeffrey Zwicker","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jeffrey Zwicker \/ Quercegen Pharmaceuticals"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zagociguat","moa":"sGC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aclaris Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATI-450","moa":"MAPK2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aclaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aclaris Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aclaris Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLPG2737","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bocidelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"Ferroportin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL Vifor \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"CSL Vifor \/ Fortrea"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"DFV890","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Histamine H3 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Romain Lazor","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nintedanib Esylate","moa":"Platelet-derived growth factor receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Romain Lazor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Romain Lazor \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"8","companyTruncated":"Romain Lazor \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Amy Tang","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amy Tang","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amy Tang \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Amy Tang \/ Pfizer Inc"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Softgel Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Itacitinib","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Incyte Corporation"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Brensocatib","moa":"Dipeptidyl peptidase I","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Children's Hospital Colorado | Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aardvark Therapeutics \/ Children's Hospital Colorado | Stanford University","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Children's Hospital Colorado | Stanford University"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Pfizer Inc"},{"orgOrder":0,"company":"River 3 Renal Corp.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"R3R01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"River 3 Renal Corp.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"River 3 Renal Corp. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"River 3 Renal Corp. \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Basmisanil","moa":"GABA(A) receptor alpha-5 (GABRA5)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Kechow Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tunlametinib","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shanghai Kechow Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shanghai Kechow Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Kechow Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"C-X-C chemokine receptor type 2 (CXCR2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Western Sydney Local Health District \/ Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne","highestDevelopmentStatusID":"8","companyTruncated":"Western Sydney Local Health District \/ Deakin University | Monash University | Royal Perth Hospital | University of Queensland | University of Melbourne"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Nova Mentis Life Science \/ KGK Science"},{"orgOrder":0,"company":"Afimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Epeleuton","moa":"Reperfusion stress","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Afimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Afimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Afimmune \/ Inapplicable"},{"orgOrder":0,"company":"Neuren Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pyrrolo(1,2-a)pyrazine-1,4-dione, hexahydro-8a-(2-propenyl)-, (8aR)-","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Neuren Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Neuren Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Neuren Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inova Health Care Services \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Inova Health Care Services \/ Pfizer Inc"},{"orgOrder":0,"company":"Aaron Logan","sponsor":"Incyte Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aaron Logan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aaron Logan \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Aaron Logan \/ Incyte Corporation"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Craig Erickson","sponsor":"Healx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gaboxadol","moa":"GABA-A receptor; agonist GABA site","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Craig Erickson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Craig Erickson \/ Healx","highestDevelopmentStatusID":"8","companyTruncated":"Craig Erickson \/ Healx"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Shionogi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Inapplicable"},{"orgOrder":0,"company":"Relay Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RLY-2608","moa":"PI3K-alpha","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Relay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Relay Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Relay Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Oslo University Hospital","sponsor":"Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oslo University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oslo University Hospital \/ Haukeland University Hospital | South-Eastern Norway Regional Health Authority | Klinbeforsk | The Dam Foundation | Elysium Health | NKS Olaviken Gerontopsychiatric Hospital"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Tebapivat","moa":"PKLR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mitapivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Catalyst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Catalyst Pharmaceuticals"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Financing","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Highbridge Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Highbridge Capital Management"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"ReveraGen BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ ReveraGen BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ ReveraGen BioPharma"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Sperogenix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Sperogenix Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Genentech \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ PTC Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"PTC Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ PTC Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ PTC Therapeutics"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0.12,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"GC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ GC Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ GC Pharma"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharming \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Inapplicable"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"Prostaglandin E2 receptor EP2 (PTGER2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Crinecerfont","moa":"Corticotropin releasing factor receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ 5Am Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ 5Am Ventures"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Omega Funds","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series B Financing","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Spruce Biosciences \/ Omega Funds","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Omega Funds"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Eversana","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eversana","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Eversana \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Eversana \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Mereo BioPharma Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mereo BioPharma Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Mereo BioPharma Group \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Mereo BioPharma Group \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"VX-814","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Imara \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Inapplicable"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"Imara","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Tovinontrine","moa":"Phosphodiesterase 9A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Imara","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Imara \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imara \/ Undisclosed"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Vamifeport","moa":"SLC40A1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Olinciguat","moa":"Soluble guanylate cyclase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Public Offering","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0.19,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.19,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Calcilytix Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Calcilytix Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Calcilytix Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Calcilytix Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Encaleret","moa":"calcium receptor antagonists","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calcilytix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calcilytix Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calcilytix Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Laurent Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"30 Technology","sponsor":"ConvaTec","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"30 Technology","amount2":0.22,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Solution for Inhalation","sponsorNew":"30 Technology \/ ConvaTec","highestDevelopmentStatusID":"8","companyTruncated":"30 Technology \/ ConvaTec"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Deutivacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Oral Tablet","sponsorNew":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL1211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tetra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Tetra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"SRW Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NEW ZEALAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fisetin","moa":"Cyclin-dependent kinase 6; Fatty acid synthase; Cyclin homolog","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SRW Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"SRW Laboratories \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SRW Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Jupiter Neurosciences","sponsor":"Spartan Capital Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Public Offering","leadProduct":"Resveratrol","moa":"NLRP3\/SIRT1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jupiter Neurosciences","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral","sponsorNew":"Jupiter Neurosciences \/ Spartan Capital Securities","highestDevelopmentStatusID":"8","companyTruncated":"Jupiter Neurosciences \/ Spartan Capital Securities"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Reata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Reata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Reata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"Orphazyme","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Arimoclomol Citrate","moa":"HSF-1 pathway","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphazyme","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Orphazyme \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphazyme \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":2.8999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":2.8999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Shionogi","sponsor":"Jordan\u2019s Guardian Angels","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Shionogi \/ Jordan\u2019s Guardian Angels","highestDevelopmentStatusID":"8","companyTruncated":"Shionogi \/ Jordan\u2019s Guardian Angels"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Tisento Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Tisento Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Tisento Therapeutics"},{"orgOrder":0,"company":"Cyclerion Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyclerion Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Tablet","sponsorNew":"Cyclerion Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cyclerion Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tisento Therapeutics","sponsor":"Invus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Zagociguat","moa":"GUCY1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tisento Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Tisento Therapeutics \/ Invus","highestDevelopmentStatusID":"8","companyTruncated":"Tisento Therapeutics \/ Invus"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inventiva Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odiparcil","moa":"Glycosaminoglycans","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inventiva Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inventiva Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inventiva Pharma \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Organovo Holdings"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Idorsia Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Suspension","sponsorNew":"Idorsia Pharmaceuticals \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Idorsia Pharmaceuticals \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Cyan Bio","sponsor":"Adge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"Elocalcitol","moa":"Vitamin D receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cyan Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Cyan Bio \/ Adge Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Cyan Bio \/ Adge Pharmaceuticals"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Alliance Global Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Public Offering","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Alliance Global Partners","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Alliance Global Partners"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Galapagos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GLPG2737","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Galapagos","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Galapagos \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Galapagos \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Private Placement","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Gemini Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Merger","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Gemini Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Gemini Therapeutics"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aardvark Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Aardvark Therapeutics \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"Aardvark Therapeutics \/ University of California"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Sanford Burnham Prebys","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"N-Acetyl-D-Leucine","moa":"Alkaline phosphatase, tissue-nonspecific isozyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ Sanford Burnham Prebys","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Sanford Burnham Prebys"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series B Financing","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alkeus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Gildeuretinol Acetate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alkeus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Alkeus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alkeus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Lonafarnib","moa":"Protein farnesyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eiger BioPharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eiger BioPharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Syros Pharmaceuticals","sponsor":"Rege Nephro","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Acquisition","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Syros Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Syros Pharmaceuticals \/ Rege Nephro","highestDevelopmentStatusID":"8","companyTruncated":"Syros Pharmaceuticals \/ Rege Nephro"},{"orgOrder":0,"company":"Tempest Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"TPST-1495","moa":"Prostaglandin E2 receptor EP2 (PTGER2)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tempest Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tempest Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tempest Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Esperion Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"||ATP-citrate synthase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Esperion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Esperion Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Esperion Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gedeon Richter","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"RGH-706","moa":"TAAR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Gedeon Richter","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gedeon Richter \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gedeon Richter \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"PXE International","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"DS-1211b","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Daiichi Sankyo \/ PXE International","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ PXE International"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VX-864","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Portal Therapeutics","sponsor":"Celerion","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PORT-77","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Portal Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Portal Therapeutics \/ Celerion","highestDevelopmentStatusID":"8","companyTruncated":"Portal Therapeutics \/ Celerion"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Pitolisant Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Celiprolol Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acer Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRT5005","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"MRT5005","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VX-522","moa":"cAMP-dependent chloride channel (CFTR)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Vertex Pharmaceuticals \/ Moderna Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"FCN-159","moa":"MEK1 \/ MEK2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Fosun Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BEAM-101","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"IONIS-ENAC-2.5Rx","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"OXB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BI 3720931","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Boehringer Ingelheim GmbH \/ OXB","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ OXB"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-01","moa":"Alpha-galactosidase A (GLA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Funding","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2023","type":"Inapplicable","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Agreement","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"Armata Pharmaceuticals","sponsor":"Innoviva","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Financing","leadProduct":"AP-PA02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Armata Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"Armata Pharmaceuticals \/ Innoviva","highestDevelopmentStatusID":"7","companyTruncated":"Armata Pharmaceuticals \/ Innoviva"},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"BiomX","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2024","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Deerfield Management Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Deerfield Management Company"},{"orgOrder":0,"company":"BiomX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2021","type":"Inapplicable","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"BiomX \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Inapplicable"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Merger","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ BiomX"},{"orgOrder":0,"company":"Adaptive Phage Therapeutics","sponsor":"BiomX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2024","type":"Merger","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Adaptive Phage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Adaptive Phage Therapeutics \/ BiomX","highestDevelopmentStatusID":"7","companyTruncated":"Adaptive Phage Therapeutics \/ BiomX"},{"orgOrder":0,"company":"BiomX","sponsor":"Laidlaw & Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Microorganism","year":"2025","type":"Private Placement","leadProduct":"BX004","moa":"P. aeruginosa biofilm","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BiomX","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Inhalation","sponsorNew":"BiomX \/ Laidlaw & Company","highestDevelopmentStatusID":"7","companyTruncated":"BiomX \/ Laidlaw & Company"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"Tyrosine-protein kinase JAK1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"St. Jude Children's Research Hospital \/ Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach","highestDevelopmentStatusID":"7","companyTruncated":"St. Jude Children's Research Hospital \/ Incyte Corporation | North American Consortium for Histiocytosis | Cures Within Reach"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZN-d5","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RBP4","sponsor":"Belite Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"RBP4","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"RBP4 \/ Belite Bio","highestDevelopmentStatusID":"7","companyTruncated":"RBP4 \/ Belite Bio"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rajshekhar Chakraborty, MD","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Rajshekhar Chakraborty, MD","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rajshekhar Chakraborty, MD \/ Genentech","highestDevelopmentStatusID":"7","companyTruncated":"Rajshekhar Chakraborty, MD \/ Genentech"},{"orgOrder":0,"company":"Alfred Chung","sponsor":"Johnson & Johnson Innovative Medicine | AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venetoclax","moa":"Apoptosis regulator Bcl-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Alfred Chung","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Alfred Chung \/ Johnson & Johnson Innovative Medicine | AbbVie Inc","highestDevelopmentStatusID":"7","companyTruncated":"Alfred Chung \/ Johnson & Johnson Innovative Medicine | AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Calico Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Calico Life Sciences","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Calico Life Sciences"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"HBI-002","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"7","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"Greenstone Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Genistein","moa":"Estrogen receptor beta (ESR2)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ Greenstone Biosciences","highestDevelopmentStatusID":"7","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ Greenstone Biosciences"},{"orgOrder":0,"company":"Disc medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Zentalis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ZN-D5","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zentalis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Zentalis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zentalis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1299999999999999,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Foundation Fighting Blindness"},{"orgOrder":0,"company":"Nacuity Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nacuity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nacuity Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nacuity Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Belite Bio","sponsor":"SVB Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Tinlarebant","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Belite Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Tablet","sponsorNew":"Belite Bio \/ SVB Securities","highestDevelopmentStatusID":"10","companyTruncated":"Belite Bio \/ SVB Securities"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"6,6-2H2 Glucose","moa":"Glucose transporter","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"University Medical Center Groningen \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"University Medical Center Groningen \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ITU512","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eidos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jemincare","sponsor":"Zhejiang Hangyu Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"JMKX003142","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jemincare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"8","companyTruncated":"Jemincare \/ Zhejiang Hangyu Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT021601","moa":"Hemoglobin (HB)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT021601","moa":"Hemoglobin (HB)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GBT021601","moa":"Hemoglobin (HB)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Omaveloxolone","moa":"Nuclear factor erythroid 2-related factor 2","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-4881","moa":"MEK1 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sage Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"SAGE-718","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sage Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sage Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sage Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Monoamine transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Panakes Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"ETD001","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enterprise Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Panakes Partners","highestDevelopmentStatusID":"8","companyTruncated":"Enterprise Therapeutics \/ Panakes Partners"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Kither Biotech \/ Avance Clinical","highestDevelopmentStatusID":"6","companyTruncated":"Kither Biotech \/ Avance Clinical"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Kither Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kither Biotech \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GRIN Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Radiprodil","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GRIN Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"GRIN Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GRIN Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Aro-Enac","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"RCT2100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PRG Science & Technology Co., Ltd.","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PRG Science & Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"PRG Science & Technology Co., Ltd. \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"PRG Science & Technology Co., Ltd. \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VX-407","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VX-828","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"VX-828","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Forma Therapeutics","sponsor":"Newco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Etavopivat","moa":"Pyruvate kinase isozymes R\/L","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Forma Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Forma Therapeutics \/ Newco","highestDevelopmentStatusID":"10","companyTruncated":"Forma Therapeutics \/ Newco"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KVD824","moa":"Plasma kallikrein (KLKB1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Muscular Dystrophy Association","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sevasemten","moa":"MYH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Edgewise Therapeutics \/ Muscular Dystrophy Association","highestDevelopmentStatusID":"8","companyTruncated":"Edgewise Therapeutics \/ Muscular Dystrophy Association"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Cystetic Medicines","sponsor":"DevPro Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Amphotericin B Cystetic","moa":"Ergosterol","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystetic Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Cystetic Medicines \/ DevPro Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Cystetic Medicines \/ DevPro Biopharma"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Krystal Biotech \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Novotech"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Funding","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Atum Bio","sponsor":"Anagram Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"ANG003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Atum Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Atum Bio \/ Anagram Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Atum Bio \/ Anagram Therapeutics"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"REN001","moa":"PARP delta","graph1":"Genetic Disease","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Bupropion Hydrochloride","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Agios Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tebapivat","moa":"Pyruvate kinase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Agios Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule","sponsorNew":"Agios Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Agios Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Edgewise Therapeutics","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sevasemten","moa":"Myosin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Edgewise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Edgewise Therapeutics \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"6","companyTruncated":"Edgewise Therapeutics \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"497833-27-9","moa":"Histone deacetylase (HDAC)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Italfarmaco \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Italfarmaco \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"JNJ-64251330","moa":"JAK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Venglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CSTI-500","moa":"Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ConSynance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Vanzacaftor","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Autifony Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AUT00201","moa":"VGKCs","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Autifony Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Autifony Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Autifony Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orphalan","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Orphalan \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Orphalan \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pasithea Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Acer Therapeutics","sponsor":"Relief Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Acer Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Acer Therapeutics \/ Relief Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Acer Therapeutics \/ Relief Therapeutics"},{"orgOrder":0,"company":"Z Factor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Z Factor \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor \/ Inapplicable"},{"orgOrder":0,"company":"Centessa Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Centessa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Centessa Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Centessa Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VX-634","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peak Bio","sponsor":"White Lion Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"PHP-303","moa":"Neutrophil elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peak Bio","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Peak Bio \/ White Lion Capital","highestDevelopmentStatusID":"8","companyTruncated":"Peak Bio \/ White Lion Capital"},{"orgOrder":0,"company":"Corino Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tolcapone","moa":"Catechol O-methyltransferase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Corino Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corino Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corino Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"National Heart, Lung, And Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ National Heart, Lung, And Blood Institute"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Global Blood Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GBT601","moa":"Hemoglobin polymerization","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Global Blood Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Global Blood Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Global Blood Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pharvaris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Pharvaris \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pharvaris \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"Betamethasone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Inflectis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Genetic Disease","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"University of Chicago \/ Inflectis Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ Inflectis Bioscience"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Chong Kun Dang Pharm","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"CKD-510","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Chong Kun Dang Pharm","amount2":1.3100000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3100000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Chong Kun Dang Pharm \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Saniona","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ABS-0871","moa":"TRPV4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Actio Biosciences \/ Saniona","highestDevelopmentStatusID":"6","companyTruncated":"Actio Biosciences \/ Saniona"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Inflazome","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Inzomelid","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inflazome","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Inflazome \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inflazome \/ Inapplicable"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Usnoflast","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Calithera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CB-280","moa":"Arginase","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Calithera Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Calithera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Calithera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETD002","moa":"Anoctamin-1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cystetic Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CM001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cystetic Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Cystetic Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cystetic Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"SION\u2011719","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Tablet","sponsorNew":"Sionna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"SION\u2011719","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.22,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.22,"dosageForm":"Oral Tablet","sponsorNew":"Sionna Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaerus Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaerus Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Spinogenix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REC-3599","moa":"PKC","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0.75,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.75,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Shionogi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Shionogi","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Shionogi"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NRL-1049","moa":"ROCK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BCX10013","moa":"Factor D","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Skyhawk Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SKY-0515","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Skyhawk Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Skyhawk Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Skyhawk Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Votoplam","moa":"HTT","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Calico Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Calico Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Calico Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Calico Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Pasithea Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"Atherogenic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baylor College of Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Baylor College of Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Reneo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Reneo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Reneo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Reneo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ASP0367","moa":"PARP delta","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Astellas Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Astellas Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Mission Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MTX652","moa":"USP-30","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Mission Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Mission Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Mission Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Piramal Pharma Solutions","sponsor":"Epirium","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Collaboration","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Piramal Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Piramal Pharma Solutions \/ Epirium","highestDevelopmentStatusID":"6","companyTruncated":"Piramal Pharma Solutions \/ Epirium"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series C Financing","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Poxel","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PXL770","moa":"AMPK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Poxel","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Poxel \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Poxel \/ Inapplicable"},{"orgOrder":0,"company":"Alebund Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AP303","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alebund Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Alebund Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alebund Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CSTI-500","moa":"Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ConSynance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ConSynance Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"CSTI-500","moa":"Triple monoamine reuptake","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ConSynance Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ConSynance Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ConSynance Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanoform","sponsor":"Nacuity Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FINLAND","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"N-Acetylcysteine Amide","moa":"Free radical","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nanoform","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Nanoform \/ Nacuity Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Nanoform \/ Nacuity Pharmaceuticals"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vaderis Therapeutics","sponsor":"Medicxi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"VAD044","moa":"AKT kinase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vaderis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Vaderis Therapeutics \/ Medicxi","highestDevelopmentStatusID":"7","companyTruncated":"Vaderis Therapeutics \/ Medicxi"},{"orgOrder":0,"company":"Kaerus Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"KER-0193","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kaerus Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kaerus Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Kaerus Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AGT-100216","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Augustine Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Augustine Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Augustine Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rigel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fostamatinib Disodium Hexahydrate","moa":"Tyrosine-protein kinase SYK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rigel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Rigel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rigel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Grace Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2022","type":"Inapplicable","leadProduct":"GTX-102","moa":"UBE3A-AS","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Grace Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Grace Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Grace Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CDX-6114","moa":"Phenylalanine","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Nestle Health Sciences SA \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nestle Health Sciences SA \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VX-668","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VX-118","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Luye Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LPM3770164","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Luye Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Sustained Release","sponsorNew":"Luye Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Luye Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BMN 349","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"VX-522","moa":"cAMP-dependent chloride channel (CFTR)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Powder for Inhalation","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB408","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ARO-ENaC","moa":"ENaC","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution for Nebulizer","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VX-407","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Satellos Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SAT-3247","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Satellos Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Satellos Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Satellos Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Enyo Pharma","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"Vonafexor","moa":"Bile acid receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Enyo Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Enyo Pharma \/ OrbiMed Advisors","highestDevelopmentStatusID":"8","companyTruncated":"Enyo Pharma \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneVentiv Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GeneVentiv Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"GeneVentiv Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneVentiv Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"GeneVentiv Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"GENV HEM","moa":"Factor Va","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"University of North Carolina \/ GeneVentiv Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"University of North Carolina \/ GeneVentiv Therapeutics"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"KGK Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"KGK Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"KGK Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"KGK Science \/ Inapplicable"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Emerald Health Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabigerol","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Emerald Health Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emerald Health Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Emerald Health Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Biotel Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2021","type":"Series B Financing","leadProduct":"SPL84-23","moa":"CFTR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SpliSense","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Oral Inhalation","sponsorNew":"SpliSense \/ Biotel Limited","highestDevelopmentStatusID":"5","companyTruncated":"SpliSense \/ Biotel Limited"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"AmideBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"AB-G023","moa":"GCGR","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"AmideBio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AmideBio \/ Inapplicable"},{"orgOrder":0,"company":"Synlogic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Labafenogene Marselecobac","moa":"Phe level","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Synlogic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Synlogic \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Synlogic \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ZKN-013","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Eloxx Pharmaceuticals","amount2":0.46999999999999997,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46999999999999997,"dosageForm":"Oral","sponsorNew":"Eloxx Pharmaceuticals \/ Almirall","highestDevelopmentStatusID":"5","companyTruncated":"Eloxx Pharmaceuticals \/ Almirall"},{"orgOrder":0,"company":"Disc medicine","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Disc medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"Disc medicine \/ National Institutes of Health"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"FTX-6058","moa":"EED","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Fulcrum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Fulcrum Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Fulcrum Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hillhurst Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Carbon Monoxide","moa":"HO metabolic pathway","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Hillhurst Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Hillhurst Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Hillhurst Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Azafaros","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Nizubaglustat","moa":"GBA2 protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Azafaros","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Azafaros \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Azafaros \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Gemfibrozil","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL00804","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neurelis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NRL-1049","moa":"ROCK","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurelis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neurelis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurelis \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Calliditas Therapeutics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Setanaxib","moa":"NADPH oxidase 4 | NADPH oxidase 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Calliditas Therapeutics AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Calliditas Therapeutics AB \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Calliditas Therapeutics AB \/ Inapplicable"},{"orgOrder":0,"company":"Allomek","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CIP-137401","moa":"MAPK\/ERK kinase kinase (MAP3K)","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NMD PHARMA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NMD670","moa":"ClC-1","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NMD PHARMA","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"NMD PHARMA \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"NMD PHARMA \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Rimtuzalcap","moa":"Calcium-sensitive potassium ion channel PAM","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"ContraFect Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"CF-370","moa":"Pseudomonas aeruginosa cell wall","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ContraFect Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ContraFect Corporation \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"ContraFect Corporation \/ Inapplicable"},{"orgOrder":0,"company":"NeuExcell therapeutics","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"NeuExcell therapeutics","amount2":0.19,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.19,"dosageForm":"Oral","sponsorNew":"NeuExcell therapeutics \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"5","companyTruncated":"NeuExcell therapeutics \/ Spark Therapeutics, Inc"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Kither Biotech","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Inhalation","sponsorNew":"Kither Biotech \/ Claris Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Kither Biotech \/ Claris Ventures"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Branaplam","moa":"survival motor neurin SMN1 and SMN2 splicing modulators","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"AlveoGene","sponsor":"Oxford Science Enterprises","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"AVG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AlveoGene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"AlveoGene \/ Oxford Science Enterprises","highestDevelopmentStatusID":"4","companyTruncated":"AlveoGene \/ Oxford Science Enterprises"},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Doxorubicin","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spirovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPIRO-2101","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Spirovant Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Spirovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Spirovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"ATA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"The University of Manchester","sponsor":"Avrobio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"AVR-RD-05","moa":"IDS","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"The University of Manchester","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"The University of Manchester \/ Avrobio","highestDevelopmentStatusID":"4","companyTruncated":"The University of Manchester \/ Avrobio"},{"orgOrder":0,"company":"Wellbeing Digital Sciences","sponsor":"Nova Mentis Life Science","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Wellbeing Digital Sciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Wellbeing Digital Sciences \/ Nova Mentis Life Science","highestDevelopmentStatusID":"5","companyTruncated":"Wellbeing Digital Sciences \/ Nova Mentis Life Science"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RCT223","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SPL23-ASO","moa":"CFTR RNA","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"Tyra Biosciences \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ RA Capital Management"},{"orgOrder":0,"company":"IMMvention Therapeutix","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Partnership","leadProduct":"IMM\u2013004","moa":"BACH1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IMMvention Therapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"IMMvention Therapeutix \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"IMMvention Therapeutix \/ Novo Nordisk"},{"orgOrder":0,"company":"Augustine Therapeutics","sponsor":"Novo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"AGT-100216","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Augustine Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Augustine Therapeutics \/ Novo Holdings","highestDevelopmentStatusID":"6","companyTruncated":"Augustine Therapeutics \/ Novo Holdings"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"CRN04777","moa":"SST5 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Renovion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ascorbic Acid","moa":"||Mucous clearance","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Renovion","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Nebulizer","sponsorNew":"Renovion \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Renovion \/ Inapplicable"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lenire Biosciences","sponsor":"University College London","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"VSN16R","moa":"KCa channel","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lenire Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lenire Biosciences \/ University College London","highestDevelopmentStatusID":"4","companyTruncated":"Lenire Biosciences \/ University College London"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"FRAXA Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Blarcamesine","moa":"sigma receptor ligands","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Liquid","sponsorNew":"Anavex Life Sciences \/ FRAXA Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anavex Life Sciences \/ FRAXA Research Foundation"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"GT-00513","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Matrix Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Financing","leadProduct":"MZE001","moa":"GYS1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Maze Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.19,"dosageForm":"Oral","sponsorNew":"Maze Therapeutics \/ Matrix Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Maze Therapeutics \/ Matrix Capital Management"},{"orgOrder":0,"company":"BioAxone BioSciences","sponsor":"Neurelis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"BA-1049","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BioAxone BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"BioAxone BioSciences \/ Neurelis","highestDevelopmentStatusID":"4","companyTruncated":"BioAxone BioSciences \/ Neurelis"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"1cBio","sponsor":"Alesta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"ALE1","moa":"PPi","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"1cBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"1cBio \/ Alesta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"1cBio \/ Alesta Therapeutics"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Allomek","sponsor":"Camac Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"CIP-137401","moa":"MAPK\/ERK kinase kinase (MAP3K)","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Allomek","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Allomek \/ Camac Partners","highestDevelopmentStatusID":"5","companyTruncated":"Allomek \/ Camac Partners"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xortx Therapeutics","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Oxypurinol","moa":"Xanthine dehydrogenase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Xortx Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Xortx Therapeutics \/ Altasciences Company Inc","highestDevelopmentStatusID":"10","companyTruncated":"Xortx Therapeutics \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Anakuria","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"AT-20494","moa":"mTORC1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anakuria","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Anakuria \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Anakuria \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Disc medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"F. Hoffmann-La Roche","amount2":0.20000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Oral","sponsorNew":"F. Hoffmann-La Roche \/ Disc medicine","highestDevelopmentStatusID":"4","companyTruncated":"F. Hoffmann-La Roche \/ Disc medicine"},{"orgOrder":0,"company":"Disc medicine","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Disc medicine","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Oral Tablet","sponsorNew":"Disc medicine \/ OrbiMed Advisors","highestDevelopmentStatusID":"9","companyTruncated":"Disc medicine \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Telomir Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Telomir-1","moa":"IL-17 receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Telomir Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Telomir Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Telomir Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Denovo Biopharma \/ Aytu BioScience","highestDevelopmentStatusID":"4","companyTruncated":"Denovo Biopharma \/ Aytu BioScience"},{"orgOrder":0,"company":"Rumpus Therapeutics","sponsor":"Aytu BioScience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Enzastaurin","moa":"Protein kinase C beta","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumpus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumpus Therapeutics \/ Aytu BioScience","highestDevelopmentStatusID":"4","companyTruncated":"Rumpus Therapeutics \/ Aytu BioScience"},{"orgOrder":0,"company":"NephroDI Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"NDI-5033","moa":"AMPK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NephroDI Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"NephroDI Therapeutics \/ Xontogeny, LLC","highestDevelopmentStatusID":"4","companyTruncated":"NephroDI Therapeutics \/ Xontogeny, LLC"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Oryzon Genomics \/ CMT Research Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ CMT Research Foundation"},{"orgOrder":0,"company":"Addex Therapeutics","sponsor":"Charcot Marie Tooth Association","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Addex Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Addex Therapeutics \/ Charcot Marie Tooth Association","highestDevelopmentStatusID":"4","companyTruncated":"Addex Therapeutics \/ Charcot Marie Tooth Association"},{"orgOrder":0,"company":"Andelyn Biosciences","sponsor":"Armatus Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Andelyn Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Andelyn Biosciences \/ Armatus Bio","highestDevelopmentStatusID":"4","companyTruncated":"Andelyn Biosciences \/ Armatus Bio"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Tablet","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Nova Mentis Life Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nova Mentis Life Science","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Nova Mentis Life Science \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nova Mentis Life Science \/ Inapplicable"},{"orgOrder":0,"company":"Generation Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Generation Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Generation Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Generation Bio \/ Inapplicable"},{"orgOrder":0,"company":"Anima Medical Centre","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Anima Medical Centre","amount2":2.4199999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":2.4199999999999999,"dosageForm":"Oral","sponsorNew":"Anima Medical Centre \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Anima Medical Centre \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"VectorY","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Inapplicable"},{"orgOrder":0,"company":"Harness Therapeutics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Harness Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"Harness Therapeutics \/ Epidarex Capital","highestDevelopmentStatusID":"4","companyTruncated":"Harness Therapeutics \/ Epidarex Capital"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"LoQus23 Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Forbion","highestDevelopmentStatusID":"4","companyTruncated":"LoQus23 Therapeutics \/ Forbion"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":1.3,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumi Scientific \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rumi Scientific \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"INV-101","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Inversago Pharma \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Forbion"},{"orgOrder":0,"company":"Rumi Scientific","sponsor":"X-Chem","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Partnership","leadProduct":"iBRD9","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rumi Scientific","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rumi Scientific \/ X-Chem","highestDevelopmentStatusID":"3","companyTruncated":"Rumi Scientific \/ X-Chem"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ CMT Research Foundation","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ CMT Research Foundation"},{"orgOrder":0,"company":"ReviR Therapeutics","sponsor":"Lapam Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ReviR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"ReviR Therapeutics \/ Lapam Capital","highestDevelopmentStatusID":"3","companyTruncated":"ReviR Therapeutics \/ Lapam Capital"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"GV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Oral Inhalation","sponsorNew":"OMass Therapeutics \/ GV","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ GV"},{"orgOrder":0,"company":"OMass Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"OMass Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"OMass Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"OMass Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Nanite","sponsor":"CMT Research Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Nanite","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nanite \/ CMT Research Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Nanite \/ CMT Research Foundation"},{"orgOrder":0,"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Exicure","amount2":1.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.02,"dosageForm":"Oral","sponsorNew":"Exicure \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Exicure \/ Ipsen"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"LoQus23 Therapeutics","sponsor":"Dementia Discovery Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"LoQus23 Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Oral","sponsorNew":"LoQus23 Therapeutics \/ Dementia Discovery Fund","highestDevelopmentStatusID":"4","companyTruncated":"LoQus23 Therapeutics \/ Dementia Discovery Fund"},{"orgOrder":0,"company":"Aitia","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Aitia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aitia \/ UCB Pharma S.A","highestDevelopmentStatusID":"2","companyTruncated":"Aitia \/ UCB Pharma S.A"},{"orgOrder":0,"company":"Voyager Therapeutics, Inc","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Voyager Therapeutics, Inc","amount2":0.63,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.63,"dosageForm":"Oral","sponsorNew":"Voyager Therapeutics, Inc \/ Pfizer Inc","highestDevelopmentStatusID":"4","companyTruncated":"Voyager Therapeutics, Inc \/ Pfizer Inc"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Neurochase","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Spark Therapeutics, Inc \/ Neurochase","highestDevelopmentStatusID":"2","companyTruncated":"Spark Therapeutics, Inc \/ Neurochase"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Clinigen Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Maralixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Mirum Pharmaceuticals \/ Clinigen Group","highestDevelopmentStatusID":"8","companyTruncated":"Mirum Pharmaceuticals \/ Clinigen Group"},{"orgOrder":0,"company":"Epirium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Epicatechin","moa":"Mitochondrial protein unspecific (MP)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Epirium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Epirium \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Epirium \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"MPM Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Oral Aerosol for Inhalation","sponsorNew":"ReCode Therapeutics \/ MPM Capital","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ MPM Capital"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"LGD","sponsor":"CEN Biotech | Assistance Publique Hopitaux De Marseille | Etablissement Fran\u00e7ais du Sang","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"NUV001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"LGD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LGD \/ CEN Biotech | Assistance Publique Hopitaux De Marseille | Etablissement Fran\u00e7ais du Sang","highestDevelopmentStatusID":"1","companyTruncated":"LGD \/ CEN Biotech | Assistance Publique Hopitaux De Marseille | Etablissement Fran\u00e7ais du Sang"},{"orgOrder":0,"company":"LGD","sponsor":"Prorelix Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"NUV001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"LGD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"LGD \/ Prorelix Research","highestDevelopmentStatusID":"1","companyTruncated":"LGD \/ Prorelix Research"},{"orgOrder":0,"company":"Myogem Health Company, S.L.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Myodm","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Myogem Health Company, S.L.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Myogem Health Company, S.L. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Myogem Health Company, S.L. \/ Inapplicable"},{"orgOrder":0,"company":"GALEN LTD","sponsor":"Birmingham Women's and Children's NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Dietary Supplement","year":"2024","type":"Inapplicable","leadProduct":"PKU Easy Microtabs Plus","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"GALEN LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"GALEN LTD \/ Birmingham Women's and Children's NHS Foundation Trust","highestDevelopmentStatusID":"1","companyTruncated":"GALEN LTD \/ Birmingham Women's and Children's NHS Foundation Trust"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fosigotifator","moa":"EIF2B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"AbbVie Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AbbVie Inc \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"VectorY","sponsor":"Wageningen University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VectorY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"VectorY \/ Wageningen University","highestDevelopmentStatusID":"4","companyTruncated":"VectorY \/ Wageningen University"},{"orgOrder":0,"company":"Children's Hospital of Fudan University","sponsor":"Hedu Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"CBT102-A","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Children's Hospital of Fudan University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Children's Hospital of Fudan University \/ Hedu Biotechnology","highestDevelopmentStatusID":"1","companyTruncated":"Children's Hospital of Fudan University \/ Hedu Biotechnology"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Centocor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Centocor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Centocor \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Centocor \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chugai Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chugai Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Burosumab","moa":"Fibroblast growth factor 23","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kyowa Kirin \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Kyowa Kirin \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Lyophilized Human C1-esterase","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Human Immunoglobulin with Recombinant Hyaluronidase","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Hormone","year":"2021","type":"Agreement","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Amryt Pharma"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Partnership","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Medison Pharma","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Givosiran Sodium","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Medison Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medison Pharma \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Medison Pharma \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Olezarsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Swedish Orphan Biovitrum AB"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Human C1 Esterase Inhibitor","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Fresenius Kabi AG \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Fresenius Kabi AG \/ Inapplicable"},{"orgOrder":0,"company":"Cycle Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cycle Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Cycle Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cycle Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Slayback Pharma","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Slayback Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Slayback Pharma \/ Sandoz B2B","highestDevelopmentStatusID":"15","companyTruncated":"Slayback Pharma \/ Sandoz B2B"},{"orgOrder":0,"company":"Adalvo","sponsor":"AmbioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"MALTA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Adalvo","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Adalvo \/ AmbioPharm","highestDevelopmentStatusID":"15","companyTruncated":"Adalvo \/ AmbioPharm"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aurobindo Pharma Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Divestment","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0.11,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Medison Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Partnership","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Medison Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Medison Pharma"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Soleo Health","sponsor":"Grifols International","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Immune Globulin (Human)","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Soleo Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Soleo Health \/ Grifols International","highestDevelopmentStatusID":"15","companyTruncated":"Soleo Health \/ Grifols International"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Pegvaliase","moa":"Phenylalanine","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Growth Hormone","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh","highestDevelopmentStatusID":"11","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Children's Hospital of Fudan University | Tongji Hospital | Children's Hospital of Nanjing Medical University | Jiangxi Province Children's Hospital | Chengdu Women's and Children's Central Hospital | Shandong Provincial Hospital | Shengjing Hospital | Sh"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Tigermed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Tigermed","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ Tigermed"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN057","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN057","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Mim8","moa":"Coagulation factor IX (F9)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Pegvaliase","moa":"Phenylalanine","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"Pegvaliase","moa":"Phenylalanine","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Amryt Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Metreleptin","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Amryt Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amryt Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amryt Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sixth Street","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Financing","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Sixth Street","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Sixth Street"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"TAK-743","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PF-06741086","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Satralizumab","moa":"IL6Ralpha\/GP130","graph1":"Genetic Disease","graph2":"Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NNC0365-3769","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Mibavademab","moa":"Leptin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genmab","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"||Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Genmab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genmab \/ GSK","highestDevelopmentStatusID":"10","companyTruncated":"Genmab \/ GSK"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"CSL","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Garadacimab","moa":"F12a","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CSL \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"ALXN1850","moa":"Alkaline phosphatase tissue-nonspecific (ALPL)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Inclisiran","moa":"PCSK9 mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.45000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Public Offering","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.45000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Collaboration","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Licensing Agreement","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Givosiran","moa":"5-aminolevulinate synthase mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Theratechnologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Licensing Agreement","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Theratechnologies","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Theratechnologies"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Expanded Collaboration","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":3.7999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":3.7999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"RareStone Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ RareStone Group","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ RareStone Group"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Marzeptacog Alfa","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Taldefgrobep Alfa","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VSA003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visirna Therapeutics HK Limited \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Licensing Agreement","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":1.04,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Millendo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Livoletide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Millendo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Millendo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Millendo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"RO7204239","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KN057","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Alphamab Oncology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"KN057","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alphamab Oncology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alphamab Oncology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alphamab Oncology \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Charite University, Berlin, Germany \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"BELGIUM","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Rozanolixizumab","moa":"IgG receptor FcRn large subunit p51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"UCB Pharma S.A","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"UCB Pharma S.A \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"UCB Pharma S.A \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Crovalimab","moa":"Complement C5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"University of Washington","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"University of Washington \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ Genentech"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ALXN1820","moa":"Complement factor P (CFP)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ypsomed","sponsor":"Astria Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2024","type":"Partnership","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ypsomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ypsomed \/ Astria Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Ypsomed \/ Astria Therapeutics"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Public Offering","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Filip Krag Knop","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Filip Krag Knop","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Filip Krag Knop \/ Zealand Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Filip Krag Knop \/ Zealand Pharma"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Percheron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Percheron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Percheron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Percheron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Arrowhead Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Belcesiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antisense Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ATL1102","moa":"ITGA4 messenger RNA (ITGA4 mRNA)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Antisense Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Antisense Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antisense Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Collaboration","leadProduct":"Lademirsen","moa":"microRNA 21","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Regulus Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Regulus Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Financing","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Hercules Capital","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Hercules Capital"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ The Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Zikani Therapeutics","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zikani Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zikani Therapeutics \/ Eloxx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Zikani Therapeutics \/ Eloxx Pharmaceuticals"},{"orgOrder":0,"company":"Paradigm Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Paradigm Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Paradigm Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Paradigm Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Lyophilized Powder","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Visen Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Visen Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Visen Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Visen Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eiger BioPharmaceuticals","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eiger BioPharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Eiger BioPharmaceuticals \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Octreotide Acetate","moa":"Somatostatin receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Acceleron Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Bristol Myers Squibb \/ Acceleron Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Acceleron Pharma"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Dalcinonacog Alpha","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"DS-5141b","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Daiichi Sankyo \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Daiichi Sankyo \/ Inapplicable"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"The National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Qbkpn SSI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ The National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ The National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Qu Biologics Inc","sponsor":"National Research Council of Canada Industrial Research Assistance Program","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"QBKPN SSI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Qu Biologics Inc","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program","highestDevelopmentStatusID":"8","companyTruncated":"Qu Biologics Inc \/ National Research Council of Canada Industrial Research Assistance Program"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ IQVIA"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Avance Clinical","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Avance Clinical"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Public Offering","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ J.P. Morgan","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ J.P. Morgan"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DT-216P2","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HMB-002","moa":"VMF\/Factor VII level","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Hemab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hemab Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HMB-002","moa":"VMF\/Factor VII level","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hemab Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hemab Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Hemab Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dicerna Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"DCR-A1AT","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Dicerna Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dicerna Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dicerna Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ IQVIA","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ IQVIA"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARO-C3","moa":"C3 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"OCTA12","moa":"||Factor VIII","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NXT007","moa":"Factor VIIIa mimetic","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"F. Hoffmann-La Roche \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"F. Hoffmann-La Roche \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Romosozumab","moa":"Sclerostin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"STAR-0215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Ribomic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Umedaptanib Pegol","moa":"FGFR-2\/FGFR-3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ribomic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ribomic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ribomic \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Ascenta Capital","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Ascenta Capital"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Series C Financing","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ADX-324","moa":"PKK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"ADARx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"ADARx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"ADARx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DT-216P2","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Design Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Design Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Design Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NNC0365-3769","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Public Offering","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Star Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Star Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Star Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Star Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"microRNA hsa-miR-17 (MIR17)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"SLN124","moa":"TMPRSS6 messenger RNA (TMPRSS6 mRNA)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Silence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Silence Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Silence Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"RGLS8429","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fitusiran","moa":"Antithrombin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"microRNA hsa-miR-17 (MIR17)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"RGLS4326","moa":"microRNA hsa-miR-17 (MIR17)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"microRNA hsa-miR-17 (MIR17)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"RGLS4326","moa":"microRNA hsa-miR-17 (MIR17)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Acquisition","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":1.7,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.7,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Acquisition","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":1.7,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":1.7,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Inapplicable","leadProduct":"ALN-TTRSC04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Public Offering","leadProduct":"CMP-CPS-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CAMP4 Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"CAMP4 Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"6","companyTruncated":"CAMP4 Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PF-07209326","moa":"E-selectin (SELE)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Crescent Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Crescent Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"BioLineRx | Biogen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Washington University School of Medicine \/ BioLineRx | Biogen","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ BioLineRx | Biogen"},{"orgOrder":0,"company":"St. Jude Children's Research Hospital","sponsor":"BioLineRx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"St. Jude Children's Research Hospital","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"St. Jude Children's Research Hospital \/ BioLineRx","highestDevelopmentStatusID":"6","companyTruncated":"St. Jude Children's Research Hospital \/ BioLineRx"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Inapplicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children\u2019s Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ St. Jude Children\u2019s Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children\u2019s Research Hospital"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"||C-X-C chemokine receptor type 4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Public Offering","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Veristat","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Zafgen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Merger","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Zafgen","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Zafgen"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Nomlabofusp","moa":"Frataxin protein","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Mim8 B","moa":"Factor VIIIa mimetic","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"MG1113","moa":"TMPRSS6","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AGA2115","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NBIP-01435","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Neurocrine Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurocrine Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"WVE-006","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Quince Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Quince Therapeutics"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Series A Financing","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ Mubadala Capital","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ Mubadala Capital"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Navenibart","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Astria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Thomas Jefferson University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Inozyme Pharma \/ Thomas Jefferson University","highestDevelopmentStatusID":"7","companyTruncated":"Inozyme Pharma \/ Thomas Jefferson University"},{"orgOrder":0,"company":"Regulus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Farabursen","moa":"miR-17","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Regulus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Regulus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Regulus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Exaluren Sulfate","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Xinvento","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"Setmelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Xinvento","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"Xinvento \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Xinvento \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"AmideBio","sponsor":"NIDDK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AmideBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AmideBio \/ NIDDK","highestDevelopmentStatusID":"4","companyTruncated":"AmideBio \/ NIDDK"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"||peptides","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2022","type":"Acquisition","leadProduct":"NOV004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Quince Therapeutics \/ Quince Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Quince Therapeutics \/ Quince Therapeutics"},{"orgOrder":0,"company":"Juvena Therapeutics","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Funding","leadProduct":"JUV-161","moa":"Myogenesis","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Juvena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Juvena Therapeutics \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Juvena Therapeutics \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CB 2679d-GT","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Catalyst Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Catalyst Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Guselkumab","moa":"Interleukin-23","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Lanadelumab","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"SHIRE PLC \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"SHIRE PLC \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Pozelimab","moa":"Complement C5","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alvotech","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ICELAND","productType":"Antibody","year":"2025","type":"Agreement","leadProduct":"Canakinumab","moa":"Interleukin-1 beta","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Alvotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alvotech \/ Advanz Pharma","highestDevelopmentStatusID":"1","companyTruncated":"Alvotech \/ Advanz Pharma"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Subcutaneous Injection","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Connoya Biomedical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM-336","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Keymed Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Keymed Biosciences"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sublingual Film","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"Ace Cells Lab","sponsor":"European Wellness Academy","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"Ace Retino","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ace Cells Lab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sublingual","sponsorNew":"Ace Cells Lab \/ European Wellness Academy","highestDevelopmentStatusID":"7","companyTruncated":"Ace Cells Lab \/ European Wellness Academy"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AAV5-hRKp.RPGR","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MeiraGTx","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.41999999999999998,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"MeiraGTx \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Syncona Limited"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Cantor Fitzgerald","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"Agtc","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Syncona Limited","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Acquisition","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Syncona Limited","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Syncona Limited"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Cotoretigene Toliparvovec","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AAV5-hRKp.RPGR","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17000000000000001,"dosageForm":"Subretinal Injection","sponsorNew":"Beacon Therapeutics \/ TCGX","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ TCGX"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Bain Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Series C Financing","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Bain Capital","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Bain Capital"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"MYO7A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"MYO7A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AAVB-081","moa":"MYO7A","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"AAVantgarde Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"AAVantgarde Bio \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"Coave Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CTx-PDE6b","moa":"PDE6B","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Coave Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Coave Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Coave Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Laruparetigene Zovaparvovec","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"MeiraGTx","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ MeiraGTx","highestDevelopmentStatusID":"7","companyTruncated":"Johnson & Johnson Innovative Medicine \/ MeiraGTx"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"MeiraGTx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"MeiraGTx","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"MeiraGTx \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"MeiraGTx \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACDN-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ascidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DSP-3077","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Sumitomo Pharma America \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sumitomo Pharma America \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"OCU410ST","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"4BIO Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ 4BIO Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ 4BIO Capital"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"SparingVision","sponsor":"Jeito Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SparingVision","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Jeito Capital","highestDevelopmentStatusID":"7","companyTruncated":"SparingVision \/ Jeito Capital"},{"orgOrder":0,"company":"Atsena Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"ATSN-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atsena Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Atsena Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Atsena Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"SB-007","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"SpliceBio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SpliceBio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"SpliceBio \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ SparingVision","highestDevelopmentStatusID":"5","companyTruncated":"Agtc \/ SparingVision"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACDN-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ascidian Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ascidian Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Ascidian Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Gamut Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Acquisition","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gamut Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Gamut Therapeutics \/ SparingVision","highestDevelopmentStatusID":"4","companyTruncated":"Gamut Therapeutics \/ SparingVision"},{"orgOrder":0,"company":"SparingVision","sponsor":"Tenpoint Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"SPVN20","moa":"GIRK","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Tenpoint Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Tenpoint Therapeutics"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Editas Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EDIT-103","moa":"AAV5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Editas Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Editas Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Editas Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"NR2E3-AAV","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"IG-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intergalactic Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Intergalactic Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intergalactic Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ocugen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"OCU400","moa":"NR2E3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ocugen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Ocugen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ocugen \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"TeamedOn","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV2tYF-CB-hRS1","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Agtc \/ TeamedOn","highestDevelopmentStatusID":"1","companyTruncated":"Agtc \/ TeamedOn"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Harmony Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20000000000000001,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Harmony Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Harmony Biosciences"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Harmony Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Harmony Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Harmony Biosciences \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Harmony Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zynerba Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/CB2 receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Zynerba Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Transdermal Gel","sponsorNew":"Zynerba Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Zynerba Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Alirocumab","moa":"Subtilisin\/kexin type 9","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Divestment","leadProduct":"Eladocagene Exuparvovec","moa":"DDC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Intraputaminal Infusion","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Eladocagene Exuparvovec","moa":"DDC","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Gen Pharmaceuticals and Health Products","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Agreement","leadProduct":"Patisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products","highestDevelopmentStatusID":"15","companyTruncated":"Alnylam Pharmaceuticals \/ Gen Pharmaceuticals and Health Products"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Ionis Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Ionis Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Ionis Pharmaceuticals"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Nektar Therapeutics","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Agreement","leadProduct":"Antihemophilic Factor Recombinant, PEGylated","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Nektar Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Nektar Therapeutics \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"Nektar Therapeutics \/ HealthCare Royalty"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Immune Globulin, Human","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"CSI Pharmacy","sponsor":"Bio Products Laboratory","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSI Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSI Pharmacy \/ Bio Products Laboratory","highestDevelopmentStatusID":"15","companyTruncated":"CSI Pharmacy \/ Bio Products Laboratory"},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"ADMA Biologics","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Public Offering","leadProduct":"Human Immunoglobulin","moa":"Fc receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ADMA Biologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"ADMA Biologics \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"ADMA Biologics \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Funding","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0.33000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"BioCryst Pharmaceuticals \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Royalty Pharma"},{"orgOrder":0,"company":"Chiesi Global Rare Diseases","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Chiesi Global Rare Diseases","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Global Rare Diseases \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Global Rare Diseases \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Orsini Specialty Pharmacy","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Orsini Specialty Pharmacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Orsini Specialty Pharmacy \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Laboratoires CTRS","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Cholic Acid","moa":"NR1H4","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Laboratoires CTRS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratoires CTRS \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Laboratoires CTRS \/ Ethypharm"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Exeltis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Exeltis","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Exeltis"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Relief Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"Amino Acids Mixture","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"APR Applied Pharma Research","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"APR Applied Pharma Research \/ Relief Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"APR Applied Pharma Research \/ Relief Therapeutics"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Amino Acids Mixture","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Granule, Controlled Release","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Apotex Inc","sponsor":"Chiesi Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Deferiprone","moa":"Iron (Fe)","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Apotex Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apotex Inc \/ Chiesi Group","highestDevelopmentStatusID":"15","companyTruncated":"Apotex Inc \/ Chiesi Group"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Ivacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cystic Fibrosis Foundation","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.65000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Cystic Fibrosis Foundation \/ Royalty Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Cystic Fibrosis Foundation \/ Royalty Pharma"},{"orgOrder":0,"company":"Alembic Pharmaceuticals Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Icatibant Acetate","moa":"Bradykinin B2 receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Alembic Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alembic Pharmaceuticals Limited \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Alembic Pharmaceuticals Limited \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"L-Glutamine","moa":"CTP synthase-1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Avenacy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tranexamic Acid","moa":"Plasminogen","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Avenacy","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avenacy \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Avenacy \/ Inapplicable"},{"orgOrder":0,"company":"Cranbury Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Deflazacort","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Cranbury Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cranbury Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cranbury Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pharming","sponsor":"NewBridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"Conestat Alpha","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharming \/ NewBridge Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Pharming \/ NewBridge Pharmaceuticals"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Agnafit Bidco","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"Efmoroctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":8,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":8,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Agnafit Bidco"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"National Health Service (Nhs)","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2020","type":"Agreement","leadProduct":"Efmoroctocog Alpha","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Swedish Orphan Biovitrum AB \/ National Health Service (Nhs)","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ National Health Service (Nhs)"},{"orgOrder":0,"company":"LFB Group","sponsor":"HEMA Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eptacog Alpha","moa":"Factor X","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"LFB Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LFB Group \/ HEMA Biologics","highestDevelopmentStatusID":"15","companyTruncated":"LFB Group \/ HEMA Biologics"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"HLS Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Porcine recombinant Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ HLS Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ HLS Therapeutics"},{"orgOrder":0,"company":"Bayer AG","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2020","type":"Acquisition","leadProduct":"Koate DVI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ WuXi Biologics","highestDevelopmentStatusID":"15","companyTruncated":"Bayer AG \/ WuXi Biologics"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Immune Globulin G","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Subcutaneous Pre-Filled Injection","sponsorNew":"CSL Behring \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Inapplicable"},{"orgOrder":0,"company":"BioCryst Pharmaceuticals","sponsor":"Neopharmed Gentili","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Divestment","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioCryst Pharmaceuticals","amount2":0.26000000000000001,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0.26000000000000001,"dosageForm":"Capsule","sponsorNew":"BioCryst Pharmaceuticals \/ Neopharmed Gentili","highestDevelopmentStatusID":"15","companyTruncated":"BioCryst Pharmaceuticals \/ Neopharmed Gentili"},{"orgOrder":0,"company":"Indiana Hemophilia &Thrombosis Center, Inc.","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Indiana Hemophilia &Thrombosis Center, Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Indiana Hemophilia &Thrombosis Center, Inc. \/ Genentech"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Swedish Orphan Biovitrum AB \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Avalglucosidase Alfa","moa":"Glycogen","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Royal College of Surgeons, Ireland","sponsor":"Imperial College London | University College Dublin | University of Limerick | Cystic Fibrosis Registry of Ireland | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medizinische Hochschule Brandenb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Kaftrio","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Royal College of Surgeons, Ireland","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Royal College of Surgeons, Ireland \/ Imperial College London | University College Dublin | University of Limerick | Cystic Fibrosis Registry of Ireland | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medizinische Hochschule Brandenb","highestDevelopmentStatusID":"11","companyTruncated":"Royal College of Surgeons, Ireland \/ Imperial College London | University College Dublin | University of Limerick | Cystic Fibrosis Registry of Ireland | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Medizinische Hochschule Brandenb"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Clinic for Special Children","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Clinic for Special Children","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Insert","sponsorNew":"Clinic for Special Children \/ Genentech","highestDevelopmentStatusID":"11","companyTruncated":"Clinic for Special Children \/ Genentech"},{"orgOrder":0,"company":"University of North Carolina, Chapel Hill","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mannitol","moa":"Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH)","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of North Carolina, Chapel Hill","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina, Chapel Hill \/ Chiesi Group","highestDevelopmentStatusID":"11","companyTruncated":"University of North Carolina, Chapel Hill \/ Chiesi Group"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Coagulation Factor IX","moa":"Factor IX","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"University of Virginia","sponsor":"Octapharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"University of Virginia","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"University of Virginia \/ Octapharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Virginia \/ Octapharma"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Moroctocog Alfa","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"American Thrombosis and Hemostasis Network","sponsor":"LFB USA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa, Recombinant","moa":"Factor VIIa","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"American Thrombosis and Hemostasis Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Thrombosis and Hemostasis Network \/ LFB USA","highestDevelopmentStatusID":"11","companyTruncated":"American Thrombosis and Hemostasis Network \/ LFB USA"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Damoctocog Alfa Pegol","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bayer AG \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Bayer AG \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ PSI CRO","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ PSI CRO"},{"orgOrder":0,"company":"Children's Hospital Los Angeles","sponsor":"Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"FVIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Children's Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Los Angeles \/ Grifols International","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital Los Angeles \/ Grifols International"},{"orgOrder":0,"company":"Institute of Hematology & Blood Diseases Hospital, China","sponsor":"Sinocelltech Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SCT800","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Institute of Hematology & Blood Diseases Hospital, China","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Hematology & Blood Diseases Hospital, China \/ Sinocelltech Ltd.","highestDevelopmentStatusID":"11","companyTruncated":"Institute of Hematology & Blood Diseases Hospital, China \/ Sinocelltech Ltd."},{"orgOrder":0,"company":"Austin Institute for Clinical Research","sponsor":"The HydraFacial Company","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ReGen-GF","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Austin Institute for Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Serum","sponsorNew":"Austin Institute for Clinical Research \/ The HydraFacial Company","highestDevelopmentStatusID":"11","companyTruncated":"Austin Institute for Clinical Research \/ The HydraFacial Company"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"PTX-022","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PTX-022","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"RZ358","moa":"Insulin receptor (INSR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Bio Sidus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Sidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Sidus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio Sidus \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Vutrisiran","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GC101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Palvella Therapeutics","sponsor":"Petrichor Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Series D Financing","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Palvella Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Topical Gel","sponsorNew":"Palvella Therapeutics \/ Petrichor Healthcare","highestDevelopmentStatusID":"10","companyTruncated":"Palvella Therapeutics \/ Petrichor Healthcare"},{"orgOrder":0,"company":"Margaret Ragni","sponsor":"Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Margaret Ragni","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Margaret Ragni \/ Health Resources and Services Administration","highestDevelopmentStatusID":"10","companyTruncated":"Margaret Ragni \/ Health Resources and Services Administration"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CAEL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CAEL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Gabrail Cancer Center Research \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Octapharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Human Normal Immunoglobulin","moa":"High affinity immunoglobulin gamma Fc receptor I; Putative high affinity immunoglobulin gamma Fc receptor IB; Low affinity immunoglobulin gamma Fc region receptor II-a; Low affinity immunoglobulin gamma Fc region receptor II-b; Low affinity immunoglobulin gamma Fc region receptor II-c; Low affinity immunoglobulin gamma Fc region receptor III-A; Low affinity immunoglobulin gamma Fc region receptor III-B; Complement C3; Complement C4-A; Complement C4-B; Complement C5","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Octapharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Octapharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Octapharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"NNC0365-3769","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Marstacimab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"IBI310","moa":"CTLA-4","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Boya Bio Pharmaceutical Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Boya Immunoglobulin","moa":"IgG","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus Brazil \/ Boya Bio Pharmaceutical Group","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Boya Bio Pharmaceutical Group"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody-protein Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Intravenous Immune Globulin","moa":"Immunoglobulins","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azidus Brazil \/ Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Giroctocogene Fitelparovec","moa":"F8 gene (Factor VIII)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Botaretigene Sparoparvovec","moa":"GTPase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Bluebird Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Betibeglogene Autotemcel","moa":"Hemoglobin beta chain","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bluebird Bio","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bluebird Bio \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bluebird Bio \/ Inapplicable"},{"orgOrder":0,"company":"Brown University","sponsor":"National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Brown University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brown University \/ National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Brown University \/ National Heart, Lung, and Blood Institute | Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Ultragenyx Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ultragenyx Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ultragenyx Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ultragenyx Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"CinnaGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRAN","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"alpha L Idosiduronase","moa":"Heparan sulfate | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"CinnaGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinnaGen \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"CinnaGen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Olezarsen","moa":"Apolipoprotein C-III mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Fazirsiran","moa":"SERPINA1 messenger RNA (SERPINA1 mRNA)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Vutrisiran Sodium","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Viltolarsen","moa":"Dystrophin pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"On Pharma","sponsor":"Hospital do Coracao","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Large Molecule","year":"2025","type":"Inapplicable","leadProduct":"Immune Globulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"On Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"On Pharma \/ Hospital do Coracao","highestDevelopmentStatusID":"10","companyTruncated":"On Pharma \/ Hospital do Coracao"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ticagrelor","moa":"Purinergic receptor P2Y12","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ IQVIA","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ IQVIA"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Albireo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Odevixibat","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Albireo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Albireo \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Albireo \/ Inapplicable"},{"orgOrder":0,"company":"Liverpool School of Tropical Medicine","sponsor":"University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroartemisinin","moa":"Ferriprotoporphyrin IX","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Liverpool School of Tropical Medicine","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liverpool School of Tropical Medicine \/ University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda","highestDevelopmentStatusID":"10","companyTruncated":"Liverpool School of Tropical Medicine \/ University of Bergen | University of Malawi | Makerere University | Indiana University | Global Health Uganda"},{"orgOrder":0,"company":"Tetra Discovery Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Discovery Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Discovery Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Discovery Partners \/ Inapplicable"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"enzyme inhibitors: inhibitors of histone deacetylase; vinca alkaloids","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italfarmaco \/ Fortrea","highestDevelopmentStatusID":"10","companyTruncated":"Italfarmaco \/ Fortrea"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma America","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dersimelagon","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Mitsubishi Tanabe Pharma America","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mitsubishi Tanabe Pharma America \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Mitsubishi Tanabe Pharma America \/ Inapplicable"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Migalastat","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Mirum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Maralixibat Chloride","moa":"Ileal bile acid transporter","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Mirum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mirum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Mirum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"Quince Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.48999999999999999,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"EryDel","sponsor":"Quince Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Steroid","year":"2023","type":"Acquisition","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"EryDel","amount2":0.48999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.48999999999999999,"dosageForm":"Intra-erythrocyte Infusion","sponsorNew":"EryDel \/ Quince Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"EryDel \/ Quince Therapeutics"},{"orgOrder":0,"company":"Khondrion","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ Inapplicable"},{"orgOrder":0,"company":"Khondrion","sponsor":"UMDF","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"Sonlicromanol","moa":"mPGES-1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Khondrion","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Khondrion \/ UMDF","highestDevelopmentStatusID":"10","companyTruncated":"Khondrion \/ UMDF"},{"orgOrder":0,"company":"Quince Therapeutics","sponsor":"Nantahala Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Steroid","year":"2025","type":"Private Placement","leadProduct":"Dexamethasone Sodium Phosphate","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Quince Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Quince Therapeutics \/ Nantahala Capital","highestDevelopmentStatusID":"10","companyTruncated":"Quince Therapeutics \/ Nantahala Capital"},{"orgOrder":0,"company":"Natco Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Natco Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natco Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Natco Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Levo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Levo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Levo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Levo Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zhengzhou Gensciences Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Efmoroctocog Alfa","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zhengzhou Gensciences Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhengzhou Gensciences Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Zhengzhou Gensciences Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Zhengzhou Gensciences Inc","sponsor":"Jiangsu Gensciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Efmoroctocog Alfa","moa":"Coagulation factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Zhengzhou Gensciences Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Zhengzhou Gensciences Inc \/ Jiangsu Gensciences","highestDevelopmentStatusID":"10","companyTruncated":"Zhengzhou Gensciences Inc \/ Jiangsu Gensciences"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Carbetocin Acetate","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Acadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Acadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GeneScience Pharmaceuticals Co Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human FSH-CTP Fusion Protein","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneScience Pharmaceuticals Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GeneScience Pharmaceuticals Co Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ PSI CRO","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ PSI CRO"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Prolastin-C","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Aryogen Pharmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRAN","productType":"Protein-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"Rfviii-Fc","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aryogen Pharmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aryogen Pharmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aryogen Pharmed \/ Inapplicable"},{"orgOrder":0,"company":"Margaret Ragni","sponsor":"Health Resources and Services Administration","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Eloctate ITI","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Margaret Ragni","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Margaret Ragni \/ Health Resources and Services Administration","highestDevelopmentStatusID":"10","companyTruncated":"Margaret Ragni \/ Health Resources and Services Administration"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAK-667","moa":"Aurora kinase A","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TAK-771","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace klinische Entwicklung","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"18-F Florbetaben","moa":"Amyloid-beta-plaque","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung","highestDevelopmentStatusID":"10","companyTruncated":"Life Molecular Imaging \/ pharmtrace klinische Entwicklung"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"TAK-771","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Fordadistrogene","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Visirna Therapeutics HK Limited","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VSA001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna Therapeutics HK Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Visirna Therapeutics HK Limited \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Visirna Therapeutics HK Limited \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical | Baxalta Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAK-881","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical | Baxalta Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical | Baxalta Pharmaceutical"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Cellavita","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Human Dental Pulp Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Dental","sponsorNew":"Azidus Brazil \/ Cellavita","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Cellavita"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Von Willebrand Factor","moa":"von Willebrand factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Unity Health Toronto \/ Inapplicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ANB-002","moa":"IL-36 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"SK Plasma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SKP-0141","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"SK Plasma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Plasma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"SK Plasma \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu BioJeTay Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jiangsu BioJeTay Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu BioJeTay Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu BioJeTay Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kyowa Kirin","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KK8398","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Kyowa Kirin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyowa Kirin \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Kyowa Kirin \/ Inapplicable"},{"orgOrder":0,"company":"Ligand Pharmaceuticals","sponsor":"Palvella Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Agreement","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ligand Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical","sponsorNew":"Ligand Pharmaceuticals \/ Palvella Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"Ligand Pharmaceuticals \/ Palvella Therapeutics"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"JR-141","moa":"Heparan sulfate | Transferrin receptor | Dermatan sulfate","graph1":"Genetic Disease","graph2":"Phase III","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"ELA026","moa":"SIRP-alpha","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Electra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Electra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Electra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Glycomine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"GLM101","moa":"Mannose-1-phosphate","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Glycomine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Glycomine \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Glycomine \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"Pegunigalsidase alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Icon Plc"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Pegunigalsidase alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Icon Plc"},{"orgOrder":0,"company":"Bambino Ges\u00f9 Hospital and Research Institute","sponsor":"University of Exeter | Radboud University Medical Center | Consorzio per Valutazioni Biologiche e Farmacologiche","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Posaconazole","moa":"Cytochrome P450 51","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Bambino Ges\u00f9 Hospital and Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bambino Ges\u00f9 Hospital and Research Institute \/ University of Exeter | Radboud University Medical Center | Consorzio per Valutazioni Biologiche e Farmacologiche","highestDevelopmentStatusID":"9","companyTruncated":"Bambino Ges\u00f9 Hospital and Research Institute \/ University of Exeter | Radboud University Medical Center | Consorzio per Valutazioni Biologiche e Farmacologiche"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"INSERM U1163","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Famotidine","moa":"Histamine H2 receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM U1163","highestDevelopmentStatusID":"9","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ INSERM U1163"},{"orgOrder":0,"company":"Tetra Discovery Partners","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Zatolmilast","moa":"Phosphodiesterase 4D","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Tetra Discovery Partners","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Discovery Partners \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Tetra Discovery Partners \/ Inapplicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"REN001","moa":"PARP delta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Indiana University","sponsor":"Global Health Uganda | Makerere University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Zinc Sulphate","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indiana University \/ Global Health Uganda | Makerere University","highestDevelopmentStatusID":"9","companyTruncated":"Indiana University \/ Global Health Uganda | Makerere University"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Camurus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"CAM2029","moa":"SST receptor","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Camurus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Camurus \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Camurus \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"TAK-672","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"rAAV2tYF-GRK1-hRPGRco","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"GNR-038","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GNR-055","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Lyophilized Powder","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TAK-881","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Prodia StemCell Indonesia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PT Prodia StemCell Indonesia \/ Inapplicable"},{"orgOrder":0,"company":"Rezolute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"RZ358","moa":"Insulin receptor (INSR)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Rezolute","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Rezolute \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rezolute \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"REC-994","moa":"Superoxide Radical","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Recursion Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Tacrolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Unity Health Toronto \/ US Department of Defense","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ US Department of Defense"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"National Institutes of Health | University of California, San Francisco","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sirolimus","moa":"FK506-binding protein 1A","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ National Institutes of Health | University of California, San Francisco"},{"orgOrder":0,"company":"Aceragen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aceragen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aceragen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aceragen \/ Inapplicable"},{"orgOrder":0,"company":"Bausch Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifaximin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bausch Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bausch Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bausch Health \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"CAEL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Peking Union Medical College Hospital \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Intergroupe Francophone du Myelome","sponsor":"Sanofi | Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Isatuximab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Intergroupe Francophone du Myelome","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intergroupe Francophone du Myelome \/ Sanofi | Bristol Myers Squibb","highestDevelopmentStatusID":"8","companyTruncated":"Intergroupe Francophone du Myelome \/ Sanofi | Bristol Myers Squibb"},{"orgOrder":0,"company":"CytoDyn","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CytoDyn","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CytoDyn \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"CytoDyn \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Children's National Research Institute","sponsor":"Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Daratumumab","moa":"Lymphocyte differentiation antigen CD38","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Children's National Research Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's National Research Institute \/ Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso","highestDevelopmentStatusID":"8","companyTruncated":"Children's National Research Institute \/ Alberta Children's Hospital | The Hospital for Sick Children | Levine Children's Hospital | Ann & Robert H Lurie Children's Hospital of Chicago | Nationwide Children\u2019s Hospital | Children's Hospital at Montefiore | Doris Duke Foundation | Johnson & Johnso"},{"orgOrder":0,"company":"Vigil Neuroscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"VGL101","moa":"TREM2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Vigil Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigil Neuroscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Vigil Neuroscience \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"AT-02","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Capricor","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Deramiocel","moa":"Exosome release","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Capricor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Capricor \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Capricor \/ Inapplicable"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"MCO-010","moa":"MCO","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"AGTC-501","moa":"X-linked retinitis pigmentosa GTPase regulator (RPGR)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Beacon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beacon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Beacon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"SAR422459","moa":"ABCR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Oxford Biomedica \/ Sanofi"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Donidalorsen","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ionis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Alabama at Birmingham","sponsor":"Children's Healthcare of Atlanta | Children's Hospital Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Polyinosinic Acid","moa":"Immune","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of Alabama at Birmingham","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Alabama at Birmingham \/ Children's Healthcare of Atlanta | Children's Hospital Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"University of Alabama at Birmingham \/ Children's Healthcare of Atlanta | Children's Hospital Los Angeles"},{"orgOrder":0,"company":"Nippon Shinyaku","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"NS-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Nippon Shinyaku","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nippon Shinyaku \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Nippon Shinyaku \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"NS-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"8","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-810","moa":"Ornithine transcarbamylase (OTC)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"PepGen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"PGN-EDO51","moa":"Exon-51","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PepGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"PepGen \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PepGen \/ Inapplicable"},{"orgOrder":0,"company":"Argo Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"BW-20805","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Argo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argo Biopharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Argo Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"NFX-179","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"NFlection Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stargazer Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Quercis Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Isoquercitrin","moa":"Aldo-keto reductase family 1 member B1; Angiotensin-converting enzyme","graph1":"Genetic Disease","graph2":"Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Heart, Lung, and Blood Institute \/ Quercis Pharma","highestDevelopmentStatusID":"8","companyTruncated":"National Heart, Lung, and Blood Institute \/ Quercis Pharma"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Mavodelpar","moa":"NR1C3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OnKure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OnKure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ML Bio Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BBP-418","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ML Bio Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"ML Bio Solutions \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ML Bio Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sulindac","moa":"Cyclooxygenase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Tufts Medical Center","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tufts Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tufts Medical Center \/ Sanofi","highestDevelopmentStatusID":"8","companyTruncated":"Tufts Medical Center \/ Sanofi"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Elizabeth Berry-Kravis","sponsor":"FRAXA Research Foundation | Purposeful IKE","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Dihydroergotoxine Mesylate","moa":"Monoamine oxidase (MAO)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Elizabeth Berry-Kravis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE","highestDevelopmentStatusID":"8","companyTruncated":"Elizabeth Berry-Kravis \/ FRAXA Research Foundation | Purposeful IKE"},{"orgOrder":0,"company":"Mayo Clinic","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Probenecid","moa":"Solute carrier family 22 member 6 | Solute carrier family 22 member 8 | Solute carrier family 22 member 11","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Mayo Clinic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mayo Clinic \/ Otsuka Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Mayo Clinic \/ Otsuka Holdings"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eloxx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"ELX-02","moa":"80S Ribosome","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Eloxx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eloxx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Eloxx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zomagen Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"VTX2735","moa":"NLRP3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zomagen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zomagen Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zomagen Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"BI1291583","moa":"DPP-1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Atumelnant","moa":"ACTH","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crinetics Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Crinetics Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Acer Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Acer Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Acer Therapeutics"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AceLink Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AceLink Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Dexmedetomidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Film","sponsorNew":"NYU Langone Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Inapplicable"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"PTC518","moa":"Huntingtin mRNA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PTC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PTC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rege Nephro Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Avance Clinical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SPG601","moa":"BK","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spinogenix \/ Avance Clinical","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Avance Clinical"},{"orgOrder":0,"company":"Italfarmaco","sponsor":"Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Italfarmaco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Italfarmaco \/ Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"Italfarmaco \/ Fortrea"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Zevra Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sodium Phenylbutyrate","moa":"Glutamine","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Zevra Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Zevra Therapeutics"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Risdiplam","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"F. Hoffmann-La Roche \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Indian Council of Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Desidustat","moa":"enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zydus Lifesciences \/ Indian Council of Medical Research","highestDevelopmentStatusID":"8","companyTruncated":"Zydus Lifesciences \/ Indian Council of Medical Research"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Ifetroban Sodium","moa":"TBXA2R","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cumberland Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cumberland Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spruce Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tildacerfont","moa":"CRHR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Spruce Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spruce Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Spruce Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"AUG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Divestment","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ AUG Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ AUG Therapeutics"},{"orgOrder":0,"company":"AMO Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tideglusib","moa":"Glycogen synthase kinase-3 beta","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"AMO Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AMO Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"AMO Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Applied Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Govorestat","moa":"enzyme inhibitors: aldose-reductase inhibitors","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Applied Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Applied Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Applied Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Trehalose","moa":"TFEB","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Bridge Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bridge Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NFlection Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NFX-179","moa":"ERK activator kinase (MEK)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"NFlection Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"NFlection Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"NFlection Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CDG Care","sponsor":"Cerecor","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Alpha-D-Galactose","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"CDG Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CDG Care \/ Cerecor","highestDevelopmentStatusID":"8","companyTruncated":"CDG Care \/ Cerecor"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"DCI Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Series B Financing","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ DCI Partners","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ DCI Partners"},{"orgOrder":0,"company":"Rege Nephro","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Tamibarotene","moa":"Retinoic acid receptor alpha | Retinoic acid receptor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rege Nephro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rege Nephro \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rege Nephro \/ Inapplicable"},{"orgOrder":0,"company":"Stargazer Pharmaceuticals","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"STG-001","moa":"RBP4","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Stargazer Pharmaceuticals","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Stargazer Pharmaceuticals \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Stargazer Pharmaceuticals \/ Organovo Holdings"},{"orgOrder":0,"company":"Solaxa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Fampridine","moa":"Voltage-gated potassium channel","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Solaxa","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Disintegrating","sponsorNew":"Solaxa \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Solaxa \/ Inapplicable"},{"orgOrder":0,"company":"Tracey McLaughlin","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Avexitide","moa":"Glucagon-like peptide 1 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tracey McLaughlin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tracey McLaughlin \/ Eiger BioPharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Tracey McLaughlin \/ Eiger BioPharmaceuticals"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Constant Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Talfirastide","moa":"AGTR1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Constant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Constant Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Constant Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Navepegritide","moa":"NPRC","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ascendis Pharma \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Ascendis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Protagonist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Rusfertide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Protagonist Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protagonist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Protagonist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recifercept","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Recifercept","moa":"receptor molecules","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"ARO-ANG","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ApcinteX","sponsor":"Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"SerpinPC","moa":"Protein C","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ApcinteX","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ApcinteX \/ Centessa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"ApcinteX \/ Centessa Pharmaceuticals"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Luspatercept","moa":"Transforming growth factor beta","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ReNeuron \/ Inapplicable"},{"orgOrder":0,"company":"AzurRx SAS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MS1819-SD","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"AzurRx SAS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AzurRx SAS \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"AzurRx SAS \/ Inapplicable"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM15136","moa":"GLP-1R\/GIPR\/GCGR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hanmi Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Hanmi Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Metro International Biotech","sponsor":"Children's Hospital of Philadelphia","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MIB-626","moa":"NAD+","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Metro International Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Metro International Biotech \/ Children's Hospital of Philadelphia","highestDevelopmentStatusID":"8","companyTruncated":"Metro International Biotech \/ Children's Hospital of Philadelphia"},{"orgOrder":0,"company":"Akershus University Hospital","sponsor":"The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Akershus University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen","highestDevelopmentStatusID":"8","companyTruncated":"Akershus University Hospital \/ The Bergesen Foundation | South-Eastern Norway Regional Health Authority | Sykehuset Innlandet HF | Oslo University Hospital | St. Olavs Hospital | Haukeland University Hospital | University Hospital of North Norway | University of Bergen"},{"orgOrder":0,"company":"Matrix Biomed","sponsor":"University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MBM-01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Matrix Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Matrix Biomed \/ University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Matrix Biomed \/ University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"David Williams","sponsor":"National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous CD34+ Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"David Williams","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"David Williams \/ National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network","highestDevelopmentStatusID":"8","companyTruncated":"David Williams \/ National Heart, Lung, and Blood Institute | California Institute for Regenerative Medicine (CIRM) | Bluebird Bio | Blood and Marrow Transplant Clinical Trials Network"},{"orgOrder":0,"company":"Columbia University","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"124-I Evuzamitide","moa":"MUC1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University \/ Attralus","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Attralus"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR447537","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SAR447537","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Thiogenesis Therapeutics, Inc.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"TTI-0102","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Thiogenesis Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Thiogenesis Therapeutics, Inc. \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Thiogenesis Therapeutics, Inc. \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"mRNA-3745","moa":"Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"Bionic Sight","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BS01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bionic Sight","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bionic Sight \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bionic Sight \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GC101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GC101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"4D-710","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Belantamab Mafodotin","moa":"Tumor necrosis factor receptor superfamily member 17 | Tubulin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ GSK","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ GSK"},{"orgOrder":0,"company":"Children's Hospital Los Angeles","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Crizanlizumab","moa":"P-selectin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital Los Angeles \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital Los Angeles \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Lu AG13909","moa":"ACTH receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"H. Lundbeck AS \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Linvoseltamab","moa":"TNFRSF17","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Private Placement","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Perceptive Advisors"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"BMN 307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"4D Molecular Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"4D-125","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"4D Molecular Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"4D Molecular Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"4D Molecular Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Sigilon Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SIG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Sigilon Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Eli Lilly \/ Sigilon Therapeutics"},{"orgOrder":0,"company":"Nanoscope Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"vMCO-I","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nanoscope Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanoscope Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Nanoscope Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"NTLA-2002","moa":"Kallikrein B1","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"BMN 331","moa":"C1-INH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BEAM-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"EXG001-307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NGGT","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGGT002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NGGT","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGGT \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGGT \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BE-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"JAG201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"NGGT Suzhou Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGGT002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NGGT Suzhou Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NGGT Suzhou Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NGGT Suzhou Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Hitachi Chemicals","sponsor":"Bluebird Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"Lentiglobin","moa":"Hemoglobin subunit beta (HBB)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Hitachi Chemicals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hitachi Chemicals \/ Bluebird Bio","highestDevelopmentStatusID":"7","companyTruncated":"Hitachi Chemicals \/ Bluebird Bio"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"AVR\u2011RD\u201104","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Divestment","leadProduct":"CTNS-RD-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Avrobio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Avrobio \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AXO-AAV-GM2","moa":"Beta-hexosaminidase subunit alpha (HEXA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Bpifrance","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Bpifrance"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":1.04,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Methylprednisolone","moa":"||Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Public Offering","leadProduct":"SIG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-201","moa":"SGSH","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ABO-101","moa":"HS","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NS-050\/NCNP-03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Next Generation Gene Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"NGGT002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Next Generation Gene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Next Generation Gene Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Next Generation Gene Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AGTC-501","moa":"X-linked retinitis pigmentosa GTPase regulator (RPGR)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"ReNeuron","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"hRPC Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ReNeuron","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"ReNeuron \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ReNeuron \/ Inapplicable"},{"orgOrder":0,"company":"Agtc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAV2tYF-GRK1-RPGR","moa":"RPGR","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Agtc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Agtc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Agtc \/ Inapplicable"},{"orgOrder":0,"company":"Exegenesis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EXG001-307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Exegenesis Bio","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Exegenesis Bio \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Exegenesis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Uniqure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrastriatal Infusion","sponsorNew":"Uniqure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Seroba","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2024","type":"Series B Financing","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Seroba","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Seroba"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"JR-441","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"JR-446","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"University of Illinois, Chicago","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"University of Illinois, Chicago","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Chicago \/ Global Blood Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"University of Illinois, Chicago \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Asklepion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Asklepion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"JNT-517","moa":"SLC6A19","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Jnana Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Jnana Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jnana Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Neurofibromatosis Therapeutic Acceleration Program | SpringWorks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Mirdametinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Neurofibromatosis Therapeutic Acceleration Program | SpringWorks Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Johns Hopkins University \/ Neurofibromatosis Therapeutic Acceleration Program | SpringWorks Therapeutics"},{"orgOrder":0,"company":"Essen Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Busulfan","moa":"DNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Essen Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essen Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Essen Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Instituto Nacional de Investigacao em Saude, Angola","sponsor":"Fundaci\u00f3n Bancaria Caixa D'estalvis I Pensions De Barcelona | Funda\u00e7ao Calouste Gulbenkian | CLINCOORD SERVICES, INC. | CLINCOORD PRESTA\u00c7\u00c3O DE SEVI\u00c7OS, LDA ANGOLA | Escola Superior de Tecnologia da Sa\u00fade de Lisboa | ClinCoord Research Center at Luanda Med","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Instituto Nacional de Investigacao em Saude, Angola","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Nacional de Investigacao em Saude, Angola \/ Fundaci\u00f3n Bancaria Caixa D'estalvis I Pensions De Barcelona | Funda\u00e7ao Calouste Gulbenkian | CLINCOORD SERVICES, INC. | CLINCOORD PRESTA\u00c7\u00c3O DE SEVI\u00c7OS, LDA ANGOLA | Escola Superior de Tecnologia da Sa\u00fade de Lisboa | ClinCoord Research Center at Luanda Med","highestDevelopmentStatusID":"7","companyTruncated":"Instituto Nacional de Investigacao em Saude, Angola \/ Fundaci\u00f3n Bancaria Caixa D'estalvis I Pensions De Barcelona | Funda\u00e7ao Calouste Gulbenkian | CLINCOORD SERVICES, INC. | CLINCOORD PRESTA\u00c7\u00c3O DE SEVI\u00c7OS, LDA ANGOLA | Escola Superior de Tecnologia da Sa\u00fade de Lisboa | ClinCoord Research Center at Luanda Med"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BMS-986470","moa":"CRBN\/ZBTB7A\/WIZ","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Bristol Myers Squibb \/ Inapplicable"},{"orgOrder":0,"company":"Spirovant Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SP-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spirovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spirovant Sciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spirovant Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Theris Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Theris Medical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Patch","sponsorNew":"Theris Medical \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Theris Medical \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Funding","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Aridis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Gallium Citrate","moa":"Bacterial growth","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Aridis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Aerosol","sponsorNew":"Aridis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aridis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dirocaftor","moa":"||cystic fibrosis transmembrane regulator (CFTR) protein modulators","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteostasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Proteostasis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Dirocaftor","moa":"||cystic fibrosis transmembrane regulator (CFTR) protein modulators","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Proteostasis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteostasis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Proteostasis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Children's Hospital of Philadelphia","sponsor":"Friedreich's Ataxia Research Alliance | Stealth Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Children's Hospital of Philadelphia","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Hospital of Philadelphia \/ Friedreich's Ataxia Research Alliance | Stealth Biotherapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Children's Hospital of Philadelphia \/ Friedreich's Ataxia Research Alliance | Stealth Biotherapeutics"},{"orgOrder":0,"company":"Clinuvel Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Afamelanotide","moa":"Melanocortin receptor 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Clinuvel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Implant","sponsorNew":"Clinuvel Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Clinuvel Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Stealth Biotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Elamipretide","moa":"peptides","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Stealth Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stealth Biotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Stealth Biotherapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Xenetic Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"SHP656","moa":"Cryptochrome circadian clock 1 (CRY1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Xenetic Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xenetic Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Xenetic Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"JCR Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lepunafusp Alfa","moa":"Heparan sulfate","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"JCR Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"JCR Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"JCR Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Megan Waldrop","sponsor":"Audentes Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"scAAV9.U7.ACCA","moa":"Dystrophin exon-51","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Megan Waldrop","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Megan Waldrop \/ Audentes Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Megan Waldrop \/ Audentes Therapeutics"},{"orgOrder":0,"company":"PT Prodia StemCell Indonesia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"PT Prodia StemCell Indonesia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT Prodia StemCell Indonesia \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"PT Prodia StemCell Indonesia \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Grifols International \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"University of Manchester","sponsor":"CTI Clinical Trial and Consulting | Great Ormond Street Hospital for Children NHS Foundation Trust | Manchester University NHS FT | LifeArc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous CD34+ Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"University of Manchester","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University of Manchester \/ CTI Clinical Trial and Consulting | Great Ormond Street Hospital for Children NHS Foundation Trust | Manchester University NHS FT | LifeArc","highestDevelopmentStatusID":"7","companyTruncated":"University of Manchester \/ CTI Clinical Trial and Consulting | Great Ormond Street Hospital for Children NHS Foundation Trust | Manchester University NHS FT | LifeArc"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ANB-004","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GC301","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GC101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"NS-050","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"NS Pharma \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ANB-002","moa":"IL-36 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"mRNA-3210","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ANB-010","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocad \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biocad \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BEAM-302","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"GeneCradle Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GC301","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GeneCradle Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GeneCradle Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"GeneCradle Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"BI3720931","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"EXG110","moa":"CD39","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"SPK-10001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spark Therapeutics, Inc \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"HM15421","moa":"GLP-1R","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"DFT383","moa":"BCL-2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Chigenovo","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ZVS203e","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Chigenovo","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Chigenovo \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Chigenovo \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BI3720931","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Bio Sidus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Agalsidase Beta","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Bio Sidus","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bio Sidus \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Bio Sidus \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series D Financing","leadProduct":"REC-994","moa":"Superoxide Radical","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Recursion Pharma","amount2":0.23999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Tablet","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"8","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Amikacin","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"PF-06741086","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Tulane University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Emicizumab","moa":"Coagulation factor IX and X","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tulane University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tulane University \/ Genentech","highestDevelopmentStatusID":"6","companyTruncated":"Tulane University \/ Genentech"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prothena","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"PRX004","moa":"ATTR protein","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Prothena","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prothena \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Prothena \/ Inapplicable"},{"orgOrder":0,"company":"Arialys Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ART5803","moa":"NMDA receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arialys Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arialys Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arialys Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"ELA026","moa":"SIRP-alpha","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Electra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Electra Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Electra Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Electra Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2022","type":"Series B Financing","leadProduct":"ELA026","moa":"SIRP-alpha","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Electra Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Electra Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"9","companyTruncated":"Electra Therapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Neurimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"NI006","moa":"Transthyretin (TTR)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Neurimmune","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurimmune \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Neurimmune \/ Inapplicable"},{"orgOrder":0,"company":"Rocket Pharma","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"RP-L401","moa":"T-cell immune regulator 1 (TCIRG1)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Rocket Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rocket Pharma \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"6","companyTruncated":"Rocket Pharma \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"ExCellThera","sponsor":"California Institute for Regenerative Medicine (CIRM)","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ECT-001-CB","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ExCellThera \/ California Institute for Regenerative Medicine (CIRM)","highestDevelopmentStatusID":"6","companyTruncated":"ExCellThera \/ California Institute for Regenerative Medicine (CIRM)"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Autologous Plasmablast","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"EXG001-307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Insmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"INS1201","moa":"dystrophin","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Insmed","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Insmed \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Insmed \/ Inapplicable"},{"orgOrder":0,"company":"Jiayin Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"EXG001-307","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Jiayin Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiayin Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiayin Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Axplora","sponsor":"Lysogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Axplora","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Axplora \/ Lysogene","highestDevelopmentStatusID":"6","companyTruncated":"Axplora \/ Lysogene"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"ET3","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expression Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Expression Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Funding","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Arbor Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"ABO-101","moa":"HS","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Arbor Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Arbor Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Dystrogen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Dystrophin Expressing Chimeric Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Dystrogen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dystrogen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Dystrogen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Hitachi Global Life Solutions","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"EXG-34217","moa":"ZSCAN4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen Therapeutics \/ Hitachi Global Life Solutions"},{"orgOrder":0,"company":"YolTech Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"YOLT-204","moa":"Fetal hemoglobin expression","graph1":"Genetic Disease","graph2":"Phase I","graph3":"YolTech Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"YolTech Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"YolTech Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Nexiguran Ziclumeran","moa":"TTR gene","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"SpliSense","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"SPL84","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"SpliSense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"SpliSense \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"SpliSense \/ Inapplicable"},{"orgOrder":0,"company":"PYC Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRALIA","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"VP-001","moa":"PRPF31","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PYC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PYC Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"PYC Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Eplontersen","moa":"Transthyretin mRNA","graph1":"Genetic Disease","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Nusinersen Sodium","moa":"SMN2 pre-mRNA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"TU7710","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"GC1130A","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Nucresiran","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alnylam Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Alnylam Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tiumbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"TU7710","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tiumbio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiumbio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tiumbio \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Other Large Molecule","year":"2023","type":"Collaboration","leadProduct":"BAY401016","moa":"Sema3A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Evotec","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bayer AG","highestDevelopmentStatusID":"6","companyTruncated":"Evotec \/ Bayer AG"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sebetralstat","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KalVista Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"KalVista Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Z Factor Limited","sponsor":"Hammersmith Medicines Research | Centessa Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ZF874","moa":"A1AT","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Z Factor Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Z Factor Limited \/ Hammersmith Medicines Research | Centessa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Z Factor Limited \/ Hammersmith Medicines Research | Centessa Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"Gabrail Cancer Center Research","sponsor":"Sanofi | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Bortezomib","moa":"26S proteasome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Gabrail Cancer Center Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"Gabrail Cancer Center Research \/ Sanofi | National Cancer Institute"},{"orgOrder":0,"company":"AceLink Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"AL01211","moa":"GCS","graph1":"Genetic Disease","graph2":"Phase I","graph3":"AceLink Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AceLink Therapeutics \/ Novotech","highestDevelopmentStatusID":"6","companyTruncated":"AceLink Therapeutics \/ Novotech"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Selumetinib","moa":"Dual specificity mitogen-activated protein kinase kinase 2 | Dual specificity mitogen-activated protein kinase kinase 1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Merck & Co","highestDevelopmentStatusID":"15","companyTruncated":"AstraZeneca \/ Merck & Co"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRELAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lefamulin Acetate","moa":"Bacterial 70S ribosome","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nabriva Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nabriva Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Salanersen","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biogen \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Voxelotor","moa":"Hemoglobin HbA","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Eliglustat","moa":"Ceramide glucosyltransferase","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"Philogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"177-Lu OncoFAP-23","moa":"FAP","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Philogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Philogen \/ Inapplicable"},{"orgOrder":0,"company":"Life Molecular Imaging","sponsor":"pharmtrace","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Florbetaben","moa":"Amyloid","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Life Molecular Imaging","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Life Molecular Imaging \/ pharmtrace","highestDevelopmentStatusID":"6","companyTruncated":"Life Molecular Imaging \/ pharmtrace"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Enavate Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"SION-638","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Enavate Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Enavate Sciences"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"SION-109","moa":"CFTR ICL4","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ovid Therapeutics","sponsor":"Graviton Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GV101","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Ovid Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ovid Therapeutics \/ Graviton Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Ovid Therapeutics \/ Graviton Bioscience"},{"orgOrder":0,"company":"Pharvaris","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Series C Financing","leadProduct":"Deucrictibant","moa":"BDKRB2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pharvaris","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Pharvaris \/ Viking Global Investors","highestDevelopmentStatusID":"6","companyTruncated":"Pharvaris \/ Viking Global Investors"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ribitol","moa":"Glycosylation","graph1":"Genetic Disease","graph2":"Phase I","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BridgeBio Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytokinetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-089","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Cytokinetics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytokinetics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytokinetics \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"R42 Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2024","type":"Series C Financing","leadProduct":"HLX-1502","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Healx","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ R42 Group","highestDevelopmentStatusID":"8","companyTruncated":"Healx \/ R42 Group"},{"orgOrder":0,"company":"Tyra Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TYRA-300","moa":"FGFR3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Tyra Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tyra Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tyra Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inversago Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Inversago Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inversago Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Inversago Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Abliva","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KL1333","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Abliva","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet, Encapsulated","sponsorNew":"Abliva \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Abliva \/ Inapplicable"},{"orgOrder":0,"company":"PRG S&Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"PRG S&Tech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PRG S&Tech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"PRG S&Tech \/ Inapplicable"},{"orgOrder":0,"company":"Praxis Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Relutrigine","moa":"NaV Channel","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Praxis Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Praxis Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vascarta","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Vascarta \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Inapplicable"},{"orgOrder":0,"company":"Pretzel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PX578","moa":"POLG","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pretzel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pretzel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pretzel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioMarin Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"BioMarin Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Immunoforge","sponsor":"PhaseBio Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Froniglutide","moa":"GLP-1 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoforge \/ PhaseBio Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Immunoforge \/ PhaseBio Pharmaceuticals"},{"orgOrder":0,"company":"Larimar Therapeutics","sponsor":"Veristat | Metrum Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"CTI-1601","moa":"Soluble guanylate cyclase (GCS)","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Larimar Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Larimar Therapeutics \/ Veristat | Metrum Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Larimar Therapeutics \/ Veristat | Metrum Research Group"},{"orgOrder":0,"company":"Aryogen Pharmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"IRAN","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eptacog Alfa","moa":"Coagulation factor VII","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Aryogen Pharmed","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aryogen Pharmed \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Aryogen Pharmed \/ Inapplicable"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"PSI CRO","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Orphan Biovitrum AB \/ PSI CRO","highestDevelopmentStatusID":"11","companyTruncated":"Swedish Orphan Biovitrum AB \/ PSI CRO"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"KER-065","moa":"Myostatin\/Activin A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Biohaven Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"Taldefgrobep Alpha","moa":"MSTN activation","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Biohaven Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Biohaven Pharmaceuticals"},{"orgOrder":0,"company":"Actinium pharmaceuticals","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2024","type":"Collaboration","leadProduct":"131-I Apamistamab","moa":"BC8","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Actinium pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actinium pharmaceuticals \/ Columbia University","highestDevelopmentStatusID":"6","companyTruncated":"Actinium pharmaceuticals \/ Columbia University"},{"orgOrder":0,"company":"Marianne Yee","sponsor":"National Heart, Lung, and Blood Institute | Cerus Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Biotin Labeled Red Blood Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Marianne Yee","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marianne Yee \/ National Heart, Lung, and Blood Institute | Cerus Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Marianne Yee \/ National Heart, Lung, and Blood Institute | Cerus Corporation"},{"orgOrder":0,"company":"Generium","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"RUSSIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"GNR-038","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II\/ Phase III","graph3":"Generium","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Generium \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Generium \/ Inapplicable"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"STSP-0601","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Attralus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabeled Compounds","year":"2022","type":"Inapplicable","leadProduct":"124-I AT03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Attralus \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Attralus \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SAR439459","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Sanofi \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sanofi \/ Inapplicable"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GC1123","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Hemogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"\u0392-Globin Restored Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shenzhen Hemogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hemogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Hemogen \/ Inapplicable"},{"orgOrder":0,"company":"Shanghai Jiaotong University School of Medicine","sponsor":"Shanghai Vitalgen BioPharma Co., Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"VGN-R09b","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shanghai Jiaotong University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shanghai Jiaotong University School of Medicine \/ Shanghai Vitalgen BioPharma Co., Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Jiaotong University School of Medicine \/ Shanghai Vitalgen BioPharma Co., Ltd."},{"orgOrder":0,"company":"Shenzhen Hemogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"\u0392-Globin Restored Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shenzhen Hemogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hemogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Hemogen \/ Inapplicable"},{"orgOrder":0,"company":"Shenzhen Hemogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"\u0392-Globin Restored Autologous Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shenzhen Hemogen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Hemogen \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shenzhen Hemogen \/ Inapplicable"},{"orgOrder":0,"company":"Elixirgen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"EXG34217","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Elixirgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Elixirgen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Elixirgen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"University of Tennessee Graduate School of Medicine","sponsor":"Attralus","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Radiolabeled Compounds","year":"2023","type":"Inapplicable","leadProduct":"99m-Tc p5+14","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"University of Tennessee Graduate School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Tennessee Graduate School of Medicine \/ Attralus","highestDevelopmentStatusID":"6","companyTruncated":"University of Tennessee Graduate School of Medicine \/ Attralus"},{"orgOrder":0,"company":"Shanghai Vitalgen BioPharma Co., Ltd.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VGM-R02b","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Shanghai Vitalgen BioPharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Vitalgen BioPharma Co., Ltd. \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Shanghai Vitalgen BioPharma Co., Ltd. \/ Inapplicable"},{"orgOrder":0,"company":"Equilibra Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"SR604","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Equilibra Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Equilibra Bioscience \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Equilibra Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"CorrectSequence Therapeutics","sponsor":"First Affiliated Hospital of Guangxi Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CS-206","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"CorrectSequence Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"CorrectSequence Therapeutics \/ First Affiliated Hospital of Guangxi Medical University","highestDevelopmentStatusID":"6","companyTruncated":"CorrectSequence Therapeutics \/ First Affiliated Hospital of Guangxi Medical University"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NNC0442-0344","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Sapropterin Hydrochloride","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relief Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relief Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Magenta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"MGTA-117","moa":"CD117","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Magenta Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Beam Therapeutics \/ Magenta Therapeutics"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"OPGx-001","moa":"LCA5","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opus Genetics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ Inapplicable"},{"orgOrder":0,"company":"Papillon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PPL-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Papillon Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Papillon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Papillon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Taysha Gene Therapies","sponsor":"PBM Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Financing","leadProduct":"TGTX-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Taysha Gene Therapies","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Taysha Gene Therapies \/ PBM Capital","highestDevelopmentStatusID":"5","companyTruncated":"Taysha Gene Therapies \/ PBM Capital"},{"orgOrder":0,"company":"Lysogene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"LYS-GM101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Lysogene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Lysogene \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Lysogene \/ Inapplicable"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Baudax Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Acquisition","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Baudax Bio","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Baudax Bio"},{"orgOrder":0,"company":"TeraImmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ Inapplicable"},{"orgOrder":0,"company":"TeraImmune","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"TeraImmune","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TeraImmune \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"TeraImmune \/ National Institutes of Health"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Canada Pension Plan Investment Board","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Series B Financing","leadProduct":"SIG-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Canada Pension Plan Investment Board"},{"orgOrder":0,"company":"Baudax Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TI-168","moa":"Factor VIII","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Baudax Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baudax Bio \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Baudax Bio \/ Inapplicable"},{"orgOrder":0,"company":"Amarna Therapeutics","sponsor":"C4 holding BV","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell and Gene therapy","year":"2021","type":"Financing","leadProduct":"AMA005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Amarna Therapeutics","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Amarna Therapeutics \/ C4 holding BV","highestDevelopmentStatusID":"5","companyTruncated":"Amarna Therapeutics \/ C4 holding BV"},{"orgOrder":0,"company":"Expression Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Lentivirus-Hematopoietic Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Expression Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Expression Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Expression Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sigilon Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"SIG-005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Sigilon Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sigilon Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Sigilon Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Iduronicrin Genleukocel-T","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immusoft Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series B Financing","leadProduct":"VTA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vita Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Vita Therapeutics \/ Cambrian Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Vita Therapeutics \/ Cambrian Biopharma"},{"orgOrder":0,"company":"Vital Therapeutics & Formulations Pvt Ltd","sponsor":"Cambrian Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Cell and Gene therapy","year":"2021","type":"Series A Financing","leadProduct":"VTA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vital Therapeutics & Formulations Pvt Ltd","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Vital Therapeutics & Formulations Pvt Ltd \/ Cambrian Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"Vital Therapeutics & Formulations Pvt Ltd \/ Cambrian Biopharma"},{"orgOrder":0,"company":"OmniaBio","sponsor":"Somite Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"SMT-M01","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"OmniaBio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OmniaBio \/ Somite Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"OmniaBio \/ Somite Therapeutics"},{"orgOrder":0,"company":"Suzhou GenAssist Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GEN6050","moa":"DMD exon 50","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Suzhou GenAssist Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou GenAssist Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Suzhou GenAssist Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cure Rare","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CRD-TMH-001","moa":"Dystrophin protein","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Cure Rare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Rare \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"5","companyTruncated":"Cure Rare \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"NS Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"NS-050\/NCNP-03","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"NS Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NS Pharma \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"NS Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"PBGENE-DMD","moa":"DMD","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Precision BioSciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Precision BioSciences \/ Inapplicable"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Series B Financing","leadProduct":"S-1117","moa":"IgG","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Seismic Therapeutic","amount2":0.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Seismic Therapeutic \/ Bessemer Venture Partners","highestDevelopmentStatusID":"5","companyTruncated":"Seismic Therapeutic \/ Bessemer Venture Partners"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Hanmi Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"alpha-galactosidase A","moa":"Globotriaosylceramide","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Hanmi Pharmaceutical","highestDevelopmentStatusID":"5","companyTruncated":"GC Biopharma \/ Hanmi Pharmaceutical"},{"orgOrder":0,"company":"Enzyvant","sponsor":"Aceragen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Acquisition","leadProduct":"Recombinant Human Acid Ceramidase","moa":"Acid ceramidase","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Enzyvant","amount2":0.23000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Enzyvant \/ Aceragen","highestDevelopmentStatusID":"5","companyTruncated":"Enzyvant \/ Aceragen"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Immusoft Corporation","sponsor":"California Institute for Regenerative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Funding","leadProduct":"Iduronate Sulfatase","moa":"Enzyme Replacement","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immusoft Corporation","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immusoft Corporation \/ California Institute for Regenerative Medicine","highestDevelopmentStatusID":"5","companyTruncated":"Immusoft Corporation \/ California Institute for Regenerative Medicine"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"French National Institute of Health and Medical Research","sponsor":"Tonix Pharmaceuticals Holding Corp","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Hormone","year":"2021","type":"Licensing Agreement","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"French National Institute of Health and Medical Research","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"French National Institute of Health and Medical Research \/ Tonix Pharmaceuticals Holding Corp","highestDevelopmentStatusID":"5","companyTruncated":"French National Institute of Health and Medical Research \/ Tonix Pharmaceuticals Holding Corp"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Mallinckrodt Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Collaboration","leadProduct":"SLN501","moa":"C3 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Silence Therapeutics","amount2":2.02,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":2.02,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"Silence Therapeutics \/ Mallinckrodt Pharmaceuticals"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"SDIC CS Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2022","type":"Series A Financing","leadProduct":"RAG-06","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ractigen Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ SDIC CS Capital","highestDevelopmentStatusID":"5","companyTruncated":"Ractigen Therapeutics \/ SDIC CS Capital"},{"orgOrder":0,"company":"University of L\u2019Aquila","sponsor":"SiSaf Ltd","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Oligonucleotide","year":"2021","type":"Collaboration","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"University of L\u2019Aquila","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of L\u2019Aquila \/ SiSaf Ltd","highestDevelopmentStatusID":"5","companyTruncated":"University of L\u2019Aquila \/ SiSaf Ltd"},{"orgOrder":0,"company":"SiSaf","sponsor":"CSSi LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiSaf \/ CSSi LifeSciences","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ CSSi LifeSciences"},{"orgOrder":0,"company":"SiSaf","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"SIS-101-ADO","moa":"CLCN7","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"SiSaf","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SiSaf \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"SiSaf \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Fibrocor Therapeutics","sponsor":"McQuade Center","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"FIB918","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Fibrocor Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fibrocor Therapeutics \/ McQuade Center","highestDevelopmentStatusID":"5","companyTruncated":"Fibrocor Therapeutics \/ McQuade Center"},{"orgOrder":0,"company":"MMJ International Holding","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"MMJ-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"MMJ International Holding","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MMJ International Holding \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"MMJ International Holding \/ Inapplicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"SION-638","moa":"NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"SION-638","moa":"||NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ OrbiMed Advisors","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ OrbiMed Advisors"},{"orgOrder":0,"company":"EV\u014cQ Nano","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"EVQ-218","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"EV\u014cQ Nano","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EV\u014cQ Nano \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"EV\u014cQ Nano \/ Inapplicable"},{"orgOrder":0,"company":"Healx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"HLX-0201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Healx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Healx \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Healx \/ Inapplicable"},{"orgOrder":0,"company":"Neuronascent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NNI-351","moa":"DYRK","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Neuronascent","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuronascent \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Neuronascent \/ Inapplicable"},{"orgOrder":0,"company":"DepYmed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"DPM-1001","moa":"PTP1B","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DepYmed","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DepYmed \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"DepYmed \/ Inapplicable"},{"orgOrder":0,"company":"Sarcomatrix","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Funding","leadProduct":"S-969","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Sarcomatrix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarcomatrix \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Sarcomatrix \/ National Institutes of Health"},{"orgOrder":0,"company":"Immunoforge","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Pemziviptadil","moa":"VPAC2 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Immunoforge","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunoforge \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Immunoforge \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Pasithea Therapeutics","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"PAS-004","moa":"MEK1\/2 receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Pasithea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pasithea Therapeutics \/ WuXi AppTec","highestDevelopmentStatusID":"6","companyTruncated":"Pasithea Therapeutics \/ WuXi AppTec"},{"orgOrder":0,"company":"Graphite Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Graphite Bio","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Graphite Bio \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Graphite Bio \/ Versant Ventures"},{"orgOrder":0,"company":"ADARx Pharmaceuticals","sponsor":"SR One Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"ADARx Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"ADARx Pharmaceuticals \/ SR One Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"ADARx Pharmaceuticals \/ SR One Capital Management"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"RTW Investments","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Avidity Biosciences","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ RTW Investments","highestDevelopmentStatusID":"5","companyTruncated":"Avidity Biosciences \/ RTW Investments"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"DTx Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"DTx Pharma \/ RA Capital Management","highestDevelopmentStatusID":"5","companyTruncated":"DTx Pharma \/ RA Capital Management"},{"orgOrder":0,"company":"Ascidian Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Ascidian Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ascidian Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"5","companyTruncated":"Ascidian Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2023","type":"Series B Financing","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ Columbus Venture Partners","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ Columbus Venture Partners"},{"orgOrder":0,"company":"ARTHEx Biotech","sponsor":"EIC Accelerator","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Oligonucleotide","year":"2022","type":"Funding","leadProduct":"ATX-01","moa":"MBNL","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"ARTHEx Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"ARTHEx Biotech \/ EIC Accelerator","highestDevelopmentStatusID":"7","companyTruncated":"ARTHEx Biotech \/ EIC Accelerator"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"mRNA-3745","moa":"Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"Arcturus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Arcturus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"HBM Alpha Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"HAT001","moa":"CRH","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"HBM Alpha Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Undisclosed","sponsorNew":"HBM Alpha Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"HBM Alpha Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Catabasis Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Catabasis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catabasis Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Catabasis Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Quellis Biosciences Inc","sponsor":"Catabasis Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"QLS-215","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quellis Biosciences Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Quellis Biosciences Inc \/ Catabasis Pharmaceuticals"},{"orgOrder":0,"company":"Selecta Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"AT845","moa":"||Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Selecta Biosciences","amount2":0.34999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Selecta Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Selecta Biosciences \/ Astellas Pharma"},{"orgOrder":0,"company":"Paradox Immunotherapeutics","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Antibody","year":"2025","type":"Financing","leadProduct":"LX-96","moa":"IgG","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Paradox Immunotherapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Paradox Immunotherapeutics \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"4","companyTruncated":"Paradox Immunotherapeutics \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"Attralus","sponsor":"University of Tennessee Graduate School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-peptide Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AT-04","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Attralus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Attralus \/ University of Tennessee Graduate School of Medicine","highestDevelopmentStatusID":"4","companyTruncated":"Attralus \/ University of Tennessee Graduate School of Medicine"},{"orgOrder":0,"company":"ExCellThera","sponsor":"IRICoR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"ECT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ExCellThera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ExCellThera \/ IRICoR","highestDevelopmentStatusID":"4","companyTruncated":"ExCellThera \/ IRICoR"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"Lipid Nanoparticles","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Tenaya Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Public Offering","leadProduct":"TN-201","moa":"MYBPC3","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tenaya Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Tenaya Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"4","companyTruncated":"Tenaya Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Krystal Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"KB407","moa":"CFTR","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Krystal Biotech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Krystal Biotech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Krystal Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Oxford Biomedica","sponsor":"BlackfinBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Acquisition","leadProduct":"BFB-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oxford Biomedica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biomedica \/ BlackfinBio","highestDevelopmentStatusID":"4","companyTruncated":"Oxford Biomedica \/ BlackfinBio"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"National Resilience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"OPGx-001","moa":"LCA5","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Opus Genetics \/ National Resilience","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ National Resilience"},{"orgOrder":0,"company":"Codexis","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"CDX-6316","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Codexis \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio \/ Solid Biosciences"},{"orgOrder":0,"company":"AavantiBio","sponsor":"Solid Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Merger","leadProduct":"AVB-202","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Solid Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"AavantiBio \/ Solid Biosciences"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Eli Lilly"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Jaguar Gene Therapy","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"JAG101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jaguar Gene Therapy","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jaguar Gene Therapy \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Jaguar Gene Therapy \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Prevail Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"PR001","moa":"Lysosomal acid glucosylceramidase (GBA1)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Prevail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracisternal Injection","sponsorNew":"Prevail Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Prevail Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"AVR-RD-06","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Avrobio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"AVR-RD-03","moa":"Alpha-galactosidase A","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Avrobio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avrobio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Avrobio \/ Inapplicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"MGX-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Inapplicable"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"P-FVIII-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Poseida Therapeutics, Inc","amount2":3.6000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":3.6000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"4","companyTruncated":"Poseida Therapeutics, Inc \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Solve GNE","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"GA-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Solve GNE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Solve GNE \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Solve GNE \/ Undisclosed"},{"orgOrder":0,"company":"Genosera","sponsor":"Solve GNE","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"GA-002","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Genosera","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genosera \/ Solve GNE","highestDevelopmentStatusID":"4","companyTruncated":"Genosera \/ Solve GNE"},{"orgOrder":0,"company":"BrainVectis","sponsor":"AskBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"BV-CYP01","moa":"CYP46A1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BrainVectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BrainVectis \/ AskBio","highestDevelopmentStatusID":"4","companyTruncated":"BrainVectis \/ AskBio"},{"orgOrder":0,"company":"AskBio","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"BV-101","moa":"CYP46A1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"AskBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AskBio \/ Bayer AG","highestDevelopmentStatusID":"4","companyTruncated":"AskBio \/ Bayer AG"},{"orgOrder":0,"company":"ViGeneron","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"VG801","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ViGeneron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ViGeneron \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"ViGeneron \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Abigail Wexner Research Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"Calpain 3","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abigail Wexner Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abigail Wexner Research Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Abigail Wexner Research Institute \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Phoenix Nest","sponsor":"Cure Sanfilippo Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Funding","leadProduct":"AAV-TT","moa":"HGSNAT","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Phoenix Nest","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Phoenix Nest \/ Cure Sanfilippo Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Phoenix Nest \/ Cure Sanfilippo Foundation"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Acquisition","leadProduct":"KT809","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kate Therapeutics","amount2":1.1000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.1000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Kate Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Vita Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VTA-110","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vita Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vita Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vita Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"FORCE-M23D","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IPS Heart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"GIVI-MPC","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPS Heart \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GTP-506A","moa":"||PCSK9","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"iECURE","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"GTP-506A","moa":"||PCSK9","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"iECURE","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"iECURE \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"iECURE \/ Inapplicable"},{"orgOrder":0,"company":"Somagenetix","sponsor":"Vi Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Cell and Gene therapy","year":"2024","type":"Series A Financing","leadProduct":"SGX-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Somagenetix","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Somagenetix \/ Vi Partners","highestDevelopmentStatusID":"4","companyTruncated":"Somagenetix \/ Vi Partners"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VTX-803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"VTX-803","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivet Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eyevensys","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"EYS611","moa":"Human transferrin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Eyevensys","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyevensys \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Eyevensys \/ Inapplicable"},{"orgOrder":0,"company":"Fujifilm Cellular Dynamics","sponsor":"BlueRock Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"OpCT-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Fujifilm Cellular Dynamics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fujifilm Cellular Dynamics \/ BlueRock Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Fujifilm Cellular Dynamics \/ BlueRock Therapeutics"},{"orgOrder":0,"company":"Axovia Therapeutics","sponsor":"A Race Against Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"AXV101","moa":"BBS1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Axovia Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Axovia Therapeutics \/ A Race Against Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Axovia Therapeutics \/ A Race Against Blindness"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Foundation Fighting Blindness","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"OPGx-RHO","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Foundation Fighting Blindness","highestDevelopmentStatusID":"4","companyTruncated":"Opus Genetics \/ Foundation Fighting Blindness"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Acquisition","leadProduct":"EMD-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Emendo Biotherapeutics","amount2":0.25,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.25,"dosageForm":"Undisclosed","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"4","companyTruncated":"Emendo Biotherapeutics \/ AnGes"},{"orgOrder":0,"company":"Abeona Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ABO-504","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Abeona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abeona Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Abeona Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Castle Creek Biosciences","sponsor":"Paragon Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"LV-FAH","moa":"FAH","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Castle Creek Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Castle Creek Biosciences \/ Paragon Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Castle Creek Biosciences \/ Paragon Biosciences"},{"orgOrder":0,"company":"IPS Heart","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"GIVI-MPC","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IPS Heart","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IPS Heart \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"IPS Heart \/ Inapplicable"},{"orgOrder":0,"company":"Erytech Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Red Blood Cell-Encapsulated Arginine Deiminase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erytech Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erytech Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erytech Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Inozyme Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"INZ-701","moa":"Ectonucleotide pyrophosphatase\/phosphodiesterase family member 1 (ENPP1)","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Inozyme Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inozyme Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Inozyme Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Soft Bones","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"Tissue Non-Specific Alkaline Phosphatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Soft Bones","highestDevelopmentStatusID":"4","companyTruncated":"Sanford Burnham Prebys Medical Discovery Institute \/ Soft Bones"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"GC Biopharma","sponsor":"Novel Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SOUTH KOREA","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Human Heparan N-Sulfatase","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"GC Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GC Biopharma \/ Novel Pharma","highestDevelopmentStatusID":"6","companyTruncated":"GC Biopharma \/ Novel Pharma"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"M041","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"M6P Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"M041","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"M6P Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M6P Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"M6P Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Hansa Biopharma","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"Imlifidase","moa":"Antibodies","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Hansa Biopharma","amount2":0.40999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Hansa Biopharma \/ Sarepta Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Hansa Biopharma \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Magnesium Potentiated Oxytocin","moa":"Oxytocin receptor","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Airna","sponsor":"Venrock Healthcare Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Series B Financing","leadProduct":"AIR-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Airna","amount2":0.16,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Airna \/ Venrock Healthcare Capital","highestDevelopmentStatusID":"4","companyTruncated":"Airna \/ Venrock Healthcare Capital"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"The Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Funding","leadProduct":"ARCT-032","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Nasal Solution for Nebulizer","sponsorNew":"ReCode Therapeutics \/ The Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ The Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ETX-148","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"E-therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"E-therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Repair Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"REP-0003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Repair Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repair Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Repair Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Biogen","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Licensing Agreement","leadProduct":"BIIB115","moa":"SMN1 messenger RNA (SMN1 mRNA)","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ionis Pharmaceuticals \/ Biogen","highestDevelopmentStatusID":"4","companyTruncated":"Ionis Pharmaceuticals \/ Biogen"},{"orgOrder":0,"company":"Repair Biotechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"REP-0003","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Repair Biotechnologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Repair Biotechnologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Repair Biotechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Vanda Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"HCB-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"hC Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"hC Bioscience \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"hC Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Affiris","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"mAB C6-17","moa":"Mutant huntingtin","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Affiris","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affiris \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Affiris \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAG-18","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ractigen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RAG-18","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ractigen Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ractigen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ractigen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2022","type":"Collaboration","leadProduct":"ENTR-701","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Agreement","leadProduct":"ENTR-701","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.73999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.73999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"NextCure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"NC605","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"NextCure","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NextCure \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"NextCure \/ Inapplicable"},{"orgOrder":0,"company":"Lixte Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Lixte Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lixte Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Lixte Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Kind Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AND017","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kind Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kind Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Kind Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"ORY-4001","moa":"HDAC-6","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oryzon Genomics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oryzon Genomics \/ Inapplicable"},{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ETX001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Enterprise Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enterprise Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Enterprise Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Porosome Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CF PT-101","moa":"CFTR","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Porosome Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porosome Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Porosome Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"TikunTX","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"BPN-36964","moa":"ELP1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"TikunTX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TikunTX \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"TikunTX \/ Inapplicable"},{"orgOrder":0,"company":"McQuade Center for Strategic Research and Development","sponsor":"Sentinel Oncology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"SOL784","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"McQuade Center for Strategic Research and Development","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology","highestDevelopmentStatusID":"4","companyTruncated":"McQuade Center for Strategic Research and Development \/ Sentinel Oncology"},{"orgOrder":0,"company":"Redx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"RXC007","moa":"ROCK2","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Redx Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Redx Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Redx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"PLX-300","moa":"PPA-alpha receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"GT-02329","moa":"GCase level","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Polaryx Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"PLX-300","moa":"PPA-alpha receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Polaryx Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Polaryx Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Polaryx Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"APR-OD031","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APR Applied Pharma Research \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"APR Applied Pharma Research \/ Inapplicable"},{"orgOrder":0,"company":"reVision Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"REV-0100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"reVision Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"reVision Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"reVision Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"4M Therapeutics","sponsor":"SynGAP Research Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Funding","leadProduct":"4MT2001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"4M Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4M Therapeutics \/ SynGAP Research Fund","highestDevelopmentStatusID":"4","companyTruncated":"4M Therapeutics \/ SynGAP Research Fund"},{"orgOrder":0,"company":"Tavanta Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TAVT-135","moa":"Chloride ion","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Tavanta Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavanta Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tavanta Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Theranexus","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Protein","year":"2024","type":"Licensing Agreement","leadProduct":"TX01","moa":"Granulocyte colony stimulating factor receptor","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Theranexus","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theranexus \/ Exelixis","highestDevelopmentStatusID":"4","companyTruncated":"Theranexus \/ Exelixis"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"Neoletix","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2021","type":"Collaboration","leadProduct":"Recombinant Human Coagulation Factor VIII","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ Neoletix","highestDevelopmentStatusID":"4","companyTruncated":"GenScript ProBio \/ Neoletix"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Guide Therapeutics","sponsor":"Beam Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Guide Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Guide Therapeutics \/ Beam Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Guide Therapeutics \/ Beam Therapeutics"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Eurostars","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Eurostars","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Eurostars"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Beam Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Beam Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beam Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Beam Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Actio Biosciences","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Actio Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Actio Biosciences \/ Canaan Partners","highestDevelopmentStatusID":"4","companyTruncated":"Actio Biosciences \/ Canaan Partners"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Pfizer Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Nasal","sponsorNew":"ReCode Therapeutics \/ Pfizer Ventures","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Pfizer Ventures"},{"orgOrder":0,"company":"Nanite","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Nanite","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Nanite \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Nanite \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Nasal","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Sail Biomedicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Sail Biomedicines","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Sail Biomedicines \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Sail Biomedicines \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ReCode Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ReCode Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ReCode Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"ReCode Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Oregon State University","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oregon State University","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"Oregon State University \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Oregon State University \/ Inapplicable"},{"orgOrder":0,"company":"Elastin BioSciences","sponsor":"Longaevus Technologies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Demerger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Elastin BioSciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elastin BioSciences \/ Longaevus Technologies","highestDevelopmentStatusID":"4","companyTruncated":"Elastin BioSciences \/ Longaevus Technologies"},{"orgOrder":0,"company":"Quris","sponsor":"Welltech Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Quris","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Quris \/ Welltech Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Quris \/ Welltech Ventures"},{"orgOrder":0,"company":"Aldevron","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Aldevron","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Aldevron \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Aldevron \/ AavantiBio"},{"orgOrder":0,"company":"Resilience","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Resilience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Resilience \/ AavantiBio"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"AavantiBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ AavantiBio","highestDevelopmentStatusID":"4","companyTruncated":"Catalent Pharma Solutions \/ AavantiBio"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Gain Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Gain Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gain Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Gain Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Edity Therapeutics","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Edity Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Edity Therapeutics \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"4","companyTruncated":"Edity Therapeutics \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"VECT-HORUS","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Series D Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"VECT-HORUS","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"VECT-HORUS \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"VECT-HORUS \/ Undisclosed"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Silence Therapeutics","amount2":1.3200000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3200000000000001,"dosageForm":"Undisclosed","sponsorNew":"Silence Therapeutics \/ Hansoh Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Silence Therapeutics \/ Hansoh Pharma"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Be Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Be Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Be Biopharma"},{"orgOrder":0,"company":"Rectify Pharma","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rectify Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Rectify Pharma \/ Atlas Venture","highestDevelopmentStatusID":"4","companyTruncated":"Rectify Pharma \/ Atlas Venture"},{"orgOrder":0,"company":"Caszyme","sponsor":"Integra Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"LITHUANIA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Caszyme","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Caszyme \/ Integra Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Caszyme \/ Integra Therapeutics"},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Kriya Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kriya Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kriya Therapeutics \/ Kriya Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Kriya Therapeutics \/ Kriya Therapeutics"},{"orgOrder":0,"company":"Erasmus University Medical Center","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Erasmus University Medical Center","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Erasmus University Medical Center \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Erasmus University Medical Center \/ Inapplicable"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Metagenomi","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ J.P. Morgan","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ J.P. Morgan"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Novo Holding","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Metagenomi","amount2":0.28000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Novo Holding","highestDevelopmentStatusID":"4","companyTruncated":"Metagenomi \/ Novo Holding"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Intellia Therapeutics","amount2":0.41999999999999998,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.41999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Intellia Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Intellia Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Wake Forest Institute for Regenerative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wake Forest Institute for Regenerative Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Forest Institute for Regenerative Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Wake Forest Institute for Regenerative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Seattle Children\u2019s Research Institute","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Seattle Children\u2019s Research Institute","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Seattle Children\u2019s Research Institute \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Chameleon Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Chameleon Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chameleon Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Chameleon Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Be Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Be Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Be Biopharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Be Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"SalioGen Therapeutics","sponsor":"GordonMD Global","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SalioGen Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"SalioGen Therapeutics \/ GordonMD Global","highestDevelopmentStatusID":"4","companyTruncated":"SalioGen Therapeutics \/ GordonMD Global"},{"orgOrder":0,"company":"SEAL Therapeutics","sponsor":"Santhera Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SEAL Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SEAL Therapeutics \/ Santhera Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"SEAL Therapeutics \/ Santhera Pharmaceuticals"},{"orgOrder":0,"company":"ASC Therapeutics","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"ASC Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ASC Therapeutics \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"ASC Therapeutics \/ UMass Chan Medical School"},{"orgOrder":0,"company":"University of Massachusetts","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"University of Massachusetts","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts \/ ASC Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"University of Massachusetts \/ ASC Therapeutics"},{"orgOrder":0,"company":"Cellectis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cellectis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectis \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cellectis \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"CANbridge Pharmaceuticals","sponsor":"UMass Chan Medical School","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"CANbridge Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CANbridge Pharmaceuticals \/ UMass Chan Medical School","highestDevelopmentStatusID":"4","companyTruncated":"CANbridge Pharmaceuticals \/ UMass Chan Medical School"},{"orgOrder":0,"company":"Casma Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Casma Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Casma Therapeutics \/ The Column Group","highestDevelopmentStatusID":"4","companyTruncated":"Casma Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"INmune Bio \/ Inapplicable"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"University of Minnesota","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ University of Minnesota","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ University of Minnesota"},{"orgOrder":0,"company":"MitoRx Therapeutics","sponsor":"Wren Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MitoRx Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"MitoRx Therapeutics \/ Wren Capital","highestDevelopmentStatusID":"4","companyTruncated":"MitoRx Therapeutics \/ Wren Capital"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Wellington Management Company","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Entrada Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Entrada Therapeutics \/ Wellington Management Company","highestDevelopmentStatusID":"4","companyTruncated":"Entrada Therapeutics \/ Wellington Management Company"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Prevail Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.56000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56000000000000005,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Prevail Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Prevail Therapeutics"},{"orgOrder":0,"company":"Code Bio","sponsor":"Northpond Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Code Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Code Bio \/ Northpond Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Code Bio \/ Northpond Ventures"},{"orgOrder":0,"company":"Capsida","sponsor":"Kate Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Capsida","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Capsida \/ Kate Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Capsida \/ Kate Therapeutics"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Dyne Therapeutics","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Vida Ventures LLC","highestDevelopmentStatusID":"4","companyTruncated":"Dyne Therapeutics \/ Vida Ventures LLC"},{"orgOrder":0,"company":"Ashvattha Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Ashvattha Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ashvattha Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ashvattha Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stoke Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Jnana Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Jnana Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Jnana Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"4","companyTruncated":"Jnana Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"GondolaBio","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Demerger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"GondolaBio","amount2":0.29999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"GondolaBio \/ BridgeBio Pharma","highestDevelopmentStatusID":"4","companyTruncated":"GondolaBio \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Biogen","sponsor":"Massachusetts Eye And Ear","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Massachusetts Eye And Ear","highestDevelopmentStatusID":"4","companyTruncated":"Biogen \/ Massachusetts Eye And Ear"},{"orgOrder":0,"company":"IVERIC bio","sponsor":"Opus Genetics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"IVERIC bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IVERIC bio \/ Opus Genetics","highestDevelopmentStatusID":"4","companyTruncated":"IVERIC bio \/ Opus Genetics"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Cure AP-4","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Cure AP-4","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Cure AP-4"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Life Science Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vico Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Life Science Partners","highestDevelopmentStatusID":"4","companyTruncated":"Vico Therapeutics \/ Life Science Partners"},{"orgOrder":0,"company":"Oak Bay Biosciences","sponsor":"FrontFundr","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Oak Bay Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oak Bay Biosciences \/ FrontFundr","highestDevelopmentStatusID":"4","companyTruncated":"Oak Bay Biosciences \/ FrontFundr"},{"orgOrder":0,"company":"Stoke Therapeutics","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Stoke Therapeutics","amount2":0.96999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.96999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Stoke Therapeutics \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Stoke Therapeutics \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Diagonal Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Diagonal Therapeutics","amount2":0.13,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.13,"dosageForm":"Undisclosed","sponsorNew":"Diagonal Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"4","companyTruncated":"Diagonal Therapeutics \/ BVF Partners"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Pharming","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"OTL-105","moa":"C1 esterase","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Orchard Therapeutics","amount2":0.20999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.20999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Pharming","highestDevelopmentStatusID":"4","companyTruncated":"Orchard Therapeutics \/ Pharming"},{"orgOrder":0,"company":"Peptris Technologies","sponsor":"Revio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"RT001","moa":"Lipid peroxidation","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Peptris Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptris Technologies \/ Revio Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Peptris Technologies \/ Revio Therapeutics"},{"orgOrder":0,"company":"Amplo Biotechnology","sponsor":"NIH-NIAMS","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"AMP-201","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amplo Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplo Biotechnology \/ NIH-NIAMS","highestDevelopmentStatusID":"4","companyTruncated":"Amplo Biotechnology \/ NIH-NIAMS"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-3139","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moderna Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Moderna Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Genetic Disease","graph2":"Phase II","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Frequency Therapeutics","sponsor":"Korro Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Frequency Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Frequency Therapeutics \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Frequency Therapeutics \/ Korro Bio"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Wave Life Sciences","amount2":3.3399999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":3.3399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Wave Life Sciences \/ GSK"},{"orgOrder":0,"company":"ViaNautis Bio","sponsor":"SomaServe","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ViaNautis Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Nasal","sponsorNew":"ViaNautis Bio \/ SomaServe","highestDevelopmentStatusID":"3","companyTruncated":"ViaNautis Bio \/ SomaServe"},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"ReCode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Intellia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Intellia Therapeutics \/ ReCode Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Intellia Therapeutics \/ ReCode Therapeutics"},{"orgOrder":0,"company":"Amber Bio","sponsor":"Playground Global","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Amber Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Amber Bio \/ Playground Global","highestDevelopmentStatusID":"3","companyTruncated":"Amber Bio \/ Playground Global"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"The University Of Colorado Anschutz Medical Campus","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ The University Of Colorado Anschutz Medical Campus"},{"orgOrder":0,"company":"Metagenomi","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Metagenomi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metagenomi \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Metagenomi \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"EdiGene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Pharmaceuticals \/ EdiGene","highestDevelopmentStatusID":"3","companyTruncated":"Arbor Pharmaceuticals \/ EdiGene"},{"orgOrder":0,"company":"Evozyne","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Evozyne","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evozyne \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evozyne \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Deep Genomics","sponsor":"SoftBank Vision Fund","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Deep Genomics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Deep Genomics \/ SoftBank Vision Fund","highestDevelopmentStatusID":"3","companyTruncated":"Deep Genomics \/ SoftBank Vision Fund"},{"orgOrder":0,"company":"Vipergen","sponsor":"Casma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vipergen \/ Casma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Casma Therapeutics"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":2.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Alnylam Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Alnylam Pharmaceuticals"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Prime Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Prime Medicine","highestDevelopmentStatusID":"4","companyTruncated":"MaxCyte \/ Prime Medicine"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Obsidian Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Obsidian Therapeutics","amount2":1.3,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"Obsidian Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Obsidian Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Ring Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ring Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Ring Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Neochromosome","sponsor":"University of Edinburgh","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Neochromosome","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neochromosome \/ University of Edinburgh","highestDevelopmentStatusID":"3","companyTruncated":"Neochromosome \/ University of Edinburgh"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"GondolaBio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ GondolaBio","highestDevelopmentStatusID":"3","companyTruncated":"n-Lorem Foundation \/ GondolaBio"},{"orgOrder":0,"company":"ElevateBio","sponsor":"Amazon Web Services","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"ElevateBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ElevateBio \/ Amazon Web Services","highestDevelopmentStatusID":"3","companyTruncated":"ElevateBio \/ Amazon Web Services"},{"orgOrder":0,"company":"Genetic Leap","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Genetic Leap","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genetic Leap \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Genetic Leap \/ Eli Lilly"},{"orgOrder":0,"company":"Enveda Bioscience","sponsor":"Lux Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Enveda Bioscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Enveda Bioscience \/ Lux Capital","highestDevelopmentStatusID":"3","companyTruncated":"Enveda Bioscience \/ Lux Capital"},{"orgOrder":0,"company":"Rampart Bioscience","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Rampart Bioscience","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Rampart Bioscience \/ OrbiMed Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Rampart Bioscience \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Protego Biopharma","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Protego Biopharma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Protego Biopharma \/ Lightspeed Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"Protego Biopharma \/ Lightspeed Venture Partners"},{"orgOrder":0,"company":"Bit Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Bit Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bit Bio \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Bit Bio \/ Inapplicable"},{"orgOrder":0,"company":"Alltrna","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Alltrna","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Alltrna \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Alltrna \/ Flagship Pioneering"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"PBGENE-HbE","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Precision BioSciences","amount2":1.48,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.48,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Precision BioSciences \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Evotec","sponsor":"Centogene","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Cell and Gene therapy","year":"2020","type":"Expanded Collaboration","leadProduct":"Induced Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Centogene","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Centogene"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"Taysha Gene Therapies","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Expanded Collaboration","leadProduct":"TSHA-112","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ Taysha Gene Therapies","highestDevelopmentStatusID":"2","companyTruncated":"UT Southwestern Medical Center \/ Taysha Gene Therapies"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Eventide Asset Management","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Eventide Asset Management"},{"orgOrder":0,"company":"CAMP4 Therapeutics","sponsor":"Fulcrum Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"CAMP4 Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"CAMP4 Therapeutics \/ Fulcrum Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"CAMP4 Therapeutics \/ Fulcrum Therapeutics"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Sanofi","sponsor":"Global Blood Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanofi","amount2":0.34999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Global Blood Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Global Blood Therapeutics"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Orna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Orna Therapeutics","amount2":0.69999999999999996,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.69999999999999996,"dosageForm":"Undisclosed","sponsorNew":"Orna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Orna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Fulcrum Therapeutics","sponsor":"MyoKardia","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Fulcrum Therapeutics","amount2":0.46999999999999997,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Fulcrum Therapeutics \/ MyoKardia","highestDevelopmentStatusID":"2","companyTruncated":"Fulcrum Therapeutics \/ MyoKardia"},{"orgOrder":0,"company":"Gensaic","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Gensaic","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Gensaic \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Gensaic \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Flagship Pioneering","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Flagship Pioneering","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Nasal","sponsorNew":"Flagship Pioneering \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Flagship Pioneering \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Moderna Therapeutics","amount2":0.46000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.46000000000000002,"dosageForm":"Nasal","sponsorNew":"Moderna Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Moderna Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Scriptr","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scriptr","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scriptr \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Scriptr \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"GERO.AI","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"GERO.AI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GERO.AI \/ Pfizer Inc","highestDevelopmentStatusID":"2","companyTruncated":"GERO.AI \/ Pfizer Inc"},{"orgOrder":0,"company":"Tottori University","sponsor":"GC Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Tottori University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tottori University \/ GC Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Tottori University \/ GC Pharma"},{"orgOrder":0,"company":"Proteros","sponsor":"Adrestia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Proteros","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Proteros \/ Adrestia Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Proteros \/ Adrestia Therapeutics"},{"orgOrder":0,"company":"BridgeBio Pharma","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"BridgeBio Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BridgeBio Pharma \/ Baylor College of Medicine","highestDevelopmentStatusID":"3","companyTruncated":"BridgeBio Pharma \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Design Therapeutics","sponsor":"Renaissance Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Design Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Design Therapeutics \/ Renaissance Capital","highestDevelopmentStatusID":"2","companyTruncated":"Design Therapeutics \/ Renaissance Capital"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Scribe Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.24,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Serotiny","sponsor":"Tessera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Serotiny","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Serotiny \/ Tessera Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Serotiny \/ Tessera Therapeutics"},{"orgOrder":0,"company":"EdiGene","sponsor":"University of Wisconsin","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EdiGene \/ University of Wisconsin","highestDevelopmentStatusID":"2","companyTruncated":"EdiGene \/ University of Wisconsin"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":1.3,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.3,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Yarrow Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"ProQR Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProQR Therapeutics \/ Yarrow Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"ProQR Therapeutics \/ Yarrow Biotechnology"},{"orgOrder":0,"company":"Scenic Biotech","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Scenic Biotech","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Scenic Biotech \/ Genentech","highestDevelopmentStatusID":"3","companyTruncated":"Scenic Biotech \/ Genentech"},{"orgOrder":0,"company":"Dyno Therapeutics","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Dyno Therapeutics","amount2":1.6200000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":1.6200000000000001,"dosageForm":"Undisclosed","sponsorNew":"Dyno Therapeutics \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Dyno Therapeutics \/ Astellas Pharma"},{"orgOrder":0,"company":"Sanegene Bio","sponsor":"Orbit Discovery","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Sanegene Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanegene Bio \/ Orbit Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Sanegene Bio \/ Orbit Discovery"},{"orgOrder":0,"company":"Ceptur Therapeutics","sponsor":"Venbio Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Ceptur Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Ceptur Therapeutics \/ Venbio Partners","highestDevelopmentStatusID":"2","companyTruncated":"Ceptur Therapeutics \/ Venbio Partners"},{"orgOrder":0,"company":"NeuBase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"NeuBase Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuBase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"NeuBase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"Decheng Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Shape Therapeutics","amount2":0.11,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"Shape Therapeutics \/ Decheng Capital","highestDevelopmentStatusID":"2","companyTruncated":"Shape Therapeutics \/ Decheng Capital"},{"orgOrder":0,"company":"PAQ Therapeutics","sponsor":"Sherpa Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"PAQ Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"PAQ Therapeutics \/ Sherpa Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"PAQ Therapeutics \/ Sherpa Healthcare"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Genevant Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Genevant Sciences \/ Novo Nordisk"},{"orgOrder":0,"company":"Light Chain Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Light Chain Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Light Chain Bioscience \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Light Chain Bioscience \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"Foundation To Fight H-Abc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"University of Massachusetts Medical School","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts Medical School \/ Foundation To Fight H-Abc","highestDevelopmentStatusID":"2","companyTruncated":"University of Massachusetts Medical School \/ Foundation To Fight H-Abc"},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"John Ballantyne","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Myosana Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Myosana Therapeutics \/ John Ballantyne","highestDevelopmentStatusID":"2","companyTruncated":"Myosana Therapeutics \/ John Ballantyne"},{"orgOrder":0,"company":"Harvard Stem Cell Institute","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Harvard Stem Cell Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Stem Cell Institute \/ Sarepta Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Harvard Stem Cell Institute \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Metrion Biosciences","sponsor":"KCNC1 Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Metrion Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Metrion Biosciences \/ KCNC1 Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Metrion Biosciences \/ KCNC1 Foundation"},{"orgOrder":0,"company":"Kate Therapeutics","sponsor":"Westlake Village BioPartners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Kate Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Kate Therapeutics \/ Westlake Village BioPartners","highestDevelopmentStatusID":"2","companyTruncated":"Kate Therapeutics \/ Westlake Village BioPartners"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Genetic Cures for Kids","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Genetic Cures for Kids","highestDevelopmentStatusID":"4","companyTruncated":"Charles River Laboratories, Inc \/ Genetic Cures for Kids"},{"orgOrder":0,"company":"Genflow Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Genflow Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genflow Biosciences \/ Inapplicable","highestDevelopmentStatusID":"2","companyTruncated":"Genflow Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"UMass Chan Medical School","sponsor":"QurAlis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"UMass Chan Medical School","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UMass Chan Medical School \/ QurAlis","highestDevelopmentStatusID":"2","companyTruncated":"UMass Chan Medical School \/ QurAlis"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"PKU Sphere","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Vitaflo International, Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"PKU Explore","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Vitaflo International, Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"PKU Sphere","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Vitaflo International, Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Evinacumab","moa":"Angiopoietin-related protein 3","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Regeneron Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Regeneron Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Hope Biosciences","sponsor":"Hope Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"HB-adMSC","moa":"Mesenchymal stem cells","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Hope Biosciences","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hope Biosciences \/ Hope Biosciences","highestDevelopmentStatusID":"1","companyTruncated":"Hope Biosciences \/ Hope Biosciences"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bioray Laboratories \/ Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ Institute of Hematology & Hospital of Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"Nanfang Hospital, Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ Nanfang Hospital, Southern Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ Nanfang Hospital, Southern Medical University"},{"orgOrder":0,"company":"Bioray Laboratories","sponsor":"First Affiliated Hospital of Guangxi Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"BRL-101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Bioray Laboratories","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Bioray Laboratories \/ First Affiliated Hospital of Guangxi Medical University","highestDevelopmentStatusID":"1","companyTruncated":"Bioray Laboratories \/ First Affiliated Hospital of Guangxi Medical University"},{"orgOrder":0,"company":"Orchard Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"OTL-102","moa":"Gene","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Orchard Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orchard Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Orchard Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genevant Sciences","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ 2Seventy Bio","highestDevelopmentStatusID":"1","companyTruncated":"Genevant Sciences \/ 2Seventy Bio"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"MegaTAL mRNA","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"1","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"AgeX Therapeutics","sponsor":"University of California San Diego","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Neural Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AgeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AgeX Therapeutics \/ University of California San Diego","highestDevelopmentStatusID":"1","companyTruncated":"AgeX Therapeutics \/ University of California San Diego"},{"orgOrder":0,"company":"Virica Biotech","sponsor":"Innovation, Science and Economic Development Canada","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Collaboration","leadProduct":"Re-engineered AAV-LPL","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Virica Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virica Biotech \/ Innovation, Science and Economic Development Canada","highestDevelopmentStatusID":"1","companyTruncated":"Virica Biotech \/ Innovation, Science and Economic Development Canada"},{"orgOrder":0,"company":"SR-Tiget","sponsor":"Genespire","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"Microrna-Regulated Lentiviral Vectors","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SR-Tiget","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SR-Tiget \/ Genespire","highestDevelopmentStatusID":"1","companyTruncated":"SR-Tiget \/ Genespire"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"GtCCR4","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Daiichi Sankyo \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"1","companyTruncated":"Daiichi Sankyo \/ Mitsubishi UFJ Capital"},{"orgOrder":0,"company":"Sio Gene Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"rAAVrh8-HexA\/HexB","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sio Gene Therapies","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intrathalamic Infusion","sponsorNew":"Sio Gene Therapies \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Sio Gene Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Sch\u00e4r AG \/ SPA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Motion","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dr. Sch\u00e4r AG \/ SPA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Sch\u00e4r AG \/ SPA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"GMPOWER","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dr. Sch\u00e4r AG \/ SPA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Sch\u00e4r AG \/ SPA","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2020","type":"Inapplicable","leadProduct":"Lipano","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dr. Sch\u00e4r AG \/ SPA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Dr. Sch\u00e4r AG \/ SPA \/ Inapplicable"},{"orgOrder":0,"company":"Biotrial","sponsor":"European Union | Nantes University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Biotrial","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biotrial \/ European Union | Nantes University Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Biotrial \/ European Union | Nantes University Hospital"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"TYR sphere","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Vitaflo International, Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Inapplicable"},{"orgOrder":0,"company":"GlycosBio, Inc.","sponsor":"Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"Glycosbio Nutritional Supplement","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"GlycosBio, Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GlycosBio, Inc. \/ Baylor College of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"GlycosBio, Inc. \/ Baylor College of Medicine"},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"PKU Express Plus","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"Vitaflo International, Ltd \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Dr Jorg Taubel","sponsor":"Richmond Pharmacology | National Amyloidosis Centre","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dr Jorg Taubel","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dr Jorg Taubel \/ Richmond Pharmacology | National Amyloidosis Centre","highestDevelopmentStatusID":"1","companyTruncated":"Dr Jorg Taubel \/ Richmond Pharmacology | National Amyloidosis Centre"},{"orgOrder":0,"company":"Brigham and Women's Hospital","sponsor":"Baylor College of Medicine | Boston Children's Hospital | Broad Institute of MIT and Harvard | Dartmouth-Hitchcock Medical Center | Harvard Pilgrim Health Care | Howard University | HudsonAlpha Institute for Biotechnology | Massachusetts General Hospital ","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Brigham and Women's Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brigham and Women's Hospital \/ Baylor College of Medicine | Boston Children's Hospital | Broad Institute of MIT and Harvard | Dartmouth-Hitchcock Medical Center | Harvard Pilgrim Health Care | Howard University | HudsonAlpha Institute for Biotechnology | Massachusetts General Hospital ","highestDevelopmentStatusID":"1","companyTruncated":"Brigham and Women's Hospital \/ Baylor College of Medicine | Boston Children's Hospital | Broad Institute of MIT and Harvard | Dartmouth-Hitchcock Medical Center | Harvard Pilgrim Health Care | Howard University | HudsonAlpha Institute for Biotechnology | Massachusetts General Hospital "},{"orgOrder":0,"company":"Vitaflo International, Ltd","sponsor":"Birmingham Women's and Children's NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"PKU UP","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vitaflo International, Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vitaflo International, Ltd \/ Birmingham Women's and Children's NHS Foundation Trust","highestDevelopmentStatusID":"1","companyTruncated":"Vitaflo International, Ltd \/ Birmingham Women's and Children's NHS Foundation Trust"},{"orgOrder":0,"company":"University Hospital, Montpellier","sponsor":"Institut de Recherche en Infectiologie de Montpellier (CNRS) | A*STAR","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University Hospital, Montpellier","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital, Montpellier \/ Institut de Recherche en Infectiologie de Montpellier (CNRS) | A*STAR","highestDevelopmentStatusID":"1","companyTruncated":"University Hospital, Montpellier \/ Institut de Recherche en Infectiologie de Montpellier (CNRS) | A*STAR"},{"orgOrder":0,"company":"Centre Hospitalier de Saint-Denis","sponsor":"INSERM U955","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Centre Hospitalier de Saint-Denis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de Saint-Denis \/ INSERM U955","highestDevelopmentStatusID":"1","companyTruncated":"Centre Hospitalier de Saint-Denis \/ INSERM U955"},{"orgOrder":0,"company":"University of Primorska","sponsor":"Biostile d.o.o. | QFarm s.r.l.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Primorska","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Primorska \/ Biostile d.o.o. | QFarm s.r.l.","highestDevelopmentStatusID":"1","companyTruncated":"University of Primorska \/ Biostile d.o.o. | QFarm s.r.l."},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Dietary Supplement","year":"2025","type":"Inapplicable","leadProduct":"GMP Intervention Product","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amicus Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"ATB200","moa":"Glycogen","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Amicus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amicus Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Amicus Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Pegunigalsidase alfa","moa":"Globotriosylceramide","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Chiesi Group","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Chiesi Group"},{"orgOrder":0,"company":"University of Illinois, Urbana-Champaign","sponsor":"BIO-CAT","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Protease","moa":"Polypeptides","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Illinois, Urbana-Champaign","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Illinois, Urbana-Champaign \/ BIO-CAT","highestDevelopmentStatusID":"1","companyTruncated":"University of Illinois, Urbana-Champaign \/ BIO-CAT"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Velmanase Alfa","moa":"High mannose oligosaccharides","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"University of Primorska","sponsor":"Biovis d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Coenzyme Q10","moa":"Mitochondrial electron transport chain","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Primorska","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Primorska \/ Biovis d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"University of Primorska \/ Biovis d.o.o."},{"orgOrder":0,"company":"Hunterian Medicine","sponsor":"Inscripta","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Licensing Agreement","leadProduct":"MAD7 Nuclease","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Hunterian Medicine","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hunterian Medicine \/ Inscripta","highestDevelopmentStatusID":"1","companyTruncated":"Hunterian Medicine \/ Inscripta"},{"orgOrder":0,"company":"Emendo Biotherapeutics","sponsor":"AnGes","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Series B Financing","leadProduct":"OMNI Nuclease","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Emendo Biotherapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Emendo Biotherapeutics \/ AnGes","highestDevelopmentStatusID":"1","companyTruncated":"Emendo Biotherapeutics \/ AnGes"},{"orgOrder":0,"company":"Vico Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Oligonucleotide","year":"2021","type":"Inapplicable","leadProduct":"VO659","moa":"RNA","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vico Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vico Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Vico Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CSPC Baike","sponsor":"Beijing Friendship Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CSPC Baike","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CSPC Baike \/ Beijing Friendship Hospital","highestDevelopmentStatusID":"1","companyTruncated":"CSPC Baike \/ Beijing Friendship Hospital"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Elexacaftor","moa":"Cystic fibrosis transmembrane conductance regulator","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vertex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"PKU Golike","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APR Applied Pharma Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"APR Applied Pharma Research \/ Inapplicable"},{"orgOrder":0,"company":"Grete Andersen, MD","sponsor":"GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Grete Andersen, MD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Grete Andersen, MD \/ GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab","highestDevelopmentStatusID":"1","companyTruncated":"Grete Andersen, MD \/ GCP-Copenhagen | Region Capital Denmark | Danish Region | Lupin Ltd | ZiteLab"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Alexion Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"PKU Golike","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"APR Applied Pharma Research \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"APR Applied Pharma Research \/ Inapplicable"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Troriluzole","moa":"EAAT2","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Biohaven Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Meta Healthcare Ltd","sponsor":"Birmingham Women's and Children's NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"L-VALINE","moa":"Propionyl-CoA carboxylase beta chain, mitochondrial; Branched-chain-amino-acid aminotransferase, cytosolic; Valine--tRNA ligase","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Meta Healthcare Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Meta Healthcare Ltd \/ Birmingham Women's and Children's NHS Foundation Trust","highestDevelopmentStatusID":"1","companyTruncated":"Meta Healthcare Ltd \/ Birmingham Women's and Children's NHS Foundation Trust"},{"orgOrder":0,"company":"Applied Science & Performance Institute","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Plant Extract\/Herbal","year":"2025","type":"Inapplicable","leadProduct":"CAS 501-94-0","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Applied Science & Performance Institute","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oil","sponsorNew":"Applied Science & Performance Institute \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Applied Science & Performance Institute \/ Inapplicable"},{"orgOrder":0,"company":"MitoChem Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"MC16","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MitoChem Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MitoChem Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"MitoChem Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Cornell University","sponsor":"reVision Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2020","type":"Licensing Agreement","leadProduct":"REV-0100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Cornell University","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cornell University \/ reVision Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cornell University \/ reVision Therapeutics"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Low Calorie Protein Substitute","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Nutricia Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"PKU\/TYR GMP Protein","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Nutricia Inc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nutricia Inc \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Nutricia Inc \/ Inapplicable"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"DSM Food Specialties","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Canola Protein","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Maastricht University Medical Center \/ DSM Food Specialties","highestDevelopmentStatusID":"1","companyTruncated":"Maastricht University Medical Center \/ DSM Food Specialties"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Korro Bio \/ Genevant Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Genevant Sciences"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"National Institutes of Health \/ Inapplicable"},{"orgOrder":0,"company":"Codexis","sponsor":"Crosswalk Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Codexis","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Codexis \/ Crosswalk Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Codexis \/ Crosswalk Therapeutics"},{"orgOrder":0,"company":"AavantiBio","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0.11,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ Sarepta Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirion Biotech \/ Sanofi","highestDevelopmentStatusID":"1","companyTruncated":"Sirion Biotech \/ Sanofi"},{"orgOrder":0,"company":"Entos Pharmaceuticals","sponsor":"BioMarin Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Entos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Entos Pharmaceuticals \/ BioMarin Pharmaceutical","highestDevelopmentStatusID":"1","companyTruncated":"Entos Pharmaceuticals \/ BioMarin Pharmaceutical"},{"orgOrder":0,"company":"Mammoth Biosciences","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Mammoth Biosciences","amount2":0.68999999999999995,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.68999999999999995,"dosageForm":"Undisclosed","sponsorNew":"Mammoth Biosciences \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mammoth Biosciences \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"AavantiBio","sponsor":"University of Florida","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"AavantiBio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AavantiBio \/ University of Florida","highestDevelopmentStatusID":"1","companyTruncated":"AavantiBio \/ University of Florida"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Anjarium Biosciences","sponsor":"Abingworth","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Anjarium Biosciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Anjarium Biosciences \/ Abingworth","highestDevelopmentStatusID":"1","companyTruncated":"Anjarium Biosciences \/ Abingworth"},{"orgOrder":0,"company":"hC Bioscience","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"hC Bioscience","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"hC Bioscience \/ Arch Ventures","highestDevelopmentStatusID":"1","companyTruncated":"hC Bioscience \/ Arch Ventures"},{"orgOrder":0,"company":"Sarepta Therapeutics","sponsor":"Personalis","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Sarepta Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sarepta Therapeutics \/ Personalis","highestDevelopmentStatusID":"1","companyTruncated":"Sarepta Therapeutics \/ Personalis"},{"orgOrder":0,"company":"University of Massachusetts Medical School","sponsor":"CANbridge Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"University of Massachusetts Medical School","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"University of Massachusetts Medical School \/ CANbridge Pharmaceuticals"},{"orgOrder":0,"company":"Vigene Bioscience","sponsor":"ASC Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Vigene Bioscience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vigene Bioscience \/ ASC Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Vigene Bioscience \/ ASC Therapeutics"},{"orgOrder":0,"company":"2Seventy Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"2Seventy Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"2Seventy Bio \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"2Seventy Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Myosana Therapeutics","sponsor":"Cureduchenne Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Myosana Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Myosana Therapeutics \/ Cureduchenne Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Myosana Therapeutics \/ Cureduchenne Ventures"},{"orgOrder":0,"company":"Duchenne research","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Duchenne research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duchenne research \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Duchenne research \/ Undisclosed"},{"orgOrder":0,"company":"CYTOO","sponsor":"Astellas Gene Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"CYTOO","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CYTOO \/ Astellas Gene Therapies","highestDevelopmentStatusID":"1","companyTruncated":"CYTOO \/ Astellas Gene Therapies"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Curamys","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Curamys","highestDevelopmentStatusID":"1","companyTruncated":"MaxCyte \/ Curamys"},{"orgOrder":0,"company":"Affinia Therapeutics","sponsor":"Vertex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Affinia Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Affinia Therapeutics \/ Vertex Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Affinia Therapeutics \/ Vertex Pharmaceuticals"},{"orgOrder":0,"company":"Dyne Therapeutics","sponsor":"Cureduchenne Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dyne Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dyne Therapeutics \/ Cureduchenne Ventures","highestDevelopmentStatusID":"1","companyTruncated":"Dyne Therapeutics \/ Cureduchenne Ventures"},{"orgOrder":0,"company":"PepGen","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"PepGen","amount2":0.050000000000000003,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"PepGen \/ RA Capital Management","highestDevelopmentStatusID":"1","companyTruncated":"PepGen \/ RA Capital Management"},{"orgOrder":0,"company":"Precision BioSciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Precision BioSciences","amount2":0.56000000000000005,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.56000000000000005,"dosageForm":"Undisclosed","sponsorNew":"Precision BioSciences \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Precision BioSciences \/ Eli Lilly"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Dewpoint Therapeutics","amount2":0.23999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.23999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Dewpoint Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"1","companyTruncated":"Dewpoint Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Guggenheim Securities","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arcturus Therapeutics \/ Guggenheim Securities","highestDevelopmentStatusID":"1","companyTruncated":"Arcturus Therapeutics \/ Guggenheim Securities"},{"orgOrder":0,"company":"Replay Bio","sponsor":"KKR","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Replay Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Replay Bio \/ KKR","highestDevelopmentStatusID":"1","companyTruncated":"Replay Bio \/ KKR"},{"orgOrder":0,"company":"SpliceBio","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SPAIN","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"SpliceBio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"SpliceBio \/ Ysios Capital","highestDevelopmentStatusID":"1","companyTruncated":"SpliceBio \/ Ysios Capital"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"ZonMw | European Commission","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gene Therapy","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Leiden University Medical Center \/ ZonMw | European Commission","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ ZonMw | European Commission"},{"orgOrder":0,"company":"Corporacion Parc Tauli","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Tridocosahexaenoine","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Corporacion Parc Tauli","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corporacion Parc Tauli \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Corporacion Parc Tauli \/ Inapplicable"},{"orgOrder":0,"company":"Western Sydney Local Health District","sponsor":"Westmead Institute for Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Beetroot","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Western Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Western Sydney Local Health District \/ Westmead Institute for Medical Research","highestDevelopmentStatusID":"1","companyTruncated":"Western Sydney Local Health District \/ Westmead Institute for Medical Research"},{"orgOrder":0,"company":"Seventh Medical Center of PLA General Hospital","sponsor":"GeneCradle Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GC301","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Seventh Medical Center of PLA General Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seventh Medical Center of PLA General Hospital \/ GeneCradle Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Seventh Medical Center of PLA General Hospital \/ GeneCradle Therapeutics"},{"orgOrder":0,"company":"He Huang","sponsor":"Lingyi Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"LY-M001","moa":"SARS-CoV-2 spike protein","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"He Huang","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"He Huang \/ Lingyi Biotech","highestDevelopmentStatusID":"1","companyTruncated":"He Huang \/ Lingyi Biotech"},{"orgOrder":0,"company":"Ajinomoto Company","sponsor":"Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Glytactin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Ajinomoto Company","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ajinomoto Company \/ Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust","highestDevelopmentStatusID":"1","companyTruncated":"Ajinomoto Company \/ Birmingham Children's Hospital | Great Ormond Street Hospital for Children NHS Foundation Trust"},{"orgOrder":0,"company":"ALPS Biotech CO. LTD","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Antrodia Cinnamomea","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"ALPS Biotech CO. LTD","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ALPS Biotech CO. LTD \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"ALPS Biotech CO. LTD \/ Inapplicable"},{"orgOrder":0,"company":"Genecombio Ltd.","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GCB-001","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genecombio Ltd.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genecombio Ltd. \/ The Children's Hospital of Zhejiang University School of Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Genecombio Ltd. \/ The Children's Hospital of Zhejiang University School of Medicine"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TAK-881","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Virchow Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Immunoglobulin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Virchow Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Virchow Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Virchow Group \/ Undisclosed"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AZD0120","moa":"MAPK pathway","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Connoya Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"CM336","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Connoya Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Connoya Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Connoya Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"IASO Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Equecabtagene Autoleucel","moa":"BCMA","graph1":"Genetic Disease","graph2":"Phase II","graph3":"IASO Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IASO Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"IASO Bio \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Suzanne Lentzsch, MD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Teclistamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Suzanne Lentzsch, MD","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Suzanne Lentzsch, MD"},{"orgOrder":0,"company":"Pharming","sponsor":"Aixial Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Leniolisib Phosphate","moa":"PI3-kinase p110-delta subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Pharming","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharming \/ Aixial Group","highestDevelopmentStatusID":"8","companyTruncated":"Pharming \/ Aixial Group"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Zodasiran","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Arrowhead Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Suncadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"SHR-1918","moa":"ANGPTL3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Beijing Suncadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Suncadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Beijing Suncadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Crinetics Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Atumelnant","moa":"MC2R","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Crinetics Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Crinetics Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Crinetics Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Columbia University","sponsor":"Actinium pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Radiolabelled Compounds","year":"2025","type":"Inapplicable","leadProduct":"131-I Apamistmab","moa":"CD45","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Columbia University \/ Actinium pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Columbia University \/ Actinium pharmaceuticals"},{"orgOrder":0,"company":"Asklepion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Citrulline","moa":"G-protein coupled receptor GPCR33 (GPRC6A)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Asklepion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Asklepion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Asklepion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Deferoxamine Mesylate","moa":"Iron","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Etranacogene Dezaparvovec","moa":"Coagulation factor IX","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Clinical Research Consultants, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Clinical Research Consultants, Inc.","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Clinical Research Consultants, Inc. \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Clinical Research Consultants, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Orphalan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Trientine Hydrochloride","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Orphalan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orphalan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Orphalan \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"IgPro","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Apitegromab","moa":"Growth\/differentiation factor 8","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Scholar Rock \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Mexiletine","moa":"Sodium channel alpha subunit","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Neurofibromatosis Therapeutic Acceleration Program | Amgen Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Talimogene Laherparepvec","moa":"Melanoma cell","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Neurofibromatosis Therapeutic Acceleration Program | Amgen Inc","highestDevelopmentStatusID":"6","companyTruncated":"Johns Hopkins University \/ Neurofibromatosis Therapeutic Acceleration Program | Amgen Inc"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Luvometinib","moa":"MEK1|MEK2","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fosun Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Fosun Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Vonicog Alfa","moa":"von Willebrand factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"VGA039","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Vega Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Vega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VX-407","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"VX-407","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Vertex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vertex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Atlas Molecular Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ciclopirox","moa":"Iron | Aluminium","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Atlas Molecular Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Solution","sponsorNew":"Atlas Molecular Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Atlas Molecular Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Belief BioMed","sponsor":"Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"BBM-D101","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Belief BioMed","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Belief BioMed \/ Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd","highestDevelopmentStatusID":"7","companyTruncated":"Belief BioMed \/ Shanghai Mianyi Biopharmaceutical Co., Ltd. | Shanghai Xinzhi BioMed Co., Ltd"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-45","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entrada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Entrada Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ENTR-601-44","moa":"Dystrophin","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Entrada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Entrada Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Entrada Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"TJ Biopharma Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"TJ Biopharma Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TJ Biopharma Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TJ Biopharma Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Eidos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Acoramidis Hydrochloride","moa":"Transthyretin","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Eidos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eidos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eidos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SION-451","moa":"CFTR NBD1","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sionna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Sionna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sionna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"SION-719","moa":"CFTR NBD1","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Sionna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sionna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sionna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"EDK060","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"ASP2957","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody-oligonucleotide Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Del-desiran","moa":"Transferrin-1 receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Avidity Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"HaiHe Biopharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CYH33","moa":"PI3K\u03b1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"HaiHe Biopharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaiHe Biopharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"HaiHe Biopharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Alpelisib","moa":"PI3-kinase p110-alpha subunit","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"PRG Science & Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Trineumin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"PRG Science & Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PRG Science & Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"PRG Science & Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Angitia Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AGA2115","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Angitia Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Angitia Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Angitia Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HuidaGene Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"HG005","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"HuidaGene Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"HuidaGene Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"HuidaGene Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jerry Vockley","sponsor":"Ultragenyx Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Triheptanoin","moa":"Triglyceride","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Jerry Vockley","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jerry Vockley \/ Ultragenyx Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Jerry Vockley \/ Ultragenyx Pharmaceutical"},{"orgOrder":0,"company":"Restem","sponsor":"SOLVE FSHD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Umbilical Cord Lining-Derived Stem Cell","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Restem","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Restem \/ SOLVE FSHD","highestDevelopmentStatusID":"6","companyTruncated":"Restem \/ SOLVE FSHD"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Vosoritide","moa":"Atrial natriuretic peptide receptor B","graph1":"Genetic Disease","graph2":"Phase III","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMarin Pharmaceutical \/ Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"BioMarin Pharmaceutical \/ Icon Plc"},{"orgOrder":0,"company":"n-Lorem Foundation","sponsor":"Hawaii Pacific Neuroscience","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"nL-ATN1-002","moa":"ATN1","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"n-Lorem Foundation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience","highestDevelopmentStatusID":"7","companyTruncated":"n-Lorem Foundation \/ Hawaii Pacific Neuroscience"},{"orgOrder":0,"company":"Avidity Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"AOC-1020","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Avidity Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avidity Biosciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Avidity Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"KalVista Pharmaceuticals","sponsor":"Pendopharm","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"Sebetralstat","moa":"KLKB1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"KalVista Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"KalVista Pharmaceuticals \/ Pendopharm Division of De Pharmascience Inc","highestDevelopmentStatusID":"15","companyTruncated":"KalVista Pharmaceuticals \/ Pendopharm Division of De Pharmascience Inc"},{"orgOrder":0,"company":"Astria Therapeutics","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"Navenibart","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Astria Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Astria Therapeutics \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Astria Therapeutics \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Vascarta","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vascarta \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ Undisclosed"},{"orgOrder":0,"company":"Cure Rare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CRD-003","moa":"FKRP","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Cure Rare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Rare \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Cure Rare \/ Undisclosed"},{"orgOrder":0,"company":"BioMarin Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Enzyme","year":"2025","type":"Inapplicable","leadProduct":"BMN 390","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"BioMarin Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMarin Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"BioMarin Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"AAVantgarde Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"AAVB-039","moa":"ABCA4 protein","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"AAVantgarde Bio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AAVantgarde Bio \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"AAVantgarde Bio \/ Undisclosed"},{"orgOrder":0,"company":"Vascarta","sponsor":"National Heart, Lung, and Blood Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vascarta","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Gel","sponsorNew":"Vascarta \/ National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"Vascarta \/ National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Rallybio","sponsor":"Recursion Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"REV102","moa":"ENPP1","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Rallybio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Rallybio \/ Recursion Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Rallybio \/ Recursion Pharma"},{"orgOrder":0,"company":"Vertex Pharmaceuticals","sponsor":"NHS England","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vanzacaftor","moa":"||CFTR","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Vertex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Vertex Pharmaceuticals \/ NHS England","highestDevelopmentStatusID":"15","companyTruncated":"Vertex Pharmaceuticals \/ NHS England"},{"orgOrder":0,"company":"Prime Medicine","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"G542X","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Prime Medicine","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Prime Medicine \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Prime Medicine \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Visirna","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"Plozasiran","moa":"APOC-3","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Visirna","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.40000000000000002,"dosageForm":"Injection","sponsorNew":"Visirna \/ Sanofi","highestDevelopmentStatusID":"10","companyTruncated":"Visirna \/ Sanofi"},{"orgOrder":0,"company":"Endure Bio","sponsor":"National Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Microorganism","year":"2025","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Endure Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endure Bio \/ National Cancer Institute","highestDevelopmentStatusID":"4","companyTruncated":"Endure Bio \/ National Cancer Institute"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Sarepta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Licensing Agreement","leadProduct":"ARO-DM1","moa":"DMPK","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":11.380000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":11.380000000000001,"dosageForm":"Infusion","sponsorNew":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Sarepta Therapeutics"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Gen Pharmaceuticals and Health Products","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Gen Pharmaceuticals and Health Products","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Gen Pharmaceuticals and Health Products"},{"orgOrder":0,"company":"Theravia","sponsor":"Norgine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cytotoxic Drug","year":"2025","type":"Acquisition","leadProduct":"Hydroxyurea","moa":"Ribonucleoside-diphosphate reductase RR1","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Theravia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Theravia \/ Norgine","highestDevelopmentStatusID":"15","companyTruncated":"Theravia \/ Norgine"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Uniphar","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Uniphar","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Uniphar"},{"orgOrder":0,"company":"Seaside Therapeutics","sponsor":"Allos Pharma","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Seaside Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Seaside Therapeutics \/ Allos Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Seaside Therapeutics \/ Allos Pharma"},{"orgOrder":0,"company":"Amplo Biotechnology","sponsor":"Andelyn Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Partnership","leadProduct":"AMP-101","moa":"DOK7","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amplo Biotechnology","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amplo Biotechnology \/ Andelyn Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Amplo Biotechnology \/ Andelyn Biosciences"},{"orgOrder":0,"company":"Santhera Pharmaceuticals","sponsor":"Ikris Pharma Network","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Vamorolone","moa":"Mineralocorticoid receptor | Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Santhera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Santhera Pharmaceuticals \/ Ikris Pharma Network","highestDevelopmentStatusID":"15","companyTruncated":"Santhera Pharmaceuticals \/ Ikris Pharma Network"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"VCA-894A","moa":"IGHMBP2","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Diagonal Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"DIAG723","moa":"ALK-1 receptor","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Diagonal Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Diagonal Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Diagonal Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pint Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"AUSTRIA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Berotralstat Hydrochloride","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Pint Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pint Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pint Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"JAPAN","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Immune Globulin Infusion (Human)","moa":"Immunoglobulin","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Hydroxypropyl-Beta Cyclodextrin","moa":"Cholesterol and lipid accumulation","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Sepiapterin","moa":"eNOS","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Powder","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Concizumab","moa":"Tissue factor pathway inhibitor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novo Nordisk \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Undisclosed"},{"orgOrder":0,"company":"Ionis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Donidalorsen Sodium","moa":"antisense oligonucleotides","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Ionis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ionis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Ionis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"KER-065","moa":"Myostatin\/Activin A","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Opus Genetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"OPGx-BEST1","moa":"BEST1 gene","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Opus Genetics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Opus Genetics \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Opus Genetics \/ Undisclosed"}]

Find Clinical Drug Pipelines for Genetic Disease

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Rilzabrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Anemia, Sickle Cell.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 16, 2025

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Olipudase Alfa

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          April 29, 2025

                          Lead Product(s) : Olipudase Alfa

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Efanesoctocog Alfa

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          April 24, 2025

                          Lead Product(s) : Efanesoctocog Alfa

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          March 30, 2025

                          Lead Product(s) : ABBV-CLS-628

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Calico Life Sciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          05

                          Lead Product(s) : SAR446268

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          February 25, 2025

                          Lead Product(s) : SAR446268

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          06

                          Lead Product(s) : Avalglucosidase Alfa

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Enzyme

                          Upfront Cash : Inapplicable

                          October 30, 2024

                          Lead Product(s) : Avalglucosidase Alfa

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          07

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 19, 2024

                          Lead Product(s) : Fosigotifator

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Abbvie Company Banner

                          08

                          Details : Under the terms of the agreement, Sionna will assume all development for ABBV-2222 (galicaftor), which is being evaluated in combination with navocaftor for the treatment of Cystic Fibrosis.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 16, 2024

                          Lead Product(s) : Galicaftor,Navocaftor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : Sionna Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          Abbvie Company Banner

                          09

                          Lead Product(s) : Avalglucosidase Alpha

                          Therapeutic Area : Genetic Disease

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Nexviazyme (avalglucosidase alfa) is a USFDA approved GAA stimulator enzyme replacement therapy. It is being evaluated for the treatment of treatment-naïve Infantile-onset Pompe disease.

                          Product Name : Nexviazyme

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          May 02, 2024

                          Lead Product(s) : Avalglucosidase Alpha

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          10

                          Lead Product(s) : Eliglustat

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 05, 2024

                          Lead Product(s) : Eliglustat

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner